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The utilization and exploration of multifaceted phosphate tethers in synthesis 
is the focus of the dissertation research described herein.  Desymmetrization of a 
readily derived psuedo-C2-symmetric monocyclic phosphate via highly 
diastereoselective anti-SN2’ allylic displacement reactions are reported.  This method 
utilizes a wide variety of zinc-derived organocuprates to afford E-1,2-syn-configured 
phosphate acid building blocks.  Extension of this protocol to unsymmetric 
monocyclic phosphates exclusively yields 1,2-anti-configured products.  Within this 
study stereoelectronic factors coupled with allylic strain ultimately govern regio- and 
diastereoselective cuprate reactions, thus further substantiating the Corey mechanism 
for organocuprate additions into allylic esters. 
An approach towards fostriecin and fostriecin-like libraries utilizing rapid 
functionalization via a bicyclic phosphate methodology was investigated. This 
compact, multifaceted core coupled with an array of selective reactive pathways 
begged the synthetic queries enacted.  Key to unraveling and expanding upon this 
central core of the molecule was realization of an exocyclic olefin oxidation and a 
diastereoselective Grignard addition where the source of Grignard used was found to 
play an important role.  Selective cross-metathesis with subsequent attack of lithium 
thiophenol exploits the orthogonal leaving group ability of the phosphate to reveal the 
 iv 
requisite stereo-tetrad of fostriecin.  Not only does this sequence serve as a proof of 
concept approach for the total synthesis of fostriecin, it also serves as an archetype for 
the generation of fostriecin-like and phoslactomycin-like libraries. 
The explorations of two synthetic approaches towards fostriecin from the 
bicyclic phosphate were embarked upon simultaneously.  Intensive studies found the 
deactivating nature of the carboxylate oxygen on the alkene of lactone in conjunction 
with the lethargic protected tertiary allylic alcohol provided unacceptable conversion 
upon metathesis, despite installation of catalyst delivery vehicles.  Attempts to utilize 
the unprotected bicyclic phosphate variant displayed preferential dimerization in the 
cross metathesis, while the relay primed analog was frustrated by competing 
elimination pathways.  Analysis of an organometallic addition of the lactone core 
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Total Syntheses of Several Natural Product Phosphatase Inhibitors: 




 Investigation of phosphatase inhibitors as pharmacologically viable targets is 
relatively new compared to investigations on kinase inhibitors.1  While initially 
phosphatases were regarded as enzymes that “clean-up” after more essential 
regulatory kinases, a large body of evidence dismisses this misconception in light of 
the pivotal role of phosphatases in the body.2  As such, naturally occurring 
phosphatase inhibitors have arisen as potent probes of the mechanisms of 
phosphatases as well as therapeutic agents in and of themselves.1  The following 
review is designed to cover some of the major total synthetic efforts towards 
particularly attractive and representative natural product phosphatase inhibitors.  Of 
the phosphatase inhibitors to be discussed (calyculins A and B, dysidiolide, 
motuporin, tautomycin, phoslactomycin A and B, spirastrellolide A methyl ester, 
okadaic acid, and fostriecin), the notable omissions of the leustroducsins and 
cytostatin are due to their more explicit treatment within the remaining chapters of 
this dissertation, vide infra.  Other omissions (Figure 1) are the cladocorans A and B,3 
coscinosulfate,4 dephostatin,5 the dinophysistoxins,6 glucolipsin A,7 gymnorrhizol,8 
microcystin-LA,9 pulchellalactam,10 thyrsiferol and thyrsiferyl 23-acetate,11 TMC-69 
and TMC-69-6H;12 the references provided for these omissions can provide 





































R = Ac, Cladocoran A










































































R = H: Thyrsiferol
























R1= R2= Me, R3 = H: Dinophysistoxin-1




Figure 1 Several Natural Product Phosphatase Inhibitors 
 The purpose of this review is to place into context the utilization of the 
phosphate ester moiety, often ascribed to be a labile, promiscuous functionality, 
within synthesis through comparison and reference to previous total syntheses.  In 
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particular the utility, stability, and efficacy of employing otherwise regarded sensitive 
functionalities in these total synthetic regimes provides a framework within which the 
following chapters’ employment of phosphate tethers can be contemplated. 
1.2 Calyculins 
 Calyculin A was isolated by Fusetani and co-workers from the marine sponge 
Discoderma calyx and its relative stereochemistry was established by subsequent X-
ray crystallographic analysis (Figure 2).13    Further discovery of calyculins B-H, 
which differ primarily in geometric orientation at Δ2 and/or Δ6 and/or an additional 
methyl group at C32, helped prompt investigation into this class of phosphatase 
inhibitor.14 Later, discovery of calyculin J, the caliculinamides A, B, and F, des-N-
methycalyculin A, and dephosphocalyculin A display the diversity and intriguing 

































Figure 2 Calyculin A 
 The first total synthesis reported was by the Evan’s group in 1992,15,16  where 
auxiliary-based reactions (aldol, alkylation, hydroxylation, conjugate addition) would 
construct 10 of the 15 stereogenic centers (Scheme 1).  The phosphate and the 
tetraene were to be installed late in the synthesis, as the phosphate was deemed a 
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“liability due to the extra reactivity that such an appendage might confer on the 
system” and the tetraene posited to be the locus of instability in the natural product.15  
A schism at the C25-C26 olefin provided two fragments that could be joined via a 
phosphorous-based olefination.  Hydroxyl groups to be protected until the conclusion 
of the synthesis would utilize silicon-based protecting groups, while hydroxyl groups 
to be manipulated would be masked with appropriate non-silicon based protecting 
groups in a strategy they termed the ‘cumulative silicon strategy’. 
Scheme 1 
Me Me






























 Generation of the first stereogenic center of the molecule occurred with 
application of an auxiliary-controlled asymmetric hydroxylation to form alcohol 2.3 
as a single diastereomer (Scheme 2).  Conversion to the Wienreb amide, PMB 
protection of the C17 alcohol and subsequent reduction of the amide to the aldehyde 
allowed for a diastereoselective (methoxyallyl)stannane addition to generate 2.4 as a 
7.5:1 mixture of diastereomers with 71% yield of the desired syn,syn isomer.  Five 
more steps provided silyl enol ether 2.5 ready for Mukaiyama aldol coupling.  The 
coupling partner was assembled using a chiral auxiliary approach to afford the C22 
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2. NaH, PMBBr, 84%
3. DIBAL-H, -78 ºC, 93%
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BF3•OEt2 mediated addition of silyl enol ether 2.5 with aldehyde 2.8 provided 
stereohexad 2.9 as a single diastereomer.  Subjecting the aldol adduct to a 
HF/CH3CN/H2O mixture provided a 5:1 diastereomeric mixture of spiroketals that 
could be separated chromatographically to provide the correct spiroketal 2.10 in 71% 
yield. 
 Formation of the northern hemisphere of calyculin A proceeded with 
formation of the C33-C37 γ-amino acid 3.5 (Scheme 3).  Two step conversion of 
sarcosine to (S)-phenylalanine-derived oxazolidinone 3.1 allowed for asymmetric 
alkylation to append a methoxymethyl unit providing 3.2 in good yield and 
diastereoselectivity.  Removal of the chiral auxiliary followed by oxidation to 
aldehyde 3.3 allowed for addition of the tin (II) enolate of glycolate imide 3.4 to 
 7 
provide anti-aldol product 3.5 in 60% yield  (excluding other diastereomers).  Boc 
removal from oxazole 3.6 followed by trimethyl aluminum-mediated tandem 
coupling with amide 3.5/PMB deprotection generated γ-amino amide 3.7.  A five step 




















THF, 0 ºC, 93%
2. (COCl)2, DMSO































1. HCl (g), EtOAc, 0 ºC






































 Spiroketal 2.10 required an 18-step procedure to generate the southern 
segment 4.1 (Scheme 4), involving auxiliary controlled formation of the C12, C13 
centers and appending the cyanotetraene through Horner-Emmons and Stille bond 
constructions.  Wittig olefination of aldehyde 4.1 with the ylide of 3.8 provided fully 
protected calyculin A as a single observable olefin isomer, with subsequent 
deprotection affording (+)-calyculin A.  This product was equal to the natural product 
in all respects except in the sign of the optical rotation, thus confirming the absolute 




















































































 The total synthesis of naturally occurring (–)-calyculin A was reported in 
1994 by the Masamune group.19  Utilizing chiral, non-racemic starting materials, 
rather than chiral auxiliaries, the Masamune group hoped to explore the 
stereoselective coupling of chiral fragments via aldol reactions towards forming the 
southern spiroketal-containing fragment. Scheme 5 illustrates a chelation-controlled 
Mukaiyama-type aldol  of silyl-enol ether 5.1 with aldehyde 5.2 providing aldol 
adduct 5.3 in good yield with 10:1 diastereoselection.  Conversion to 5.4 allowed for 
investigations into the C10,11,12,13 anti,anti,anti stereoisomer 5.6.  Adduct 5.6 was 
the ‘worst’ mismatched pair possible for the aldol product, and achiral addition 
provided a 1:4 distribution of diastereomers with isomer 5.6 as the minor component.  
Overriding substrate control by employing  E(O)-enolate 5.5 allowed for isomer 5.6 
 9 
to be provided in good yield and with 12:1 diastereoselection.  Similarly, construction 
of the carbon skeleton of the southern hemisphere 5.9 relied on coupling ketone 5.7 
with aldehyde 5.8 to selectively generate the C21 stereogenic center.  Surveying a 
variety of achiral boron reagents provided the insight that increasing size of the boron 
ligands enhanced diastereoselectivity, thus utilizing dicyclohexyl boron chloride 

























TsOH, 83% (2 steps)











































































 Coupling of the northern and southern fragments is noteworthy, as it 
proceeded via a Julia-Lythgoe olefination in the presence of the protected phosphate 
(Scheme 6).  The total synthesis of Evans group beforehand and the total syntheses 
appearing after the Masamune group report rely on Wittig or Horner-Emmons type 
couplings in the presence of the phosphate.  Utilizing the spiroketal generated from 
5.9, sulfone 6.1 was deprotonated by phenyllithium to subsequently react with 
 10 
oxazole 6.220 (in the presence of the unprotected amide and the phosphate), followed 
by benzoylation and sodium amalgam mediated reductive elimination to provide E-
olefin 6.3 as the major product.  (–)-Calyculin A was provided in 4 more steps to 


































































































1. Swern ox. 82%





















 In 199821 and 1999,22 the Smith group reported their approach to (+)-calyculin 
A as well as the total synthesis of (–)-calyculin B.  The similar splitting of the 
molecule into a northern and southern hemisphere was noted, with the exception that 
the cyanotetraene would be produced in the last two bond forming steps of the 










































(+)-Calyculin A, R1= CN, R2= H




























 The Smith group approach centered on the efficient and large scale production 
of four key advanced synthons, with generation of the spiroketal 7.4 initiating from 
Brown allylboration of 3-benyloxypropanal to yield alcohol 8.1 (Scheme 8).  
Protection as the tert-butyl carbonate followed by IBr-induced diastereoselective 
cyclization produced the desired sterotriad 8.2, which was converted in two steps to 
epoxide 8.3.  (S)-Malic acid derived alcohol 8.4 provided dithiane 8.5 in two steps, 
where coupling of the anion of dithiane 8.5 with epoxide 8.3 provided masked aldol 
product 8.6 to afford 120 g in a single experiment.  Subsequent manipulations 



















BF3•OEt2, THF, -78 ºC;






2. IBr, PhMe, -85 ºC


















Et 1. (COCl)2, DMSO, Et3N
2. HS(CH2)3SH, BF3•OEt2


























Hoping to complete the southern hemisphere, attempts to couple dithiane 9.1 with 
epoxide 7.4 suffered from lack of reactivity, despite multiple studies indicating the 
feasibility of the attempt.  Utilizing a vinyl cuprate addition of bromide 7.3 with 
epoxide 7.4, however, produced alcohol 9.2 in 83% yield on ~2 g scale.  The southern 
































































 Construction of the northern hemisphere engaged upon a short synthesis of the 
γ-amino subunit 7.1, where commercially available isopropylidene-D-
erythronolactone 10.1 was converted into lactam 10.2 (Scheme 10).  The silyl enol 
ether of pinacolone was added to lactam 10.2 to efficiently and selectively generate 












































 The requisite subunit 7.1 was provided in three more steps, which was 
eventually coupled with the oxazole subunit 7.2 to generate the northern hemisphere.  
The northern and southern hemispheres were joined via Wittig coupling to yield 11.2, 
which was converted in three steps to ketone 11.3.  Peterson olefination provided a 
1.7:1 E/Z mixture, with radial chromatography separating fully protected (–)-
calyculin B and fully protected (+)-calyculin A, respectively.  Global deprotection 
provided (+)-calyculin A and (–)-calyculin B, where analysis of (–)-calyculin B 





































































1. DIBAL-H, -78 ºC, 87%
2. TPAP, NMO, 84%
3. n-BuLi, E.6, -78 ºC;














































 The Armstrong group reported the total synthesis of naturally occurring 
calyculin C in 1998, where their investigations provided interesting insight into 
remote protecting group effects on the diastereoselectivity of Brown 
crotylborations.23  In previous studies, it was found that ozonolysis followed by 
Brown crotylboration of 12.1 (Scheme 12) provided the desired C10, C11, C12 anti-
anti diastereomer 12.2 in 40% isolated yield, separable from a 4:3 mixture of anti-
anti: anti-syn.  Employing this protocol with TBS-protected 12.3, however, provided 
adduct 12.4 as the single, undesired anti-syn diastereomer.  Inferring that this was due 
to the protecting group change at C13, replacement of the C13 as a benzoyl protected 
 15 
alcohol while keeping the synthetically more tenable silyl protecting groups at C21 
and C25 allowed for crotylboration of 12.5.  While the effect of the β-alkoxy 
protecting group on stereoselectivity was evident as formation of the desired product 
12.6 occurred, it was the minor component of the product distribution, the major 








































































BF3•OEt2, THF, -78 ºC







































 This discrepancy between the diastereomeric ratios of generated from 12.1 
and 12.5 suggested to the Armstrong group that remote effects of the protecting 
groups at C21 and C25 could be at play.  One further experiment illustrated this 
hypothesis, that in which a simple replacement of the C25 TPS group of 12.1 was 
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replaced with a TBS group to generate 13.1.  The two-step ozonolysis/Brown 
crotylboration protocol produced a 35:39 ratio of desired to undesired diastereomers; 
the seemingly simple change of a TPS group to a TBS group at the remote C25 
position changed the product distribution to favor the undesired anti-syn product.  All 
anti-anti diastereomers were taken on to the completion of the molecule, which 

























































 Dysidiolide is a neo-isolabdanoid sesterterpene isolated from the marine 
sponge Dysidea etheria de Laubenfels collected off the Bahamian islands (Figure 
3).24  It was the first known natural inhibitor of the dual specificity phosphatase 
enzyme Cdc25A (IC50 9.4 µM), inhibiting the growth of A-549 human lung 
carcinoma (IC50 4.7 µM) and P388 murine leukemia cells (IC50 1.5 µM).24  While 
Blanchard and co-workers suggested the inhibition to be caused by an unidentified 
component in the crude extract,25 Shirai and co-workers confirmed the inhibitory 
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activity against Cdc25A (recording IC50 35 µM) and found dysidiolide additionally 
inhibits Cdc25B (IC50 87 µM).26  Given the structural novelty and promising anti-
mitotic properties of dysidiolide, it is not surprising that the first three total syntheses 


















Figure 3 (–)-Dysidiolide 
 Corey’s group reported the first enantioselective total synthesis of the natural 
product in 1997.27  The synthesis initiated from readily available 14.1 (Scheme 14), 
where selective reduction of the α,β-enone forms an enolate that is trapped by allyl 
bromide to provide the geminal methyl allyl ketone 14.2.  The C7-C8 unsaturated 
ketone is then formed followed by axial addition of TMSLi to provide β-TMS ketone 
14.3, a moiety the proved essential in forming the natural product.  A 
methylenation/position selective Sharpless hydroxylation protocol followed by 
periodate mediated glycol cleavage, reduction, TBDPS protection, and 
diastereoselective hydrogenation afforded ketone 14.4.  In generating tertiary alcohol 
14.5, attempts to add the requisite 4-methyl-4-pentenyl group by organolithium, 
magnesium, and cerium reagents returned starting material.  Addition of 






O OMe O OMeLi-NH3, THF
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1. KH, DMSO, Ph3PCH3Br, 97%
2. Sharpless Dihydroxylation, 97%
3. NaIO4 then NaBH4, 0ºC, 94%
4. PPTS, 4:1 acetone:H2O, 100%
5. TBDPSCl, DMAP, 2,6-lut., 97%























 The necessity of the C8 TMS group is revealed upon conversion of tertiary 
alcohol 15.1 to the fully substituted bicyclic core 15.2 (Scheme 15).  Utilization of 
analogues with a hydrogen or Ph(Me)2Si group instead of TMS provided little, if any, 
desired rearrangement product under myriad conditions.  The BF3(g) mediated 
rearrangement of 15.1 provided rearranged adduct 15.2 in 70% yield, where the β-
silicon group in addition to specific double bond generation facilitates the reaction.  
Elaborating 15.2 to aldehyde 15.3 allows for 3-lithiofuran addition to provide 
epimeric secondary alcohols 15.4 and 15.5 as a 1:1 mixture.  Facile separation 
allowed for conversion of 15.5 to 15.4 via an oxidation/CBS reduction protocol, 
noting that attempts to invert via Mitsunobu conditions only progressed partially and 
attempts at diastereoselective reduction with L-Selectride, NaBH4, and LiBH4 
provided 15.5 as the major product.  Singlet oxygen addition to furan 15.4 provided 

































































1. DMP, pyr., 100%
2. A, BH3•DMS











 The Danishefsky group reported the racemic total synthesis two months later 
in 1998,28,29 where a Diels-Alder between dioxolenium activated dienophile 16.1 and 
racemic diene 16.2 was the key step (Scheme 16).  TMSOTf catalyzed the reaction to 
afford 67% of the endo-dioxolane product 16.3 along with 5% of an undetermined 
stereoisomer.  Attempts at performing the same reaction utilizing trisubstituted ester 
analogues, rather than acetal, were ineffective in the Diels-Alder reaction.  
Elaboration of the C4 silyl protected alcohol 16.3 to the racemic natural product 
occurred in five steps to present a 12 step total synthesis of (±)-dysidiolide.  Further 
testing of the racemate showed growth arrest on four cancer cell lines, with PC3, 

























n-BuOH, 150 ºC, 74%


































2. DIBAL-H, 0 ºC








 Seven days after submission of Danishefsky’s racemic synthesis, the 
Boukouvalas group submitted their total synthesis of (+)-dysidiolide (published 
1998).30  Similarly, the key step in the Boukouvalas group sequence was a Diels-
Alder between chiral, non-racemic diene 17.2 and doubly activated dienophile 17.3 
(Scheme 17).  Diene 17.3 was itself available from commercially available ketoester 
17.1, which can be obtained as either antipode.  Utilizing (+)-ketoester 17.1 allowed 
for quick generation of 17.2, which upon cycloaddition with dienophile 17.3 provides 
two  (out of a possible eight) diastereomeric adducts with the major being adduct 
17.4.  Subsequent modification to aldehyde 17.5 allowed for a siloxyfuranyl addition, 
reminiscent of the Corey and Danishefsky approaches with the notable exception that 
addition would occur via the titanium reagent.  This (siloxyfuranyl)titanium reagent 
provided a 2.2:1 desired: undesired mixture of epimeric alcohols, although isolation 
 21 
provided 58% yield of desired 17.6 and 14% yield of the epimer.  Dimethyldioxirane 
oxidation followed by treatment with Amberlyst-1531 provided (+)-dysidiolide in a 
total of 15 linear steps and 5.26% overall yield.  At the time of writing, this 
established the absolute stereochemistry of naturally occurring dysidiolide as the 
enantiomer of (+)-dysidiolide, however, the Corey group’s paper published sixteen 


















































DMDO, acetone, 1 h
then Amberlyst-15,








 The Hashimoto-Shirai group’s total synthesis of (–)-dysidiolide in 2000 
explored the Diels-Alder approach towards generating analogs for structure-activity 
relationship inquiries.32  Utilizing ketoester (S)-(–)-17.1, the group synthesized chiral, 
non-racemic diene ent-17.2 (Scheme 18) which was combined with crotonaldehyde 
(18.1) to produce four inseparable adducts in 83% yield, where subsequent reduction 
allowed for identification of the isomeric products 18.2a-d.  Isomer 18.2a was taken 
 22 
on to synthesize (–)-dysidiolide in 8 more steps, with isomers 18.2b-d illustrating the 













-30 ºC ! 0 ºC, 83%


























 The Forsyth group provided a total synthesis of racemic dysidiolide in 2000 
that relied on highly diastereoselective sequential transfer of stereochemical 
information to install the core stereogenic centers of the bicyclic natural product. 33,34  
Starting with racemic vinylogous acyl chloride 19.1, selective methylation anti to the 
C7 methyl group provided ketoester 19.2 (Scheme 19).  Addition of sodium ethoxide 
to provide the vinylogous ester prior to lithium aluminum hydride reduction allows 
for acid catalyzed rearrangement to form enone 19.3.  TMS protection of the primary 
alcohol allows for cyanocuprate addition to effect a conjugate addition anti to silyl 
protected oxymethyl group at C6 to yield ketone 19.4.  Ketone 19.4 underwent a 
global deprotection followed by Jones oxidation and esterification, allowing for 
annulation to afford bicyclic enone 19.5.  The β,β-disubstituted bicyclic enone 19.5 
underwent an exquisitely stereoselective 1,4-addition by the Gilman cuprate formed 
 23 
from 5-bromo-2-methylpentene, delivering the bicyclic core of dysidiolide (19.6).  




































































 In 2001 Yamada’s group presented the total synthesis of (–)-dysidiolide 
utilizing an intramolecular Diels-Alder reaction to construct the bicyclic core.35,36 
Chiral, non-racemic enone 20.137 was converted to dienone 20.2 in two steps 
(Scheme 20), followed by conjugate addition of thiophenol and DIBAL reduction to 
afford epimeric alcohols 20.3a and 20.3b. Attempting to acylate the alcohol with the 
diene intact provided a 4:17 mixture of tandem acylation/Diels-Alder adduct 20.5 
with SN2’ adduct, thus necessitating thiophenol masking of the diene functionality.  
The readily separated epimers were each oxidized to the sulfoxide, where the correct 
C12 epimer 20.3a was directly acylated with propiolic acid to generate 20.4, while 
the undesired 20.3b was converted to the requisite propionate ester 20.4 via 
 24 
Mitsunobu inversion. Refluxing sulfoxide 20.4 in toluene with the presence of ethyl 
propiolate and pyridine unmasked the diene moiety in situ and provided 
intramolecular Diels-Alder adduct 20.5.  Subsequent stereoselective methylation with 
Me2CuLi provided tricycle 20.6 in 91% yield with a 30:1 C7α:C7β ratio.  This rigid 
tricycle set the stage for selective generation of the C6 quaternary stereogenic center 
by deprotonation of 20.7 and alkylation with THP protected 2-iodoethanol to provide 
20.8 in 92% yield as the sole product.  Subsequent elaboration of the fully 
functionalized core yielded a 27 step synthesis of naturally occurring dysidiolide in 





















































































1.4 Motuporin/Nodularin V 
 Motuporin (nodularin-V) is a cyclic pentapeptide isolated in 1992 from the 
marine sponge Theonella swinhoei Gray (Figure 4).38  In addition to containing the 
unusual β-amino acid Adda, motuporin is one of the most potent PP1 inhibitors 
known (IC50 < 1.0 nM) and shows strong cytotoxicity against a variety of human 
cancer cells.38  As motuporin is available from a much less readily accessible source 
than other members of its class (okadaic acid class), much of the information on it has 
been extrapolated from data on nodularin and the microcystins.  While sharing similar 
biological properties, important functional differences exist between the microcystins 
and nodularins (motuporin included) such as microcystin covalent bonding to PP1 





























Figure 4 Motuporin 
 The first total synthesis of (–)-motuporin was unveiled in 1995 by the 
Schreiber group where all the stereocenters arrived from common amino acids or D-
mandelic acid.40  Key to the route was realizing the generation of the C20 amino acid 
(2S,3S,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyl-4,6-decadienoic acid 
(Adda)41 and D-erythro-β-methylaspartate (β-MeAsp),42 which the group chose to 
access via a novel route from D-threonine towards a common intermediate.  To 
 26 
achieve this, protected D-threonine 21.1 (Scheme 21) was converted to tosylaziridine 
21.2, followed by cyanide addition and methanolysis to afford γ-lactone 21.3.  This 
proved to be the common intermediate for formation of the C1-C4 backbone of Adda 






































 The key generation of protected Adda continued with conversion of 
mandelaldehyde 22.1 (Scheme 22) through Lewis acid promoted crotylstannane 
addition to produce the C8 and C9 stereogenic centers followed by methylation to 
provide alkene 22.2.  Elaboration to the α,β-unsaturated ester 22.3 allowed for 






















































Sulfone 22.4 underwent a stereoselective diene-forming addition with aldehyde 21.4 
by utilizing a modified Julia olefination to provide protected Adda 22.5 as the only 
detectable diene isomer. 
 Given the presence of several amino acid linkages lacking α-amino 
substituents, convergent coupling of the fragments was performed without 
troublesome epimerization.  As such, the linear precursor to the desired natural 
product, 23.1, was quickly in hand (Scheme 23).  Neutralization of an acidic solution 
of 23.1 by Hünig’s base allowed for macrolactamization to yield the desired 
macrocycle 23.2.  The methyl esters of 23.2 were deprotected with aqueous Ba(OH)2 
with the unexpected complete dehydration of the N-methyl-D-threonine subunit to 





























































































 The Toogood laboratory provided the second total synthesis of (–)-motuporin 
in 1999 along with synthesis of 5-[L-Ala]-motuporin (Figure 5) to investigate the 
 28 
contribution of the N-methyldehyrobutyrine residue, a moiety the authors suggested 
was inessential to activity since it did not undergo covalent modification unlike the 
dehydroalanine in microcystin-LR.43  In these efforts, the Toogood group developed 
another synthesis of Adda they deemed suitable for larger scale generation and 

























































Figure 5 (–)-Motuporin and the 5-[L-Ala] analogue 
 In forming amino acid Adda, Evans aldol adduct 24.1 was converted to 
trisubstituted alkene 24.2 (Scheme 24).  Gem-dimethyl alkene 24.2 was 
regioselectively oxidized to alcohol 24.3 by SeO2, with a Luche reduction of the 
crude mixture to convert minor overoxidized product from SeO2 into alcohol 24.3.  
The C1-C4 fragment originated from (R)-3-pentyn-2-ol, where three chemical steps 
provide 24.4 poised for a highly diastereoselective Claisen rearrangement, followed 
by methylation of the acid, reduction to the alcohol, and subsequent protection to 
afford 24.5.  Conversion of the alkene to the methyl ester followed Marshall’s 
procedure,44 followed by selective silyl deprotection with NBS according to Taylor’s 
method45 and oxidation to aldehyde 24.6.  Despite numerous attempts to circumvent 
the poor E-olefin selectivity of the triphenylphosphonium ylide of 24.7 with aldehyde 
 29 
24.6, the described conditions provided the best results to yield a 2:1 E:Z mixture 
with 41% yield of the desired E-olefin.  Fortunately, the Toogood group found the 
undesired isomer could be converted to E-isomer 24.8a, thus completing the synthesis 




















































































 Achieving the necessary macrolactamization for completing the phosphatase 
inhibitor proved to be fraught with complications.  Utilizing Schreiber’s cyclization 
conditions provided the cleanest product, by a small degree, but was not reproducible 
(Scheme 25).  Cyclization with pentafluorophenyl diphenylphosphinate (FDPP) 
proceeded smoothly and consistently, while utilizing diphenylphosphoryl azide 
(DPPA)46 provided yields of only 26%.  Investigation of the N-methyldehyrobutyrine 
residue containing variant 25.2 was expected to provide a higher yield of cyclized 
product due to additional conformational constraint enforced by the olefin, yet 
cyclization provided a 1:4 mixture of desired product 25.3 to the C22 epimer.  Similar 
 30 
results were obtained in synthesizing 5-[L-Ala]-motuporin.  Noting additional 
epimerization during saponification to the natural product, the authors suggest that 
future endeavors employ acid labile carboxyl protecting groups.  Subsequent assays 
showed that 5-[L-Ala]-motuporin was a slightly weaker inhibitor of PPA compared to 
(–)-motuporin, indication diastereomers of motuporin and motuporin analogues may 
































































































































 Just sixteen days after the publication of the Toogood investigations, the 
Panek group report was revealed to the scientific community,47 with a further 
publication in 200248 providing the synthesis in greater detail with improved 
macrocyclization conditions.  Panek’s report featured introducing six of the eight 
stereogenic centers through asymmetric crotylsilane bond constructions, yet another 
approach to constructing Abba, and a method for late stage introduction of the diene 
within the valine-Abba dipeptide. The valine-Abba dipeptide synthesis initiated with 
 31 
acetal 26.1 (Scheme 26), where BF3•OEt2 promoted addition of (S)-chiral silane 26.2 
to afford homoallylic ether 26.3 in 92% yield with 10:1 syn/anti diastereoselectivity.  
Ozonolysis followed by a dibromo-olefination and a subsequent Corey-Fuchs 
reaction, where the acetylenic anion is trapped by MeI to provide acetylene 26.4.  The 
acetylene was then transformed into dipeptide 26.6 by a hydrozirconation/Negishi 
coupling strategy with iodide 26.5 to generate valine-Abba dipeptide 26.6 in 81% 
yield with exquisite selectivity for the desired diene isomer.  The success of the cross-
coupling was nested in the double transmetallation of a low kinetic barrier 








































1. Cp2Zr(H)Cl, 1 h

























 Also notable was the Panek group’s approach to the penultimate 
macrolactamization.  TFA deprotection of the amine Boc group of acyclic 27.1 
provides an amine ready for HATU coupling with the C26 carboxylic acid, yielding 
adduct 23.2 in 79% yield.  Further treatment with 2 N Ba(OH)2 provided the natural 
product in 52% yield, constituting a 16 linear step synthesis (from chiral crotylsilane 
































































 The Armstrong group reported an Ugi four-component coupling reaction to 
synthesize the 2-(N)-methylaminobutenyl residue and a Matteson dihalo-
methyllithium insertion methodology49 for constructing the C26-C29 3-
methylaspartyl residue in their 1999 total synthesis.50  Use of the Ugi technology was 
postulated to overcome the difficult coupling of a secondary amine and a carboxylic 
acid using standard peptide coupling methods.  Combining protected acid 28.1 
(Scheme 28), aldehyde 28.2, methylamine (28.3), and cyclohexenyl isocyanide (28.4) 
provided cyclohexenamide dipeptide 28.5 as a mixture of separable diastereomers, 
which upon treatment with preheated aqueous hydrochloric acid provided free 
carboxylic acid 28.6 (47% over 2 steps).  The diastereomers were taken through the 
synthesis as elimination in the latter part of the synthesis renders the mixture 
inconsequential.  Compared to the traditional route, which afforded 
diastereomerically pure 28.6 in 21% overall yield in 4 steps, the authors noted the 






































59%28.1 28.2 28.3 28.4
28.528.6  
 Synthesis of the C26-C29 3-methylaspartyl residue began with triisopropyl 
borate 29.1 which was subsequently transformed into protected alcohol 29.2 (Scheme 
29).  Chain extension was affected with dichloromethyllithium followed by 
subsequent ZnCl2 addition to instigate rearrangement of the ate-complex to provide 
α-chloroborate ester 29.3.  Stereospecific chloride displacement generates the α-
methyl borate, followed by homologation to α-bromoborate 29.4.  Conversion to the 
azide 29.5 occurred under phase transfer catalyst conditions, notably the only step 
utilizing this methodology that yielded any detectable amount of diastereomer (in 
accord with Matteson’s observations).  Final homologation followed by oxidative 
removal of boron (where order of addition of the NaOH and H2O2 proved to be 
nontrivial) provided the C26-C29 3-methylaspartyl residue 29.6, which after 









































































29.6 29.7  
1.5 Tautomycin 
 Tautomycin was reported in 1987 by Isono and co-workers as an isolate from 
soil bacteria Streptomyces spiroverticillatus that exhibited potent antifungal activity 
against Sclerotinia sclerotiolum (Figure 5).51  Later, it was reported that tautomycin 
induced a morphological change in human leukemia cells K56252 and inhibited PP1 
and PP2A with IC50 of 22-32 with a weak preference for PP1.53  It was found that the 
anhydride moiety along with the C18-C26 region was crucial for activity, with the 
C1-C17 spiroketal bearing region varying affinity between PP1 and PP2A.54  Since 
differentiation of the roles of PP1 and PP2A require specific inhibitors of each, and 
specific inhibitors of PP1 are scarce,54 efforts towards to total synthesis of tautomycin 





























Figure 5 Tautomycin 
 The first total synthesis was reported in 1994 by Oikawa and Ichihara’s 
group,55 where derivatizations and degradations of the natural product provided 
insight into the synthetic route they implemented.56  Key to the synthesis was the 
coupling of two large subunits, the western aldehyde 30.1 and the eastern ketone 30.2 
(Scheme 30).  Synthesis of the eastern spiroketal was to be afforded by spiroketal 
















































 Synthesis of the C1-C10 fragment reached a crucial juncture upon coupling 
sulfone 31.1 (Scheme 31) with 2-methyl-δ-valerolactone (31.2) to yield ketone 31.3 
as a mixture of four isomers.  MOM deprotection and concomitant spiroketalization 
occurred with TMSBr, followed by warming to 0 ºC to provided crystalline 
 36 
thermodynamically favored spiroketal 31.4 as a single diastereomer.  Desulfurization 
and subsequent acetal reduction provided tetrahydropyran 31.5 with high regio- and 
stereoselection.  Further elaboration including Mitsunobu inversion of the C6 carbinol 
provided the C1-C10 fragment 30.4, illustrating the utility of the spiroketal templated 















































 Coupling of the C1-C10 fragment 30.4 with the C11-C18 fragment 30.3 
provided western ketone 30.2 after some additional linear modifications.  The 
essential coupling the western ketone 30.2 with the eastern aldehyde 30.1 was then 
investigated (Scheme 32), with the authors noting that the desired product 
necessitated an anti-Felkin aldol to achieve the requisite diastereomer.  Utilizing 
LiHMDS to generate a lithium enolate provided a the undesired C22-(S) epimer 
preferentially, and using Evans’ chlorotitanium enolate method provided only 15% 
desired C22-(R) epimer 32.1 along with 48% of the undesired epimer.  While the 
epimers could be easily separated, the authors extensively explored more efficient 
conditions.  Highly selective coupling was attained by utilizing Mukaiyama aldol 
conditions, where ketone 30.2 is converted to the silyl enol ether followed by 
 37 
treatment with aldehyde 30.1 in the presence of TiCl4 afforded the desired C22-(R) 
32.1 as the sole isomer.  The authors posit that the high diastereoselection arrived 
from chelation of the Lewis acid with the α-ether oxygen versus the β-acyl oxygen.  
Subsequent Wacker oxidation of the C1-C2 olefin followed by optimized TESOTf 
mediated anhydride formation provided (+)-tautomycin, confirming the relative and 




















1. TMSOTf, Et3N, 3 ºC
then
TiCl4, CH2Cl2, -78 ! -15 ºC


















1. O2, PdCl2, CuCl
DMF:H2O, 72%
2. TESOTf, 2,6-lut.




























 The Isobe group was next to publish their total synthesis of (+)-tautomycin the 
next year,57 with a full report subsequently detailing their efforts.58  The Isobe group 
divided the molecule into 3 major fragments to facilitate a convergent total synthesis.  
Two key steps stood out towards realizing the total synthesis (Scheme 33): 1. the 
coupling of C17-C26 epoxide 33.1 with C1-C16 sulfone 33.2, and 2. the esterification 













































O 33.1 33.233.3  
 The two key events were performed within 3 steps of each other.  First, 
coupling of the sulfone fragment 33.2 with epoxide 33.1 occurred by generating the 
anion of 33.2 with subsequent addition of BF3•OEt2 activated epoxide 33.1.  This 
provided the western carbon skeleton 34.1 in 78% yield as a mixture of epimers at the 
C16 sulfone.  Subsequent desulfonlylation followed by protecting group manipulation 































































 The esterification had been extensively studied with particularly fruitful 
observations.  One was that TBS protection of the C22 alcohol of 34.2 caused a 
serious steric interaction that hampered esterification (28% yield).  Noting that 
selective esterification of model diols proceeded smoothly, the selective esterification 
of diol 34.2 with fully elaborated anhydride acid 33.1 was attempted under 
Yamaguchi conditions (Scheme 35).  Gratifyingly, protected tautomycin 35.1 was 
























































 Shibasaki’s group published their approach to the natural product in 1996.59  
Their approach to the coupling the C16-C17 bond was envisioned to proceed through 
an aldol reaction60 rather than an epoxide addition as Isobe’s report detailed.  Also 
explored was a similar Yamaguchi esterification to append the maleic anhydride 
fragment, with insight as to an appropriate species to employ issuing from the 
investigations.  Generation of the necessary fragments for providing the aldol 
substrates occurred from 2-deoxyglucose to afford C17-C26 fragment 36.1 (Scheme 
 40 
36) and from (+)-diethyl tartrate to provide C1-C16 spiroketal aldehyde 36.2.  The 
essential aldol condensation was accomplished by generating the dianion of keto-
alcohol 36.1, allowing for addition into aldehyde 36.2 to afford the adduct 36.3 as a 
diastereomeric mixture in 82% yield.  Bis-acylation of the diol 36.3 followed by DBU 
promoted elimination at C16-C17 provided the enone.  While hydrogenation with 
Wilkinson’s catalyst failed, mild conjugate reduction using NaTeH afforded saturated 
ketone 36.4 quantitatively.  Subsequent diastereoselective reduction with L-
Selectride® provided the final stereogenic center at C18 in a 2:1 ratio of desired S to 


































































































 Rigorous investigation of the key unifying esterification highlighted the 
sensitivity of the reaction to remote steric interactions.  Attempting to couple western 
diester acid 37.1 with eastern spiroketal 37.2 (Scheme 37) was deemed plausible 
based on model studies with acid 37.1 under a variety of coupling conditions, all of 
 41 
which proceeded in good yield.  On the actual spiroketal alcohol 37.2, however, 
attempting to couple utilizing DCC in THF provided no product and instead yielded 
dicyclohexylurea adduct 37.3.  Utilizing Keck’s method (DCC, PhMe) with 
DMAP•HCl yielded no DCC adduct 37.3, but also no desired coupling product.  
When three other methods failed to provide any product, the authors reevaluated the 
















































































implicated in the recalcitrant esterification.  Coupling furanyl acid 37.4 with alcohol 
37.5 (only slightly modified from 37.2 to circumvent an unexpected acyl migration 
during TES deprotection) under modified Yamauchi conditions utilizing a large 
 42 
excess of DMAP provided ester 37.6.  Six additional functional group manipulations 
yielded the natural product. 
 Chamberlin and co-workers expounded upon a different approach to (+)-
tautomycin in 1997.61  Production of the natural product was to originate with (S)-
citronellene and (2R,3S)-geraniol epoxide to form the C1-C21 segment of the 
phosphatase.  In this vein, synthesis of the C1-C8 fragment began with selective 
oxidative cleavage of (S)-citronellene (38.1, Scheme 38) via a two step Ireland 
procedure.62  Attempts to convert aldehyde 38.2 to the anti aldol adduct 38.3 
surveyed several types of enantioselective routes, with the authors choosing the 
Duthaler reagent63 due to its excellent enantioselectivity, convenient scalability, and 
consistency. Silylation of the C6 hydroxyl, DIBAL reduction of the ester, and 































1. TBSOTf, 2,6-lut., 94%














 The C1-C8 iodide 38.4 was joined to acetone and C12-C18 iodide 39.1 
(Scheme 39) via a three step, one pot double alkylation procedure to afford the 
 43 
hydrazone, followed by concomitant silyl deprotection and spiroketalization to 
provide ketal 39.2 as a single isomer in 77% overall yield.  While oxidative cleavage 
provided disappointing yields of aldehyde 39.3 (52%) on large scale, the ready 
abundance of 39.2 prevented the step from being insurmountable.  Utilizing the 
Dunthaler reagent once more provided a 7:1 mixture of inseparable isomers, favoring 
adduct 39.4, in 67% yield.  Subsequent saponification (without detectable 
epimerization), Wienreb amide formation and methylation provided the methyl 
































2. H5IO4, Et2O, 52%
Dunthaler's
Reagent
















 To complete the synthesis, anti-Felkin chelation controlled Mukaiyama aldol 
coupling cleanly combined the C1-C21 segment 40.1 with the western ester 40.2 to 
provide a single aldol diastereomer 40.3 after silyl deprotection.  Wacker oxidation 
provided the C1-C2 methyl ketone without notable epimerization, allowing for 
hydrogenolysis to complete the synthesis of the natural product.  In summary, the 
Chamberlin group total synthesis of (+)-tautomycin proceeded in 19 linear steps from 






















TiCl4, CH2Cl2, -78 ºC ! -20 ºC




















1. PdCl2, CuCl, O2, 94%



























 Phoslactomycins A-F and I are a class of polyketide natural products bearing a 
phosphate that exhibit antitumor, antiviral, antibiotic and antifungal properties.64  The 
inhibitory activity selective for human protein phosphatase 2A (PP2A)65 has 
prompted intensive investigations into this class of molecules.  Such investigations 
have yielded the binding site that interacts with the crucial phosphate group,66 the 
cloning and sequencing of the biosynthetic gene cluster,67 and the origin of the 
biosynthetically unusual cis olefins in the natural product.68 
 The first total synthesis of phoslactomycin B was reported by Kobayashi and 
co-workers in 2006,69,70 where the authors initially sought to construct the molecule 
in an analogous manner to the synthetic route utilized for fostriecin.  After 
investigation, however, it was found that certain key transformations such as the 
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RCM of the lactone ring were inefficient in application towards phoslactomycin B, as 























Figure 6 Attempted Ring-Closing Metathesis by Kobayashi and co-workers 
 This observation led to a synthesis where the lactone ring would be afforded 
by Lewis acid lactonization of the acyclic γ-hydroxy ester (Figure 7).  Installation of 
the C8 stereocenter would occur by chelation controlled diastereoselective Grignard 
addition governed by the C9 stereocenter.  The key Z,Z-diene would proceed from 





























Figure 7 Kobayashi’s Retrosynthesis 
 The initial C9 stereocenter was provided by kinetic resolution of racemic (E)-
ethyl 3-hydroxyhex-4-enoate by Sharpless asymmetric epoxidation.  Another 14 steps 
provides ketone 41.1 (Scheme 41), where a diastereoselective vinylmagnesium 
bromide addition provided the C8 stereocenter of 41.2 as a single diastereomer, 
ultimately proven to be the desired configuration upon completion of the molecule.  
Protection of the C8 alcohol followed by ozonolysis and Horner-Wadsworth-Emmons 
olefination produced ester 41.3, setting the stage for completion of the carbon 
 46 
skeleton on the natural product.  Enyne 41.5 was afforded through Sonogashira 
coupling of the acetlyenic carbon with Z-vinyl iodide 41.4.  Installation of the lactone 















































































 Cleavage of the oxazolidinone followed by aldehyde formation and 
olefination provided the acyclic lactone precursor 42.1 (Scheme 42).  Removal of the 
C8 TES group allowed for titanium(IV) isopropoxide mediated transesterification to 
afford lactone 42.2, again noting that attempts to generate the lactone by RCM to fuse 
the C2-C3 olefin were fruitless.  Generation of the Z,Z-diene then commenced by 














1. PPTS (3 mol %)
MeOH:THF (3:1), 86%


























 Completion of the synthesis occurred after Mitsunobu introduction of the 
amine, where deprotection of the C9 PMB group of 43.1 (Scheme 43) in the presence 
of the Z,Z-diene afforded the alcohol in good yield.  Phosphate introduction by the 
phosphoramidite and subsequent oxidation provided fully protected inhibitor 43.2, 
which after acidic deprotection of the silyl groups and palladium mediated 
deallylation yielded (+)-phoslactomycin B.  The total synthesis thus proceeded in 38 




































 The second reported total synthesis came from Hatakeyama’s group in 2008.71  
The authors dissected the molecule as presented in Figure 8 where a Stille-type 
coupling would append the vinylcyclohexyl group onto the carbon skeleton.  RCM 
 48 
would generate the lactone from the acyclic diene, while the amine bearing chain 
from C8 would be incorporated via a Suzuki-Miyaura coupling with a Sharpless 
asymmetric dihydroxylation providing the C8 and C9 stereocenters.  The group 
wished to install the C4 and C5 stereogenic centers through an asymmetric 
pentenylation in a Brown or Roush asymmetric crotylation fashion, a feat that was 





















Figure 8 Hatakeyama’s Retrosynthetic Dissection 
 The risky asymmetric pentenylation of aldehyde 44.1 was first attempted with 
Brown conditions (Scheme 44).  Initially, the pentenyl borane reagent was prepared 
from 2-pentenylmagnesium bromide and (+)-Ipc2BOMe to provide a 98% yield of a 
1:3 desired syn to undesired anti mixture.  The authors deduced that a partial 
isomerization was occurring when preparing the Grignard from (Z)-2-pentenyl 
bromide, and thus opted to use 2-pentenylpotassium.  The Brown reagent prepared 
from 2-pentenylpotassium yielded highly diastereo- and enantioselective 
pentenylation to provide the syn isomer 44.2 in 82% yield as a sole diastereomer in 
93% ee.  This set the stage for the Suzuki-Miyaura coupling step, where the C8-
aminoethyl group was appended smoothly to provide alcohol 44.3.  Acryloylation of 
alcohol 44.3 allowed for ring-closing metathesis of the resulting acrylate to cleanly 
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cyclize to lactone 44.4 in 76% yield.  This interesting result contrasts with the 
Kobayashi group’s investigations, vide supra.  The C8 and C9 stereocenters were then 
set by utilizing Super-AD-mix with (DHQD)2-PHAL as a chiral ligand to afford a 
87:13 mixture of the C8-C9 dihydroxylated product 44.5 with the minor C6-C7 
dihydroxy isomer.  It was also found that diol 44.5 was generated as an exclusive 
enantiomer, suggesting a concomitant kinetic resolution of 44.4 during the reaction.  
Taking 13 more steps to provide (+)-phoslactomycin B, the total synthesis proceeded 









t-BuOK, n-BuLi, -78 ºC
then (+)-Ipc2BOMe, BF3•OEt2




Pd(dppf)2 (5 mol %)







































 The only (as of this writing) synthesis of phoslactomycin A, depicted in 
Figure 9, that has been reported is that of the Koert group in 2009.72  The group 
utilized transformations similar to those described for the phoslactomycin B syntheses 
(vide supra) as well as for the synthesis of leustroducsin B,73,74 with key contributions 
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in the synthesis of the C14-C21 cyclic fragment and the coupling of the C13-C14 




















Phoslactomycin A  
Figure 9 Phoslactomycin A 
 Synthesis of the C14-C21 fragment began with conjugate asymmetric addition 
of E-styrylboronic acid to cyclohexenone (45.1) mediated by Hayashi’s catalytic 
conditions75 to afford ketone 45.2 in 96% yield with 94% ee (Scheme 45).   Sodium 
borohydride reduction and subsequent TBS protection provided alkene 45.3, followed 
by ozonolysis, Stork-Zhou olefination, and stannylation to give vinyl stannane 45.4.  























































 The final union of the C14-C21 fragment 45.5 to the C1-C14 subunit 46.1 was 
carefully examined (Scheme 46).  While a Pd-catalyzed Stille reaction would be 
suitable for alkenyl iodide couplings with alkenyl stannanes, the presence of the C9 
allyl protected phosphate gives pause to palladium mediated couplings.  Utilizing Cu-
 51 
mediated Liebeskind coupling76 prevents side reactions, and copper(I) thiophene 
carboxylate (CuTC) proved to provided the desired coupling to afford the protected 
inhibitor 46.2 in 61% yield.  The advantage of this method is clear as only a 
protecting group removal remained in the total synthesis, which was enacted with 



































































phoslactomycin A  
 
1.7 Spirastrellolide A Methyl Ester 
 The isolation of spirastrellolide A and spirastrellolide A methyl ester (Figure 
10) from Spirastrella coccinea was reported in 2003 by Andersen and co-workers, 
drawn to discover the inhibitor responsible for mitotic arrest in their cell-based 
assays.77  More, although not complete, stereochemical detail was provided in 2004, 
but of interest was the fact that spirastrellolide A was a potent inhibitor of PP2A (IC50 
 52 
= 1 nM) that did not effect tubulin polymerization as did other antimitotic sponge 
macrolides.78  Instead, it accelerates the entry of cells into mitosis from other stages 
of the cell cycle then induces arrest, similar to the okadaic acid class of molecules.78  
The 47 carbon backbone of the molecule contains 21 stereocenters, three cyclic ether 
subunits including the unique DEF chlorosubstituted 5,6,6-trioxadispiroketal, and an 
exocyclic non-conjugated Z,E-diene.  Given the small amount of spirastrellolide 
which was isolated coupled with the unique architecture and biological activity, with 
the added complication of several unresolved stereochemical issues, earnest 



















R = H, Spirastrellolide A















Figure 10 Spirastrellolide A and spirastrellolide A methyl ester 
 The first and, as of this writing, only total synthesis of the spirastrellolide 
family was reported in back to back publications by Paterson and co-workers in 2008 
on their work synthesizing spirastrellolide A methyl ester.80  Key to their efforts was 
the efficient and improved synthesis of the C25-C40 bisspiroketal fragment 47.7, 
which had been previously reported (Scheme 47).81 Oehlschlager-Brown 
chloroallylation82 of aldehyde 47.1 followed by methylation enantioselectively 
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provided ketone 47.2 in good yield with excellent diastereoselectivity.  Formation of 
the boron enolate of 47.2 allowed addition to aldehyde 47.3 which, after elimination, 
provided triene 47.4 on 10 gram scale.  Conversion of triene 47.4 to diene dione 47.5 
allowed for the pivotal tandem double-Sharpless asymmetric 
dihydroxylation/spiroketalization tactic, where subsequent TES protection provided 



















-95 ºC ! -78 ºC








1. Cy2BCl, Me2NEt, 0 ºC
then A.3, -78 ºC, 88%





































 The crucial coupling of the C17-C24 subunit with the DEF subunit 47.7 could 
be afforded through a modified Julia olefination, however it was rather lengthy and 
faced disappointing yields.  This led the Paterson group to explore an ambitious sp2-
sp3 coupling of iodide 48.1 with hydroborated alkene 48.2 (Scheme 48), which 
afforded the trisubstituted olefin 48.3 in 83% yield.  Substrate controlled bis-
hydroboration of alcohol 48.3 provided the C23 stereocenter, followed by protection 
 54 
and formation of the C17 aldehyde 48.4.  Addition of the lithium anion of C1-C16 
bearing alkyne 48.5 to aldehyde 48.4 provided a mixture of epimeric alcohols, 
rendered inconsequential by the subsequent Lindlar reduction and oxidation of the 
epimeric alcohols to the enone.  All three PMB ethers were cleaved with DDQ (with 
the unexpected TES deprotection at C23) to achieve stereoselective BC 
spiroacetalization affording hexacyclic diol 48.6 and a mere two step oxidation 















































































 The critical macrocyclization of seco acid 49.1 (Scheme 49) was found to 
occur quite readily via the Yamaguchi protocol to rapidly yield the corresponding 
macrolide 49.2.  What seemed to be a simple selective deprotection of the primary 
C40 TBS group turned out to be fraught with difficulty, however, necessitating global 
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deprotection and reprotection followed by transformation to the olefin and a gentle 
cross-metathesis (which did not degrade starting material) to provide allylic carbonate 
49.3.  A crucial π-allyl Stille cross-coupling performed extremely well to append 
stannane 49.4 to provide the desired 40E,43Z diene, where cleavage of the acetonide 
groups yielded (+)-spirastrellolide A methyl ester.  In total, the pioneering synthesis 






















































































1.8 Okadaic Acid 
 Okadaic acid (Figure 11) was first isolated as a potent antitumor agent from 
Pacific and Caribbean marine sponges Halichondria okadai and Halichondria 
 56 
melanodocia (respectively) during a search for chemotherapies.83  The isolation group 
elucidated the structure via X-ray crystallography.  In 1982, Yasumoto and co-
workers identified okadaic acid as the major diarrhetic shellfish toxin in Mytilus 
edulis and concluded the natural product was accumulated from a dinoflagellate, 
Dinophysis fortii, as the original producer.84  It was found that okadaic acid is a 
potent inhibitor of PP1 and PP2A,85 and is the most widely used tool for probing the 
roles of these phosphatases.86  Comprehensive and definitive studies to determine the 
structural basis of inhibition, however, have been limited by lack of designed 
structural variants.87  Combined with the exquisite architecture of the molecule, these 
attributes have provided much impetus in the rational design of synthetic pathways to 
































Figure 11 Okadaic acid 
 Isobe and co-workers reported the first synthesis of okadaic acid in 1986.88,89  
The group divided the molecule into three segments: the C1-C14 containing segment 
A, C15-C27 dispiroketal segment B, and C28-C38 segment C.  Segment A was to be 
synthesized from two glucose derivatives, initiating with 2-acetoxy glucal 50.1 
(Scheme 50).  Generation of 50.2 allowed for deprotection and oxidation of C1 
followed by Wittig olefination, formation of epimeric chloroethylglycosides and ester 
reduction to yield allylic alcohol 50.3.  The key acyclic C2 hydroxyl group was 
introduced through selective oxymercuration/demercuration to provided diol 50.4.  
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Acetonide protection of the diol masked the C2 hydroxyl group until the final stages 
of the synthesis, while the chloroethyl glycoside was cleaved with sodium sulfinate to 
provide lactol 50.5, where oxidation to the lactone 50.6 by molecular bromine in a 























































 The C9-C14 fragment of segment A relied on a substrate directed approach to 
introduce the C13 stereogenic center.  Formation of heteroolefin 51.2 from D-glucose 
derivative 51.1 (Scheme 51) occurred in six steps and allowed for application of a 











































heteroconjugate addition of methylmagnesium bromide stereoselectively installed the 
C13 methyl group in alcohol 51.3.  Subsequent acylation provided protected lactol 
51.4 as the necessary precursor for generating segment A. 
 The group approached segment C from lactone 52.1, available in nine steps 
from D-glucose (Scheme 52).  Opening of the lactone by the anion of protected butyl 
sulfone 52.2 provided α-sufinyl ketone 52.3.  Reduction followed by immediate 
treatment with PPTS in refluxing ethanol with 2,2-dimethoxypropane as a 
dehydrating agent provided spiroether 52.4 in 81% yield.  Benzyl deprotection and 
oxidation of the unmasked alcohol produced aldehyde 52.5, which after Peterson 
olefination with PhS(TMS)2CLi and oxidation of the sulfide produced 52.6.  
Chelation controlled heteroconjugate addition afforded the C29 methyl group 


































































 Final elaboration of the molecule was set into motion by the coupling of 
segment C sulfone 52.7 with segment B aldehyde 53.1 to afford sulfonate alcohol 
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53.2 (Scheme 53).  Subsequent oxidation of the C27 alcohol followed by 
desulfurization and sodium borohydride reduction produced BC alcohol 53.3 as a 
single C27 isomer.  Six further modifications allowed for union of the A segment 
53.5 with BC aldehyde 53.4, which after elimination provided the unified molecule 
53.6.  Acetonide deprotection, two step oxidation to the C1 carboxylic acid, and 
benzyl deprotection provided the first totally synthetic okadaic acid, a feat that 





















































































































 It was eleven years until the next reported total synthesis of okadaic acid.  The 
Forsyth group synthesis of okadaic acid was published in 1997,91 with additional 
details provided in 1998.87,92  While the authors note the disconnections in their 
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synthesis are similar to Isobe’s work, the authors caution that their route relies upon 
incorporating maximum functionality in each fragment.  These highly functionalized 
fragments were then to be utilized in direct and chemoselective coupling methods to 
minimize post-coupling transformations. 
 The C1-C14 fragment was assembled from alkyne 54.1 (Scheme 54), 
generated from known pentylidene protected triol 54.2, and lactone 54.3 which arises 
from Isobe’s isopropyl glycoside 54.4.  Addition of the lithium acetylide derived from 
54.1 to lactone 54.3 provided the crude ynone that was immediately silylated.  
Subsequent conjugate addition of dimethylcuprate provided β-methyl enone 54.5, 
which upon treatment of the crude enone with TsOH•H2O promoted spiroketalization 
to give 54.6, analogous to Isobe’s work.  Investigations into incorporating the α-
hydroxyl, α-methyl carboxylate at this early stage initially sought to add lactate 
pivalidene enolate 54.8 to C3 through halide or sulfonate displacement, but numerous 
attempts proved unsuccessful, potentially due to the crowded steric environment.  
Addition of enolate 54.8 to the C3 aldehyde 54.7, however, was successful, albeit in 
much lower than anticipated facial selectivity in forming the C2 stereocenter of 54.9.  
The authors reason this may be due to unfavorable double diastereoselection between 
the mismatched pair, where the secondary steric interactions erode the facial 
selectivity based on the t-butyl substituent.  Subsequent deoxygenation of C3 and 
deprotection/oxidation of C14 of 54.9 formed C1-C14 aldehyde 54.10, primed for 
coupling.  This provided an 11 step synthesis of C1-C14 fragment 54.10 from lactone 






















































































1. n-BuLi, then 54.3,
then TMSCl, 82%


























Realization of the total synthesis relied upon coupling aldehyde 54.10 with 
advanced intermediate 55.1 in order to unify the carbon skeleton (Scheme 55).  The 
Horner-Wadsworth-Emmons reaction was performed under the mildly basic 
Masamune-Roush conditions to fuse the two fragments, providing enone 55.2 as a 
single olefin isomer.  Regio- and stereoselective reduction of enone 55.2 was 
accomplished with (S)-CBS and BH3 to yield the (R)-allylic alcohol 55.3.  Since 
alcohol 55.3 was partially cyclized following acidic workup of the CBS reduction, the 
crude product mixture was directly subjected to acid-catalyzed spiroketalization to 
yield protected okadaic acid 55.4.  A two step deprotection completed the total 
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 Ley and co-workers reported their approach to the total synthesis of the 
inhibitor in 1998,93 where the authors intended to provide a route to the natural 
product by chemical methods developed in their laboratories.  In producing the C1-
C14 fragment, the group chose to employ chemistry specifically developed for the 
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asymmetric synthesis of α-hydroxy acids.  Glycolic acid was reacted with (S,S)-
bis(dihydropyran) 56.1 (Scheme 56) in the presence of Ph3P•HBr to generate 
dispiroketal 56.2 as a diastereomerically pure crystalline solid.  The authors explain 
that the selectivity is governed by the strong equatorial preference of the phenyl 
groups in combination with the optimal anomeric effects at the newly formed spiro-
centers.  Sequential alkylation of dispiroketal 56.2 with methyl iodide and the allyl 
bromide yields 56.3, which following by Sharpless dihydroxylation and Sharpless-
Kolb epoxidation provides epoxide 56.4.  Further vinyl addition, hydroboration, and 
TPAP oxidation provided lactone 56.5 as the C1-C7 component.  Further elaboration 
















then BuLi, MeI, 87%
2. LDA, DMPU











t-BuOH:H2O, 0 ºC, 82%
2. (MeO)3CMe, PPTS
then AcBr, 80%

























































 The generation of the C27-C28 fragment employed a Ley protocol for 
spiroketalization.  Reaction of the anion from 2-(phenylsulfonyl)tetrahydropyran with 
iodide 57.1 (Scheme 57) followed by treatment with camphorsulfonic acid in 
methanol produced spiroketal 57.2 in 90% yield.  In the reaction, alkylation of iodide 
57.1 is followed by spontaneous antiperiplanar elimination of sufinic acid.  Upon 
addition of camphorsulfonic acid, acid mediated isopropylidene deprotection and enol 
ether protonation instigate spirocyclization.  Subsequent oxidation to the aldehyde 
followed by Corey-Fuchs elaboration to the alkyne 57.3 provides the necessary C27-
C38 fragment.  This was coupled to the C15-C26 central subunit 57.4 via 
deprotonation of alkyne 57.3 and transmetallation with dimethylaluminum chloride 
provides a Lewis acidic reagent that increases the sulfone reactivity by chelating with 
the ortho-methoxy group on the sulfone aryl ring, providing fused alkyne 57.5 in 70% 
yield.  An additional eight steps provided aldehyde 57.6 for completion of the carbon 
skeleton.  Coupling of aldehyde 57.6 with the anion of 56.6 provides the desired E-
olefin 57.7 as the major product.  Silyl deprotection followed by reductive removal of 
the benzyl group and diphenyldispiroketal provided okadaic acid.  The Ley group 
synthesis proceeded in 60 steps, with 24 step longest linear sequence from (S,S)-
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 Fostriecin (CI-920, Figure 12) is a biologically potent metabolite first isolated 
from Streptomyces pulveraceus in 1983 by workers at Warner Lambert-Parke 
Davis.94  It displays in vitro activity against a broad range of cancerous cell lines 
including lung cancer, breast cancer, and ovarian cancer,95 as well as in vivo 
antitumor activity.  In addition, fostriecin has demonstrated activity against leukemia 
(L1210, IC50 0.46 µM and P338).96  Its mode of action appears to operate via an 
inhibitory pathway of the mitotic entry checkpoint. Evidence of this pathway is 
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shown in fostriecin's potent and selective inhibition of a number of protein 
phosphatases.97,98  In 1997, Boger and coworkers determined the relative and absolute 
stereochemistry in fostriecin that confirmed previous assignments in a family of 
biologically active and structurally related natural products, including leustroducsin 
B, phospholine (phoslactomycin B), and phosphazomycin C.99  It is the most selective 















 The Boger group published the first total synthesis of fostriecin in 2001.101  
The synthesis initiated with the generation of the lactone skeleton from 5-hexenoic 
acid (58.1, Scheme 58).  Conversion to the ester followed by Sharpless asymmetric 
dihydroxylation provided the C5 stereocenter in 88-92% ee, which upon 
recrystallization provided the diol 58.2 in 98% ee.  Selective protection of the primary 
alcohol followed by TFA-mediated lactonization and subsequent deprotonation in the 
presence of PhSeBr allowed for formation of α-phenylselenyl lactone 58.3.99 Lactone 
58.3 was summarily oxidized to the corresponding selenoxide followed by in situ 
elimination to generate the internal olefin.  Subsequent Dibal-H reduction and 
protection with isopropanol provided lactol 58.4.  Deprotection of the primary 
TBDPS ether allowed for oxidation to aldehyde 58.5, the necessary partner for 





































 Generation of the C7-C18 backbone realized installation of the C11 hydroxyl 
group via a Sharpless asymmetric dihydroxylation of dihydrofuran 59.1 to produce 
lactol 59.2 (Scheme 59).  The newly formed C11 hydroxyl group was then TBS 
protected and the lactol condensed with the Still-Gennari phosphonate 59.3 to yield 
the Z-olefin bearing ester 59.4.  The authors note that attempts to utilize the Stork-
Zhao protocol102 to afford the Z-iodoalkene were not successful.  The two-step 
reduction/oxidation protocol to generate the aldehyde 59.5 from ester 59.4 proceeded 
smoothly, at which point the authors attempted to form the Z,Z-iododiene only to 
witness modest stereoselectivity, an inability to separate the isomers, and 
interconversion of the isomers during purification.  Instead, selective generation of 
the chromatographically stable Z,Z-bromodiene 59.6 was achieved via Corey-Fuchs 
homologation of aldehyde 59.5 followed by exchange of the PMB group for an acetyl 
group and subsequent selective reduction of the dibromide with Bu3SnH-Pd(PPh3)4.  
Vinyl bromide 59.6 then underwent Stille coupling under rigorously investigated 
conditions to yield triene 59.7 in good yield with excellent preservation of the olefin 
geometries present.  Deaceylation/oxidation of triene 59.7 allowed for addition of the 
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anion of diethyl methylphosphonate, where addition in toluene was found to be far 
superior than addition in THF.  Oxidation of the resulting epimeric mixture provided 

































































 Coupling the ketophosphate 59.8 with aldehyde 58.5 afforded α,β-unsaturated 
ketone 60.1 (Scheme 60).  Installation of the methyl group via an organometallic 
addition proved to be difficult, with the authors discovering the best results required 
introduction of a toluene solution of ketone 60.1 to a MeLi/CeCl3 slurry in THF at -78 
ºC to provide tertiary alcohol 60.2 as a 3:1 mixture of diastereomers.  The TES group 
was selectively deprotected (with concomitant exchange of the isopropoxy group of 
the lactol for ethoxy) under acidic conditions and the C8 alcohol selectively protected 
by addition of TBSOTf at -20 ºC, where at this elevated temperature (versus -78 ºC, 
which provided C9 protection) the C9-to-C8 O-silyl migration presumably occurs to 
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deliver the selectively protected alcohol 60.3.  Deprotection of the lactol followed by 
oxidation with Fetizon’s reagent to provide the lactone allowed for phosphorylation 
to yield protected fostriecin 60.4.  Brief treatment with HF (15 min.) allowed for 
cleavage of the PMB esters followed by addition of pyridine to slowly deprotect the 
silyl ethers under buffered conditions, thereby affording the first total synthesis of the 
natural product (+)-fostriecin in 27 linear steps.  The authors did not provide a yield 
























THF, -78 ºC, 5 min









1. PPTS, EtOH, 93%
2. TBSOTf, 2,6-lut.








1. 0.5 M HCl, acetone
-15 ! 0 ºC, 50%
2. Ag2CO3•Celite, 81%













aq. HF, CH3CN (15 min)
then pyridine (1 week)
(+)-fostriecin
 
 The Jacobsen group provided the second total synthesis of the natural product 
later that year,103 embarking upon the synthesis via synthons derived from their 
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hydrolytic kinetic resolution methodology104 and their asymmetric hetero-Diels-Alder 
methodology.105  Application of the former to the epoxide derived from methyl vinyl 
ketone (61.1, Scheme 61) proved to be challenging as under standard conditions the 
catalyst precipitated as the reduced complex with low substrate conversion.  The 
solution to the problem involved running the reaction under O2 atmosphere instead of 
































Generation of the western lactone skeleton was approached through the 
aforementioned asymmetric hetero-Diels-Alder methodology.  Formation of the 
desired lactol precursor106 in the total synthesis proceeded with a formal hetero-Diels-
Alder annulation of diene 62.1107 and aldehyde 62.2108 mediated by catalyst 62.3 
(Scheme 62) to provide benzylated lactol 62.4 in high enantiomeric excess.  
Subsequent deprotection and epimerization of the anomer leads to terminal alkyne 
62.5, followed by conversion to the isopropyl acetal 62.6.109  This protocol efficiently 
 71 
established the C5 stereogenic center as well as provides a synthon readily available 









4 Å M. S., 90%
94% ee, d.r. 95:5
1. TBAF, THF, 0 ºC
2. 1 mol % TsOH, 2 h
3. recrystallization




















 The Jacobsen group desired to directly append the lactone skeleton while 
simultaneously establishing the C8 stereogenic center via a direct hydrometallation of 
the terminal alkyne with subsequent addition of this species into the epoxyketone 
61.1.  This approach was predicated on Wipf’s hydrozirconation110/zinc 
transmetallation protocol111 for addition to aldehydes, where the Jacobsen group 
posited that the enhanced electrophilicity of the α-oxy ketone could exhibit enhanced 
reactivity in contrast to a typical ketone's unreactive nature.  The Jacobsen group 
found that employing equimolar quantities of Schwartz’s reagent, alkyne 62.6, and 
Me2Zn with 1.5 equivalents α-epoxyketone 61.1 at 25 ºC provided 63.1 in >30:1 
diastereoselectivity and 45% yield (Scheme 63).   TES protection of the C8 alcohol 
followed by dithiane addition, two-step lactol oxidation, cleavage of the dithiane and 
C9 PMB protection afforded ketone 63.2.  Ketone 63.2 was transformed 
stereoselectively into the desired C11 alcohol 63.4 by Noyori’s transfer 
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2. Me2Zn, -78 ºC
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2. n-BuLi, 63.2, 89%






































2. AgNO3, NIS, 95%
3. DDQ, 100%






















OTBDPS1. PCl3, pyr.; then PMBOH;
then t-BuOOH, 65%
2. HF (aq), CH3CN, 35 min;
then pyr., 2 d, 45%
(+)-fostriecin
 
Four more steps, including diimide reduction to set the C12-C13 Z-olefin, provided 
vinyl iodide 63.5 which was transformed to the desired Z,Z,E-triene 63.6 via Stille 
coupling.  Phosphate installation and global deprotection were performed in an 
analogous manner to the Boger group synthesis to provide (+)-fostriecin in 19 linear 
steps from commercially available material. 
 The Falck group’s report detailing their total synthesis of the natural product 
appeared in 2002.113  Enantioselective generation of the C11 hydroxyl group occurred 
with asymmetric allylation of propynal 64.1 followed by protection of the alcohol to 
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produce alkyne 64.2.  The terminal alkene was then oxidized to the aldehyde and 
subsequently homologated to (E)-α,β-unsaturated ester 64.3, allowing for Sharpless 
asymmetric dihydroxylation to provide the C8 and C9 stereocenters as a 3:1 mixture 
with the undesired diastereomeric diol.  Acetonide protection allowed for separation 
of the diastereomers to provide alkyne 64.4.  Bromination of the terminal alkyne 
followed by diimide reduction set the C12-C13 Z-olefin, which was subjected to a 






allylMgBr, -100 ºC, 1 h
then H2O2, NaOH, 0 ºC
2. TBDPSCl, imidazole






1. OsO4, NMO, 4 h
then NaIO4/SiO2, 4 h
2. EtO2CC(Me)PPh3








4 ºC, 48 h
2. CH2C(OMe)Me
PPTS, CH2Cl2









1. NBS, AgNO3, 2 h
2. (KO2CN=)2, AcOH
3. LiAlH4, 58% (3 steps)
4. (COCl)2, DMSO










 Installation of the final stereogenic center occurred by homologation of 
aldehyde 64.5 to α,β-unsaturated aldehyde, followed by asymmetric allylation to 
stereoselectively afford the C5 alcohol 65.1 (Scheme 65).  Acylation with acryloyl 
chloride provided the ring closing metathesis (RCM) primed ester, where ring closing 
metathesis with Grubbs II catalyst yielded the essential unsaturated lactone 65.2.  
Acetonide deprotection provided the diol, which was summarily modified via Suzuki-
Miyaura coupling to provide triene 65.3.  Protection of the C8 alcohol prevented 
formation of a cyclic phosphate upon phosphorylation, a problem encountered during 
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the authors’ attempts at selective phosphorylation.  Deprotection of the 
trimethylsilylethyl phosphate allowed for the authors to avoid acidic cleavage 
conditions, such that utilizing Olah’s reagent for 5 days provided (+)-fostriecin and 












allylMgBr, -100 ! 23 ºC












CH2Cl2, 0 ºC, 2 h, 86%
2. Grubbs II, CH2Cl2









1. Montmorillonite K 10

















-20 º C, 1 h, 86%
2. PCl3, pyr., 10 min
then TMSCH2CH2OH
then H2O2, 83%














 November of that same year, the Hatakeyama group’s synthesis of fostriecin 
was unveiled to the literary arena.114  The first stereogenic center, the C5 center, was 
set via Brown asymmetric allylation of aldehyde 66.1 to afford alcohol 66.2 (Scheme 
66), where the enantiopurity was not determined due to instability issues.  
Acryloylation allowed for selective RCM of the terminal alkenes to form lactone 
66.3, where the authors noted that no RCM product from participation of the 
conjugated diene was observed.  Diene 66.3 was determined to be a 77% ee mixture 
by chiral HPLC, where the subsequent selective Sharpless asymmetric 
dihydroxylation of the less hindered olefin produced enantiomerically pure C8,C9 
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diol 66.4 as a single regio- and diastereomer in 80% yield.  The authors note that the 
asymmetric dihydroxylation was accompanied by a kinetic resolution, thereby 






































66.4, 100% ee 66.3, 77% ee
66.266.1
 
 Five steps later, installation of the C12-C13 Z-olefin was attempted on ynone 
67.1 utilizing Kishi’s solventless conditions115 only to afford the thermodynamically 
stable, and undesired, E-isomer.  Experimentation by the authors found that running 
in acetone with 2 equivalents of NaI and 1 equivalent of AcOH at room temperature 
provided the desired Z-iodide 67.2 as the major product of a chromatographically 
separable 91:9 mixture in 63% yield (Scheme 67). Following selective TES 
deprotection of the C9 hydroxyl, generation of the C11 stereogenic center occurred 
via Evan’s anti-selective reduction.116  The desired diol was afforded in 84% de, 
which was selectively TBS protected at the C11 hydroxyl to afford the C9 exposed 
alcohol 67.3.  This was then transformed into the triene via Stille coupling, 
phosphorylated at C9 to yield the bis-allyl phosphate, phosphate deprotected with 
Pd(PPh3)4, and silyl deprotected to provide fostriecin.  Overall, the total synthesis of 





















I 1. 47% HF:pyr:H2O:MeCN
(1:4:2:20), 0 ºC, 81%
2. Me4NB(OAc)3H, AcOH
MeCN, -30 ºC, 99%, 84% de
























 Imanishi’s group reported their approach to the total synthesis in 2003, where 
they include an interesting attempt towards installing the triene via a Wittig reaction 
as well as utilizing a previously unutilized method to install the C9 phosphate.117  
With regard to the Wittig, the group decided to probe whether an ylide conjugated 
with a Z-olefin could form a Z-olefinic bond.118  The group thus attempted 
condensation of their advanced aldehyde intermediate 68.1 with Wittig salt 68.2 
under a variety of conditions, but all attempts provided the E-isomer product 68.3 
(Scheme 68).  The authors postulate that serious steric repulsion prevents the 
formation of the desired C12-C13 Z-olefin in this fashion.  They therefore opted to 
generate the Z-iodide via the Stork-Zhao protocol102 followed by acetonide 
deprotection to afford triol 68.4.  Five more steps provided fostriecin in 7% yield 















NaHMDS, THF, -78 ! 0 ºC












HMPA, THF, -100 ! 0 ºC
61%, Z:E = 4:1












 The Imanishi group attempted selective phosphorylation of the C9 alcohol 
(with a C11 protected alcohol) in the presence of the unprotected C8 tertiary alcohol 
only to yield diphosphate or a cyclic phosphate as explicitly found in similar 
investigations by the Falck group.113  The Imanishi group, however, sought to utilize 
a selective cleavage of the cyclic phosphate to facilitate the synthetic endeavor.  Thus, 
Stille coupling of 68.4 followed by selective TBS protection of the C11 hydroxyl 
provided diol 69.1.  Treatment of diol 69.1 with POCl3 and allyl alcohol provided the 
cyclic triester, which was immediately hydrolyzed to provide monoanion 69.2 as the 
major product.  Deprotection of the allyl phosphate followed by global silyl 
deprotection provided fostriecin, a six step sequence from triol 68.4 in 23% yield 
























1. POCl3, pyr., 0 ºC; then allylOH
















(1:19:6), rt, 20 h, 63% (2 steps)
 
1.10 Conclusions 
 The previous highlights of phosphatase inhibitor total syntheses draws 
attention to a several aspects important to the context of synthetic efforts in phosphate 
tether methodology.  In particular, the incorporation of suspected highly reactive 
functionalities can be realized, and in several cases enhances the overall efficiency 
and success of the total synthesis.  Explicit examples of this are the calyculins 
(various transformations in the presence of the phosphate), Isobe group synthesis of 
tautomycin with the intact anhydride, and the Koert group synthesis of 
phoslactomycin A.  The appeal of a robust methodology to generate stereogenic 
centers and/or facilitate synthetic elaborations is evident.  Danishefsky and 
Boukouvalas’s approach to dysidiolide generated stereochemical complexity in a 
concise fashion, condensing the requisite number of transformations.  It is also 
noticeable, in regard to the Corey’s synthesis of dysidiolide, that engaging 
functionally compact molecular entities in chemospecific, stereoelectronically 
governed transformations elegantly construct complexity in a rigorously defined 
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scenario.  In this light, the previous review of synthetic accomplishments in formation 
of various natural product phosphatase inhibitors provides a lens with which to 
examine the doctoral work presented.  This work embodies two underdeveloped areas 
of phosphate chemistry, namely their use as (i) temporary tethers119 that are capable 
of (ii) multivalent activation (activating one, two or all three of the phosphate ester 
appendages), where the following dissertation provides additional empirical evidence 
that counters historical and traditional views associated with the utilization of 




(1)  Pinna, L. A.; Cohen, P. T. W. Inhibitors of Protein Kinases and Protein 
Phosphatases. Handbook of Experimental Pharmacology 2005, 167, preface 
pp V-VI. 
(2)  Honkanen, R. E. “Serine/Threonine Protein Phosphatase Inhibitors with 
Antitumor Activity” in Inhibitors of Protein Kinases and Protein 
Phosphatases. Handbook of Experimental Pharmacology 2005, 167, 295-317. 
(3)  (a) Marcos, I. S.; Pedrero, A. B.; Sexmero, M. J.; Diez, D.; Basabe, P.; 
Hernández, F. A.; Broughton, H. B.; Urones, J. G. Synthesis and Absolute 
Configuration of the Supposed Structure of Cladocoran A and B. Synlett 2002, 
105-109. (b) Miyaoka, H.; Yamanishi, M.; Kajiwara, Y.; Yamada, Y. Total 
Synthesis of Cladocorans A and B: A Structural Revision. J. Org. Chem. 
2003, 68, 3476-3479 and pertinent references therein. 
(4)  (a) Loukaci, A.; Le Saout, I.; Samadi, M.; Leclerc, S.; Damiens, E.; Meijer, 
L.; Debitus, C.; Guyot, M. Coscinosulfate, a CDC25 Phosphatase Inhibitor 
from the Sponge Coscinoderma Mathewsi. Bioorg. Med. Chem. 2001, 9, 
3049-3054. (b) Poigny, S.; Nouri, S.; Chiaroni, A.; Guyot, M.; Samadi, M. 
Total Synthesis and Determination of the Absolute Configuration of 
Coscinosulfate. A New Selective Inhibitor of Cdc25 Protein Phosphatase. J. 
Org. Chem. 2001, 66, 7263-7269 and pertinent references therein.  
(5)  Yu, L.; McGill, A.; Ramirez, J.; Wang, P. G.; Zhang, Z.-Y. Synthesis and 
Bioassy of a Protein Tyrosine Phosphatase Inhibitor, Dephostatin. Bioorg. 
Med. Chem. Lett. 1995, 5, 1003-1006 and pertinent references therein. 
(6)  Forsyth, C. J.; Wang, C. Synthesis and stereochemistry of the terminal 
spiroketal domain of the phosphatase inhibitor dinophysistoxin-2. Bioorg. 
Med. Chem. Lett. 2008, 18, 3043-3046 and pertinent references therein. 
(7)  (a) Fürstner, A.; Ruiz-Caro, J.; Prinz, H.; Waldmann, H. Structure 
Assignment, Total Synthesis, and Evaluation of the Phosphatase Modulating 
Activity of Glucolipsin A. J. Org. Chem. 2004, 69, 459-467. (b) Kang, E. J.; 
Lee, E. Total Synthesis of Oxacyclic Macrolide Natural Products. Chem. Rev. 
2005, 105, 4348-4378 and pertinent references therein. 
(8)  Gong, J.-X.; Shen, X.; Yao, L.-G.; Jiang, H.; Krohn, K.; Guo, Y.-W. Total 
Synthesis of Gymnorrhizol, an Unprecedented 15-Membered Macrocyclic 
Polydisulfide from the Chinese Mangrove Bruguiera gymnorrhiza. Org. Lett. 
2007, 9, 1715-1716 and pertinent references therein. 
(9)  (a) Toivola, D. M.; Eriksson, J. E.; Brautigan, D. L. Identification of protein 
phosphatase 2A as the primary target for microcystin-LR in rat liver 
homogenates. FEBS Lett. 1994, 344, 175-180. (b) Humphrey, J. M.; Aggen, J. 
 81 
 
B.; Chamberlin, A. R. Total Synthesis of the Serine-Threonine Phosphatase 
Inhibitor Microcystin-LA. J. Am. Chem. Soc. 1996, 118, 11759-11770 and 
pertinent references therein. 
(10)  (a) Li, W.-R.; Lin, S. T.; Hsu, N.-M.; Chern, M.-S. Efficient Total Synthesis 
of Pulchellalactam, a CD45 Tyrosine Phosphatase Inhibitor. J. Org. Chem. 
2002, 67, 4702-4706. (b) Bryans, J. S.; Chessum, N. E. A.; Huther, N.; 
Parsons, A. F.; Ghelfi, F. Metal-catalysed radical cyclisations leading to N-
heterocycles: new approaches to gabapentin and pulchellalactam. Tetrahedron 
2003, 59, 6221-6231. (c) Mangaleswaran, S.; Argade, N. P. A Facile 
Synthesis of CD45 Protein Tyrosine Phosphatase Inhibitor Marine Natural 
Product Pulchellalactam. Synthesis 2004, 1560-1562. (d) Hermet, J.-P.; 
Caubert, V.; Langlois, N. Short Synthesis of Pulchellalactam. Synth. Commun. 
2006, 36, 2253-2257. (e) Chavan, S. P.; Pathak, A. B.; Dhawane, A. N.; 
Kalkote, U. R. Total Synthesis of Pulchellalactam via an RCM Strategy. 
Synth. Commun. 2007, 37, 1503-1510. (f) Felluga, F.; Ghelfi, F.; Pagnoni, U. 
M.; Parsons, A. F.; Pattarozzi, M.; Roncaglia, F.; Valentin, E. A Novel Short 
Approach to (Z)-Pulchellalactam through Transition-Metal-Catalyzed Atom-
Transfer Radical Cyclization of 1-Isopropylprop-2-enyl Dichloroacetate. 
Synthesis 2007, 1882-1886 and pertinent references therein. 
(11)  (a) Hashimoto, M.; Kan, T.; Nozaki, K.; Yanagiya, M.; Shirahama, H.; 
Matsumoto, T. Total Synthesis of (+)-Thyrsiferol, (+)-Thyrsiferyl 23-Acetate, 
and (+)-Venustatriol.  J. Org. Chem. 1990, 55, 5088-5107. (b) González, I. C.; 
Forsyth, C. J. Total Synthesis of Thyrsiferyl 23-Acetate, a Specific Inhibitor 
of Protein Phosphatase 2A and an Anti-Leukemic Inducer of Apoptosis. J. 
Am. Chem. Soc. 2000, 122, 9099-9108. (c) Nishiguchi, G. A.; Graham, J.; 
Bouraoui, A.; Jacobs, R. S.; Little, R. D. 7,11-epi-Thyrsiferol: Completion of 
Its Synthesis, Evaluation of Its Antimitotic Properties, and the Further 
Development of an SAR Model. J. Org. Chem. 2006, 71, 5936-5941 and 
pertinent references therein. 
(12)  (a) Fürstner, A.; Feyen, F.; Prinz, H.; Waldmann, H. Total Synthesis and 
Reassignment of the Phosphatase-Inhibitory Activity of the Antitumor Agent 
TMC-69-6H. Angew. Chem. Int. Ed. 2003, 42, 5361-5364. (b) Fürstner, A.; 
Feyen, F.; Prinz, H.; Waldmann, H. Synthesis and evaluation of the antitumor 
agent TMC-69-6H and a focused library of analogs. Tetrahedron 2004, 60, 
9543-9558 and pertinent references therein. 
(13) Kato, Y.; Fusetani, N.; Matsunaga, S.; Hashimoto, K.; Fujita, S.; Furuya, T. 
Calyculin A, a Novel Antitumor Metabolite from the Marine Sponge 
Discodermia calyx. J. Am. Chem. Soc. 1986, 108, 2780-2781. 
(14) (a) Kato, Y.; Fusetani, N.; Matsunaga, S.; Hashimoto, K.; Koseki, K. Isolation 
and Structure Elucidation of Calyculins B, C, and D, Novel Antitumor 
Metabolites, from the Marine Sponge Discodermia calyx. J. Org. Chem. 1988, 
 82 
 
53, 3930-3932. (b) Matsunaga, S.; Fujiki, H.; Sakata, D.; Fusetani, N. 
Calyculins E, F, G, and H, additional inhibitors of protein phosphatases 1 and 
2a, from the marine sponge Discodermia calyx. Tetrahedron 1991, 47, 2999-
3006. 
(15) Evans, D. A.; Gage, J. R.; Leighton, J. L. Total Synthesis of (+)-Calyculin A. 
J. Am. Chem. Soc. 1992, 114, 9434-9453. 
(16) For a detailed report on the Evan’s group efforts towards calyculin A, see: (a) 
Evans, D. A.; Gage, J. R.; Leighton, J. L. Asymmetric Synthesis of Calyculin 
A. 1. The C1-C25 Spiroketal Fragment. J. Org. Chem. 1992, 57, 1958-1961. 
(b) Evans, D. A.; Gage, J. R.; Leighton, J. L.; Kim, A. S. Asymmetric 
Synthesis of Calyculin A. 2. The C26-C37 γ-Amino Acid Fragments. J. Org. 
Chem. 1992, 57, 1961-1964. (c) Evans, D. A.; Gage, J. R.; Leighton, J. L. 
Asymmetric Synthesis of Calyculin A. 3. Assemblage of the Calyculin 
Skeleton and the Introduction of a New Phosphate Monoester Synthesis. J. 
Org. Chem. 1992, 57, 1964-1966. 
(17) In late 1991 two studies established that the absolute stereochemistry of 
naturally occuring calyculin A was enantiomeric to (+)-calyculin A (the 
structure reported in 1986) see: (a) Matsunaga, S.; Fusetani, N. Absolute 
Stereochemistry of the Calyculins, Potent Inhibitors of Protein Phosphatases 1 
and 2A. Tetrahedron Lett. 1991, 32, 5605-5606. (b) Hamada, Y.; Tanada, Y.; 
Yokokawa, F.; Shioiri, T. Stereoselective Synthesis of 2,3-dihydroxy-4-
dimethylamino-5-methoxypentanoic acid, a fragment of calyculins – 
determination of the absolute configuration of calyculins. Tetrahedron Lett. 
1991, 32, 5983-5986. 
(18) In 2001, a formal total synthesis was reported utilizing 
crotyldiisopinocampheylboranes to generate key northern and southern 
hemisphere advanced intermediates; see Anderson, O. P.; Barret, A. G. M.; 
Edmunds, J. J.; Hachiya, S.-I.; Hendrix, J. A.; Horita, K.;  
Malecha, J. W.; Parkinson, C. J.; VanSickle, A. Applications of 
crotyldiisopinocampheylboranes in synthesis: a formal total synthesis of (+)-
calyculin A. Can. J. Chem. 2001, 79, 1562-1592. 
(19) Tanimoto, N.; Gerritz, S. W.; Sawabe, A.; Noda, T.; Filla, S. A.; Masamune, 
S. The Synthesis of Naturally Occuring (–)-Calyculin A. Angew. Chem. Int. 
Ed. Engl. 1994, 33, 673-675. 
(20) The authors note the improvement in synthesizing this fragment since a prior 
publication regarding the enantiomer, see: Vaccaro, H. A.; Levy, D. E.; 
Sawabe, A.; Jaetsch, T.; Masamune, S. Towards the Synthesis of Calyculin: A 
Synthetic Intermediate Corresponding to the C(26)-C(37) Fragment. 
Tetrahedron Lett. 1992, 33, 1937-1940. 
(21) Smith, A. B., III; Friestad, G. K.; Duan, J. J.-W.; Barbosa, J.; Hull, K. G.; 
 83 
 
Iwashima, M.; Qiu, Y.; Spoors, P. G.; Bertounesque, E.; Salvatore, B. A. 
Total Synthesis of (+)-Calyculin A and (–)-Calyculin B. J. Org. Chem. 1998, 
63, 7596-7597. 
(22) (a) Smith, A. B., III; Friestad, G. K.; Barbosa, J.; Bertounesque, E.; Hull, K. 
G.; Iwashima, M.; Qiu, Y.; Salvatore, B. A.; Spoors, P. G.; Duan, J. J.-W. 
Total Synthesis of (+)-Calyculin A and (–)-Calyculin B: Asymmetric 
Synthesis of the C(9-25) Spiroketal Dipropionate Subunit. J. Am. Chem. Soc. 
1999, 121, 10468-10477. (b) Smith, A. B., III; Friestad, G. K.; Barbosa, J.; 
Bertounesque, E.; Duan, J. J.-W.; Hull, K. G.; Iwashima, M.; Qiu, Y.; Spoors, 
P. G.; Salvatore, B. A. Total Synthesis of (+)-Calyculin A and (–)-Calyculin 
B: Cyanotetraene Construction, Asymmetric Synthesis of the C(26-37) 
Oxazole, Fragment Assembly, and Final Elaboration. J. Am. Chem. Soc. 1999, 
121, 10478-10486. 
(23) Ogawa, A. K.; Armstrong, R. W. Total Synthesis of Calyculin C. J. Am. 
Chem. Soc. 1998, 120, 12435-12442.  See also: (a) Ogawa, A. K.; DeMattei, 
J. A.; Scarlato, G. R.; Tellew, J. E.; Chong, L. S.; Armstrong, R. W. 
Asymmetric Synthesis of Calyculin C. 2. Synthesis of the C26-C37 Fragment 
and Model Wittig Couplings. J. Org. Chem. 1996, 61, 6153-6161. (b) 
Scarlato, G. R.; DeMattei, J. A.; Chong, L. S.; Ogawa, A. K.; Lin, M. R.; 
Armstrong, R. W. Asymmetric Synthesis of Calyculin C. 1. Synthesis of the 
C1-C25 Fragment. J. Org. Chem. 1996, 61, 6139-6152. 
(24) Gunasekera, G. P.; McCarthy, P. J.; Kelly-Borges, M.; Lobkovsky, E.; Clardy, 
J. Dysidiolide: A Novel Protein Phosphatase Inhibitor from the Caribbean 
Sponge Dysidea etheria de Laubenfels. J. Am. Chem. Soc. 1996, 118, 8759-
8760. 
(25) Blanchard, J. L.; Epstein, D. M.; Boisclair, M. D.; Rudolph, J.; Pal, K. 
Dysidiolide and related γ-hydroxy butenolide compounds as inhibitors of the 
protein tyrosine phosphatase, cdc25. Bioorg. Med. Chem. Lett. 1999, 9, 2537-
2538. 
(26) Takahashi, M.; Dodo, K.; Sugimoto, Y.; Aoyagi, Y.; Yamada, Y.; Hashimoto, 
Y.; Shirai, R. Synthesis of the novel analogues of dysidiolide and their 
structure-activity relationship. Bioorg. Med. Chem. Lett. 2000, 10, 2571-2574. 
(27) Corey, E. J.; Roberts, B. E. Total Synthesis of Dysidiolide. J. Am. Chem. Soc. 
1997, 119, 12425-12431. 
(28) Magnuson, S. R.; Sepp-Lorenzino, L.; Rosen, N.; Danishefsky, S. J. A 
Concise Total Synthesis of Dysidiolide through Application of a 
Dioxolenium-Mediated Diels-Alder Reaction. J. Am. Chem. Soc. 1998, 120, 
1615-1616. 
(29) While the endgame of the Danishefsky group echoes that of the Corey group, 
 84 
 
the Danishefsky publication was submitted before the Corey report was 
published; see 27 and 28. 
(30) Boukouvalas, J.; Cheng, Y.-X.; Robichaud, J. Total Synthesis of (+)-
Dysidiolide. J. Org. Chem. 1998, 63, 228-229. 
(31) Boukouvalas, J.; Lachance, N. A Mild, Efficient and General Method for the 
Synthesis of Trialkylsilyl (Z)-4-Oxo-2-alkenoates and γ-Hydroxybutenolides. 
Synlett 1998, 31-32. 
(32) Takahashi, M.; Dodo, K.; Hashimoto, Y.; Shirai, R. Concise asymmetric 
synthesis of dysidiolide. Tetrahedron Lett. 2000, 41, 2111-2114. 
(33) Demeke, D.; Forsyth, C. J. Novel Total Synthesis of the Anticancer Natural 
Product Dysidiolide. Org. Lett. 2000, 2, 3177-3179. 
(34) A detailed account of the synthetic efforts invoved were disclosed in 2002: 
Demeke, D.; Forsyth, C. J. Total synthesis of (±)-dysidiolide. Tetrahedron 
2002, 58, 6531-6544. 
(35) Miyaoka, H.; Kajiwara, Y.; Hara, Y.; Yamada, Y. Total Synthesis of Natural 
Dysidiolide. J. Org. Chem. 2001, 66, 1429-1435. 
(36) The Yamada group had previously reported the racemic total synthesis of 
dysidiolide utilizing the intramolecular Diels-Alder route; see: Miyaoka, H.; 
Kajiwara, Y.; Yamada, Y. Synthesis of marine sesterterpenoid dysidiolide. 
Tetrahedron Lett. 2000, 41, 911-914. 
(37) Miyaoka, H.; Kajiwara, Y.; Hara, M.; Suma, A.; Yamada, Y. Synthesis of 
optically active 3-alkoxy-6-hydroxymethyl-6-methyl-2-cyclohexenone. 
Tetrahedron: Asymmetry 1999, 10, 3189-3196. 
(38) Dilip de Silva, E.; Williams, D. E.; Andersen, R. J.; Klix, H.; Holmes, C. F. 
B.; Allen, T. M. Motuporin, A Potent Protein Phosphatase Inhibitor Isolated 
from the Papua New Guinea Sponge Theonella swinhoel Gray. Tetrahedron 
Lett. 1992, 33, 1561-1564. 
(39) Maynes, J. T.; Luu, H. A.; Cherney, M. M.; Andersen, R. J.; Williams, D.; 
Homes, C. F. B.; James, M. N. G. Crystal Structures of Protein Phosphatase-1 
Bound to Motuporin and Dihydromicrocystin-LA: Elucidation of the 
Mechanism of Enzyme Inhibition by Cyanobacterial Toxins. J. Mol. Biol. 
2006, 356, 111-120. 
(40) Valentekovich, R. J.; Schreiber, S. L. Enantiospecific Total Synthesis of the 
Protein Phosphatase Inhibitor Motuporin. J. Am. Chem. Soc. 1995, 117, 9069-
9070. 
(41) For other syntheses of protected Adda, refer to: (a) Namikoshi, M.; Rinehart, 
K. L.; Dahlem, A. M.; Beasley, V. R.; Carmichael, W. W. Total Synthesis of 
Adda, the unique C20 amino acid of cyanobacteial hepatotoxins. Tetrahedron 
 85 
 
Lett. 1989, 30, 4349-4352. (b) Chakraborty, T. K.; Joshi, S. P. Total synthesis 
of N-phthaloyl adda methyl ester: All stereocenters originating from a single 
chiral epoxyalcohol. Tetrahedron Lett. 1990, 31, 2043-2046. (c) Beatty, M. F.; 
Jennings-White, C.; Avery, M. A. (2S,3S,8S,9S,4E,6E)-3-amino-9-methoxy-
2,6,8-trimethyl-10-phenyl-4,6-decadienoic acid (Adda), the amino acid 
characteristic of microcystins and nodularin. J. Chem. Soc., Perkin Trans. 1 
1992, 1637-1641 as well as references 43, 47, and 48. 
(42) For other syntheses of β-alkyl aspartates, please regard: (a) Dener, J. M.; 
Zhang, L.-H.; Rapoport, H. An Effective Chirospecific Synthesis of (+)-
Pilocarpine from L-Aspartic Acid. J. Org. Chem. 1993, 58, 1159-1166. (b) 
Hanessian, S.; Sumi, K.; Vanasse, B. The Stereocontrolled Synthesis of 
(2S,3R)-3-Alkyl-L-aspartic Acids Using a 2-Azetidinone Framework as a 
Chiral Template. Synlett 1992, 33-34. (c) Seebach, D.; Wasmuth, D. 
Alkylation of Amino Acids without Loss of Optical Activity: α- and β-
Alkylation of an Aspartic Acid Derivative. Angew. Chem. Int. Ed. Engl. 1981, 
20, 971. (d) Baldwin, J. E.; Moloney, M. G.; North, M. Non-proteinogenic 
amino acid synthesis. The β-anion derived from aspartic acid, and its 
application to α-amino acid synthesis. Tetrahedron 1989, 45, 6309-6318 as 
well as reference 43. 
(43) Samy, R.; Kim, H. Y.; Brady, M.; Toogood, P. L. Total Synthesis of 
Motuporin and 5-[L-Ala]-Motuporin. J. Org. Chem. 1999, 64, 2711-2728. 
(44) Marshall, J. A.; Garofalo, A. W. Oxidative Cleavage of Mono-, Di-, and 
Trisubstituted Olefins to Methyl Esters through Ozonolysis in Methanolic 
NaOH. J. Org. Chem. 1993, 58, 3675-3680. 
(45) Batten, R. J.; Dixon, A. J.; Taylor, R. J. K. A New Method for Removing the 
t-Butyldimethylsilyl Protecting Group. Synthesis 1980, 234-235. 
(46) Shiori, T.; Ninomiya, K.; Yamada, S.-I. Diphenylphosphoryl Azide. A New 
Convenient Reagent for a Modified Curtius Reaction and for the Peptide 
Synthesis. J. Am. Chem. Soc. 1972, 94, 6203-6205. 
(47) Hu, T.; Panek, J. S. Total Synthesis of (–)-Motuporin. J. Org. Chem. 1999, 64, 
3000-3001. 
(48) Hu, T.; Panek, J. S. Enantioselective Synthesis of the Protein Phosphatase 
Inhibitor (–)-Motuporin. J. Am. Chem. Soc. 2002, 124, 11368-11378. 
(49) (a) Matteson, D. S.; Sadhu, K. M. Synthesis of 1-Amino-2-phenylethane-1-
boronic Acid Derivatives. Organometallics 1984, 3, 614-618. (b) Matteson, 
D. S.; Beedle, E. C. A directed chiral synthesis of amino acids from boronic 
esters. Tetrahedron Lett. 1987, 28, 4499-4502. (c) Matteson, D. S.; Beedle, E. 
C. A Chiral Synthesis of (2S,3S)-phenylalanine-3-2H via boronic esters. J. 
Labeled Compd. Radiopharm. 1988, 25, 675-683. (d) Matteson, D. S.; Kandil, 
 86 
 
A. A.; Soundararajan, R. Synthesis of Asymmetrically Deuterated Glycerol 
and Dibenzylglyceraldehyde via Boronic Esters. J. Am. Chem. Soc. 1990, 112, 
3964-3969. (e) Matteson, D. S. Recent advances in asymmetric synthesis with 
boronic esters. Pure Appl. Chem. 1991, 63, 339-344. 
(50) Bauer, S. M.; Armstrong, R. W. Total Synthesis of Motuporin (Nodularin-V). 
J. Am. Chem. Soc. 1999, 121, 6355-6366. 
(51) Cheng. X.-C.; Kihara, T.; Kusakabe, H.; Magae, J.; Kobayashi, T.; Fang, R.-
P.; Ni, Z.-F.; Shen, Y.-C.; Ko, K.; Yamaguchi, I.; Isono, K. A New Antibiotic, 
Tautomycin. J. Antibiot. 1987, 40, 907-909. 
(52) Magae, J.; Watanabe, C.; Osada, H.; Cheng, X.-C.; Isono, K. Induction of 
Morphological Change of Human Myeloid Leukemia and Activation of 
Protein Kinase C by a Novel Antibiotic, Tautomycin. J. Antibiot. 1988, 41, 
932-937. 
(53) (a) Magae, J.; Osada, H.; Fujiki, H.; Saido, T. C.; Suzuki, K.; Nagai, K.; 
Yamasaki, M.;  Isono, K. Morphological Changes of Human Myeloid 
Leukemia K562 Cells by a Protein Phosphatase Inhibitor, Tautomycin. Proc. 
Jpn. Acad. Ser. B. 1990, 66, 209-212. (b) MacKintosh, C.; Klumpp, S. 
Tautomycin from the bacterium Streptomyces verticillatus. Another potent 
and specific inhibitor of protein phosphatases 1 and 2A. FEBS Lett. 1990, 277, 
137-140. (c) Takai, A.; Sasaki, K.; Nagai, H.; Mieskes, G.; Isobe, M.; Isono, 
K.; Yasumoto, T. Inhibition of specific binding of okadaic acid to protein 
phosphatase 2A by microcystin-LR, calyculin-A, and tautomycin: methods of 
analysis of interactions of tight-binding ligands with target protein.  Biochem. 
J. 1995, 306, 657-665. 
(54) (a) Takai, A.; Tsuboi, K.; Koyasu, M.; Isobe, M. Effects of modification of 
the hydrophobic C1-C16 segment of tautomycin on its affinity to type-1 and 
type-2 protein phosphatases. Biochem. J. 2000, 350, 81-88. (b) Oikawa, H. 
Synthesis of Specific Protein Phosphatase Inhibitors, Tautomycin and 
Tautomycetin toward Structure-Activity Relationship Study. Curr. Med. 
Chem. 2002, 9, 2033-2054. 
(55) Oikawa, H.; Oikawa, M.; Ueno, T.; Ichihara, A. Total Synthesis of 
Tautomycin: Efficient aldol coupling of two large subunits. Tetrahdedron 
Lett. 1994, 35, 4809-4812. 
(56) Oikawa, M.; Ueno, T.; Oikawa, H.; Ichihara, A. Total Synthesis of 
Tautomycin. J. Org. Chem. 1995, 60, 5048-5068. 
(57) Ichikawa, Y.; Tsuboi, K.; Jiang, Y.; Naganawa, A.; Isobe, M. Total synthesis 
of (+)-tautomycin. Tetrahedron Lett. 1995, 36, 7101-7104. 
(58) Tsuboi, K.; Ichikawa, Y.; Jiang, Y.; Naganawa, A.; Isobe, M. Total Synthesis 
of (+)-Tautomycin. Tetrahedron 1997, 53, 5123-5142. 
 87 
 
(59) Shimizu, S.; Nakamura, S.; Nakada, M.; Shibasaki, M. Total Synthesis of (+)-
Tautomycin. Tetrahedron 1996, 52, 13363-13408. 
(60) Nakamura, S.; Shibasaki, M. Synthetic studies on tautomycin. Stereoselective 
construction of the C1-C26 region. Tetrahedron Lett. 1994, 35, 4145-4148. 
(61) Sheppeck, J. E., II; Liu, W.; Chamberlin, A. R. Total Synthesis of the 
Serine/Threonine-Specific Protein Phosphatase Inhibitor Tautomycin. J. Org. 
Chem. 1997, 62, 387-398. 
(62) (a) Ireland, R. E.; Anderson, R. C.; Badoud, R.; Fitzsimmons, B. J.; 
McGarvey, G. J.; Thaisrivongs, S.; Wilcox, C. S. The Total Synthesis of 
Ionophore Antibiotics. A Convergent Synthesis of Lasalocid A (X537A). J. 
Am. Chem. Soc. 1983, 105, 1988-2006. (b) Ireland, R. E.; Thaisrivongs, S.; 
Dussualt, P. H. An Approach to the Total Synthesis of Aplysiatoxin. J. Am. 
Chem. Soc. 1988, 110, 5768-5779. 
(63) (a) Oertle, K.; Beyeler, H.; Dunthaler, R. O.; Lottenbach, W.; Riediker, M.; 
Steiner, E. A Facile Synthesis of Optically Pure (–)-(S)-Ipsenol Using a Chiral 
Titanium Complex. Helv. Chim. Acta 1990, 73, 353-358. (b) Dunthaler, R. O.; 
Herold, P.; Wyler-Helfer, S.; Riediker, M. Enantio- and Diastereoselective 
Aldol-Reaction of 2,6-Dimethylphenyl Propionate Using Titanium-
Carbohydrate Complexes. Helv. Chim. Acta 1990, 73, 659-673. 
(64) (a) Fushimi, S.; Nishikawa, S.; Shimazu, A.; Seto, H. Studies on New 
Phosphate Ester Antifungal Antibiotics Phoslactomycins. I. Taxonomy, 
Fermentation, Purification and Biological Activities. J. Antibiot. 1989, 42, 
1019-1025. (b) Fushimi, S.; Furihata, K.; Seto, H. Studies on New Phosphate 
Ester Antifungal Antibiotics Phoslactomycins. II. Structure Elucidation of 
Phoslactomycins A to F. J. Antibiot. 1989, 42, 1026-1036. (c) Ozasa, T.; 
Suzuki, K., Sasamata, M.; Tanaka, K.; Kobori, M.; Kadota, S.; Nagai, K.; 
Saito, T.; Watanabe, S.; Iwanami, M. Novel Antitumor Antibiotic 
Phospholine. 1. Production, Isolation and Characterization. J. Antibiot. 1989, 
42, 1331-1338. (d) Ozasa, T.; Tanaka, K.; Sasamata, M.; Kaniwa, H.; 
Shimizu, M.; Matsumoto, H.; Iwanami, M. Novel Antitumor Antibiotic 
Phospholine. 2. Structure Determination. J. Antibiot. 1989, 42, 1339-1343. 
(65) (a) Usui, T.; Marriot, G.; Inagaki, M.; Swarup, G.; Osada, H. Protein 
Phosphatse 2A Inhibitors, Phoslactomycins. Effects on the Cytoskeleton in 
NIH/3T3 Cells. J. Biochem. 1999, 125, 960-965. (b) Lewy, D. S.; Gauss, C.-
M.; Soenen, D. R.; Boger, D. L. Fostriecin: Chemistry and Biology. Curr. 
Med. Chem. 2002, 9, 2005-2032. (c) Buck, S. B.; Hardouin, C.; Ichikawa, S.; 
Soenen, D. R.; Gauss, C.-M.; Hwang, I.; Swingle, M. R.; Bonness, K. M.; 
Honkanen, R. E.; Boger, D. L. Fundamental Role of the Fostriecin 
Unsaturated Lactone and Implications for Selective Protein Phosphatase 
Inhibition. J. Am. Chem. Soc. 2003, 125, 15694-15695. 
 88 
 
(66) Teruya, T.; Simizu, S.; Kanoh, N.; Osada, H. Phoslactomycin targets cysteine-
269 of the protein phosphatase 2A catalytic subunit in cells. FEBS Lett. 2005, 
579, 2463-2468. 
(67) Palaniappan, N.; Kim, B. S.; Sekiyama, Y.; Osada, H.; Reynolds, K. A. 
Enhancement and Selective Production of Phoslactomycin B, a Protein 
Phosphatase IIa Inhibitor, through Identification and Engineering of the 
Corresponding Biosynthetic Gene Cluster. J. Bio. Chem. 2003, 278, 35552-
35557. 
(68) Alhamadsheh, M. M.; Palaniappan, N.; DasChouduri, S.; Reynolds, K. A. 
Modular Polyketide Synthases and cis Double Bond Formation: Establishment 
of Activated cis-3-Cyclohexylpropenoic Acid as the Diketide Intermediate in 
Phoslactomycin Biosynthesis. J. Am. Chem. Soc. 2007, 129, 1910-1911. 
(69) Wang, Y.-G.; Takeyama, R.; Kobayashi, Y. Total Synthesis of 
Phoslactomycin B and Its Biosynthetic Deamino Precursor. Angew. Chem. Int. 
Ed. 2006, 45, 3320-3323. 
(70) In 2007, the group published an improvement in the generation of the central 
core of the molecule: Nonaka, H.; Maeda, N.; Kobayashi, Y. Improved 
synthesis of the polyhydroxylated central part of phoslactomycin B. 
Tetrahedron Lett. 2007, 48, 5601-5604. 
(71) Shibahara, S.; Fujino, M.; Tashiro, Y.; Takahashi, K.; Ishihara, J.; 
Hatakeyama, S. Asymmetric Total Synthesis of (+)-Phoslactomycin B. Org. 
Lett. 2008, 10, 2139-2142. 
(72)  König, C. M.; Gebhardt, B.; Schleth, C.; Dauber, M.; Koert, U. Total 
Synthesis of Phoslactomycin A. Org. Lett. 2009, 11, 2728-2731. 
(73)  Shimada, K.; Kapuragi, Y.; Fukuyama, T. Total Synthesis of Leustroducsin B. 
J. Am. Chem. Soc. 2003, 125, 4048-4049.  
(74)  Miyashita, K.; Tsunemi, T.; Hosokawa, T.; Ikejiri, M.; Imanishi, T. Total 
Synthesis of Leustroducsin B. J. Org. Chem. 2008, 73, 5360-5370.  
(75)  (a) Hayashi, T. Rhodium-Catalyzed Asymmetric 1,4-Addition of 
Organoboronic Acids and Their Derivatives to Electron Deficient Olefins. 
Synlett 2001, 879-887. (b) Hayashi, T.; Yamasaki, K. Rhodium-Catalyzed 
Asymmetric 1,4-Addition and Its Related Asymmetric Reactions. Chem. Rev. 
2003, 103, 2829-2844.  
(76)  Allred, G. D.; Liebeskind, L. S. Copper-Mediated Cross-Coupling of 
Organostannanes with Organic Iodides at or below Room Temperature. J. Am. 
Chem. Soc. 1996, 118, 2748-2749.  
 89 
 
(77)  Williams, D. E.; Roberge, M.; Van Soest, R.; Andersen, R. J. Spirastrellolide 
A, An Antimitotic Macrolide Isolated from the Caribbean Marine Sponge 
Spirastrella coccinea. J. Am. Chem. Soc. 2003, 125, 5296-5297.  
(78)  Williams, D. E.; Lapawa, M.; Feng, X. D.; Tarling, T.; Roberge, M.; 
Andersen, R. J. Spirastrellolide A: Revised Structure, Progress toward the 
Relative Configuration, and Inhibition of Protein Phosphatase 2A. Org. Lett. 
2004, 6, 2607-2610.  
(79)  For a reviews detailing the stereochemical confirmation of spirastrellolide A 
via synthesis and synthetic efforts undertaken, please see: (a) Perkins, M. V. 
Total Synthesis of Enzyme Inhibitor Spirastrellolide A – Stereochemical 
Confirmation. Angew. Chem. Int. Ed. 2008, 47, 2921-2925. (b) Paterson, I.; 
Dalby, S. M. Synthesis and stereochemical detemination of the 
spirastrellolides. Nat. Prod. Rep. 2009, 26, 865-873. 
(80)  (a) Paterson, I.; Anderson, E. A.; Dalby, S. M.; Lim, J. H.; Genovino, J.; 
Maltas, P.; Moessner, C. Total Synthesis of Spirastrellolide A Methyl Ester – 
Part 1: Synthesis of an Advanced C17-C40 Bis-spiroacetal Subunit. Angew. 
Chem. Int. Ed. 2008, 47, 3016-3020. (b) Paterson, I.; Anderson, E. A.; Dalby, 
S. M.; Lim, J. H.; Genovino, J.; Maltas, P.; Moessner, C. Total Synthesis of 
Spirastrellolide A Methyl Ester – Part 2: Subunit Union and Completion of the 
Synthesis. Angew. Chem. Int. Ed. 2008, 47, 3021-3025.  
(81)  Paterson, I.; Anderson, E. A.; Dalby, S. M.; Lim, J. H.; Maltas, P.; Moessner, 
C. Synthesis of the DEF-bis-spiroacetal of spirastrellolide A exploiting a 
double asymmetric dihydroxylation/spiroacetalisation strategy. Chem. 
Commun. 2006, 4186-4188. 
(82)  Hu. S.; Jayaraman, S.; Oehlschlager, A. C. Diastereo- and Enantioselective 
Synthesis of syn-α-Vinylchlorohydrins and cis-Vinylepoxides. J. Org. Chem. 
1996, 61, 7513-7520. 
(83)  Tachibana, K.; Scheuer, P. J.; Tsukitani, Y.; Kikuchi, H.; Enger, D. V.; 
Clardy, J.; Gopichand, Y.; Schmitz, F. Okadaic Acid, a Cytotoxic Polyether 
from Two Marine Sponges of the Genus Halichondria. J. Am. Chem. Soc. 
1981, 103, 2469-2471.  
(84)  (a) Muraka, Y.; Oshima, Y.; Yasumoto, T. Identification of Okadaic Acid As 
a Toxic Component of a Marine Dinoflagellate Prorocentrum lima. Bull. 
Japan Soc. Sci. Fish. 1982, 48, 69-72. (b) Murata, M.; Shimatani, M.; 
Sugitani, H.; Oshima, Y.; Yasumoto, T. Isolation and Structural Elucidation of 
the Causative Toxin of the Diarrhetic Shellfish Poisoning. Bull. Japan Soc. 
Sci. Fish. 1982, 48, 549-552. 
 90 
 
(85)  Bialojan, C.; Takai, A. Inhibitory effect of marine-sponge toxin, okadic acid, 
on protein phosphatases. Specificity and kinetics. Biochem. J. 1988, 256, 283-
290. 
(86)  Boudreau, R. T. M.; Hoskin, D. W. The use of okadaic acid to elucidate the 
intracellular role(s) of protein phosphatase 2A: Lessons from the mast cell 
model system. Int. Immunopharmacol. 2005, 5, 1507-1518. 
(87)  Urbanek, R. A.; Sabes, S. F.; Forsyth, C. J. Efficient Synthesis of Okadaic 
Acid. 1. Convergent Assembly of the C15-C38 Domain. J. Am. Chem. Soc. 
1998, 120, 2523-2533. 
(88)  Isobe, M.; Ichikawa, Y.; Goto, T. Synthetic Studies Toward Marine Toxic 
Polyethers [5] The Total Synthesis of Okadaic Acid. Tetrahedron Lett. 1986, 
27, 963-966.  
(89)  For a full account, see the following four successive publications: (a) 
Ichikawa, Y.; Isobe, M.; Bai, D.-L.; Goto, T. Synthesis of a marine polyether 
toxin, okadaic acid [1] – Strategy and synthesis of segment A. Tetrahedron 
1987, 43, 4737-4748. (b) Ichikawa, Y.; Isobe, M.; Goto, T. Synthesis of a 
marine polyether toxin, okadaic acid [2] – Synthesis of segment B. 
Tetrahedron 1987, 43, 4749-4758. (c) Ichikawa, Y.; Isobe, M.; Masaki, H.; 
Kawai, T.; Goto, T. Synthesis of a marine polyether toxin, okadaic acid [3] – 
Synthesis of segment C. Tetrahedron 1987, 43, 4759-4766. (d)Isobe, M.; 
Ichikawa, Y.; Bai, D.-L.; Masaki, H.; Goto, T. Synthesis of a marine polyether 
toxin, okadaic acid [4] – Total synthesis. Tetrahedron 1987, 43, 4767-4776.  
(90)  Isobe, M.; Ichikawa, Y.; Funabashi, Y.; Goto, T. Acyclic stereocontrol by 
heteroconjugate addition-4 Anti-diastereoselection by a β-chelation effect. 
Tetrahedron 1986, 42, 2862-2872.  
(91)  Forsyth, C. J.; Sabes, S. F.; Urbanek, R. A. An Efficient Total Synthesis of 
Okadaic Acid. J. Am. Chem. Soc. 1997, 119, 8381-8382.  
(92)  Sabes, S. F.; Urbanek, R. A.; Forsyth, C. J. Efficient Synthesis of Okadaic 
Acid. 2. Synthesis of the C1-C14 Domain and Completion of the Total 
Synthesis. J. Am. Chem. Soc. 1998, 120, 2534-2542. 
(93)  Ley, S. V.; Humphries, A. C.; Eick, H.; Downham, R.; Ross, A. R.; Boyce, R. 
J.; Pavey, J. B. J.; Pietruszka, J. Total synthesis of the protein phosphatase 
inhibitor okadaic acid. J. Chem. Soc., Perkin Trans. 1 1998, 3907-3911. 
(94) (a) Tunac, J. B.; Graham, B. D.; Dobson, W. E. Novel antitumor agents CI-
920, PD 113,270 and PD 113,271. I. Taxonomy, fermentation and  
biological properties. J. Antibiot. 1983, 36, 1595-1600.  
(b) Stampwala, S. S.; Bunge, R. H.; Hurley, T. R.; Willmer, N. E.; 
Brankiewicz, A. J.; Steinman, C. E.; Smitka, T. A.; French, J. C. Novel 
 91 
 
antitumor agents CI-920, PD 113,270 and PD 113,271. II. Isolation and 
characterization. J. Antibiot. 1983, 36, 1601-1605. (c) Hokanson, G. C.; 
French, J. C. Novel antitumor agents CI-920, PD 113,270, and PD 113,271. 3. 
Structure determination. J. Org. Chem. 1985, 50, 462-466. 
(95)  (a) Jackson, R. C.; Fry, D. W.; Boritzki, T. J.; Roberts, B. J.; Hook, K. E.; 
Leopold, W. R. The biochemical pharmacology of CI-920, a structurally novel 
antibiotic with antileukemic activity. Adv. Enzyme Regul. 1985, 23, 193-215. 
(b) De Jong, R. S.; De Vires, E. G. E.; Mulder, N. H. Fostriecin: a review of 
the preclinical data. Anti-Cancer Drugs 1997, 8, 413-418. 
(96)  Scheithauer, W.; Von Hoff, D. D.; Clark, G. M.; Shillis, J. L.; Elslager, E. F. 
In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a 
human tumor cloning assay. Eur. J. of Cancer Clin. Oncol. 1986, 22, 921-926. 
(97)  Walsh, A. H.; Cheng, A.; Honkanen, R. E. Fostriecin, an antitumor antibiotic 
with inhibitory activity against serine/threonine protein phosphatases types 1 
(PP1) and 2A (PP2A), is highly selective for PP2A. FEBS Lett. 1997, 416, 
230-234. 
(98)  Hastie, C. J.; Cohen, P. T. W. Purification of protein phosphatase 4 catalytic 
subunit: inhibition by the antitumor drug fostriecin and other tumor 
suppressors and promoters. FEBS Lett. 1998, 431, 357-361. 
(99)  Boger, D. L.; Hikota, M.; Lewis, B. M. Determination of the Relative and 
Absolute Stereochemistry of Fostriecin (CI-920). J. Org. Chem. 1997, 62, 
1748-1753. 
(100)  Walsh, A. H.; Cheng, A.; Honkanen, R. E. Fostriecin, an antitumor antibiotic 
with inhibitory activity against serine/threonine protein phosphatases types 1 
(PP1) and 2A (PP2A), is highly selective for PP2A. FEBS Lett. 1997, 416, 
230-234. 
(101)  Boger, D. L.; Ichikawa, S.; Zhong, W. Total Synthesis of Fostriecin (CI-920). 
J. Am. Chem. Soc. 2001, 123, 4161-4167. 
(102)  Stork, G.; Zhao, K. A stereoselective synthesis of (Z)-1-iodo-1-alkenes. 
Tetrahedron Lett. 1989, 30, 2173-2174. 
(103)  Chavez, D. E.; Jacobsen, E. N. Total synthesis of fostriecin (CI-920). Angew. 
Chem, Int. Ed. 2001, 40, 3667-3670. 
(104)  (a) Tokunaga, M.; Larrow, J. F.; Kakiuchi, F.; Jacobsen, E. N. Asymmetric 
Catalysis with Water: Efficient Kinetic Resolution of Terminal Epoxides by 
Means of Catalytic Hydrolysis. Science 1997, 277, 936-938. (b) Jacobsen, E. 
N. Asymmetric Catalysis of Epoxide Ring-Opening Reactions. Acc. Chem. 
Res. 2000, 33, 421-431. 
(105) (a) Dossetter, A. G.; Jamison, T. F.; Jacobsen, E. N. Highly Enantio- and 
 92 
 
Diastereoselective Hetero-Diels-Alder Reactions Catalyzed by New Chiral 
Tridentate Chromium(III) Catalysts. Angew. Chem. Int. Ed. 1999, 38, 2398-
2400. (b) Gademann, K.; Chavez, D. E.; Jacobsen, E. N. Highly 
Enantioselective Inverse-Electron Demand Hetero-Diels-Alder Reactions of 
a,b-unsaturated Aldehydes Angew. Chem. Int. Ed. 2002, 41, 3059-3061. (c) 
Chavez, D. E.; Jacobsen, E. N.; Grabowski, E. J. J.; Kubryk, M. An efficient, 
highly diastereo- and enantioselective hetero-Diels-Alder catalyst. Preparation 
of (2S,6R)-6-(tert-butyldimethylsiloxymethyl)-2-methoxy-2,5-dihydropyran. 
Organic Synthesis 2005, 82, 34-42. 
(106) While no experimentals are provided in the report, full details and 
experimentals are provided in the following reference: Chavez, D. E. The 
Total Synthesis of Fostriecin (CI-920). The Development and Applications of 
an Asymmetric Hetero-Diels-Alder Reaction. Ph. D. Thesis, Harvard 
University, Cambridge, MA, 2003. 
(107) Burke, S. D.; Cobb, J. E.; Takeuchi, K. Total Synthesis of (+)-Phyllanthocin. 
Introduction of Intramolecular Hydroformylation for Complex Molecule 
Functionalization. J. Org. Chem. 1990, 55, 2138-2151. 
(108) Cruciani, P.; Stammler, R.; Aubert, C.; Malacria, M. New Cobalt Catalyzed 
Cycloisomerization of ε-Acetylenic β-Keto Esters. Application to a Powerful 
Cyclization Reactions Cascade. J. Org. Chem. 1996, 61, 2699-2708. 
(109) The isopropyl acetal was found to be the superior form of this protected lactol 
for the desired transformations.  See references 103 and 106. 
(110) For a review of hydrozirconation, see: Wipf, P.; Jahn, H. Synthetic 
applications of organochlorozirconocene complexes. Tetrahedron 1996, 52, 
12853-12910. 
(111) (a)  Wipf, P.; Xu, W. Preparation of allylic alcohols by alkene transfer from 
zirconium to zinc. Tetrahedron Lett. 1994, 35, 5197-5200. (b) Wipf, P.; Ribe, 
S. Zirconocene-Zinc Transmetalation and in Situ Catalytic Asymmetric 
Addition to Aldehydes. J. Org. Chem. 1998, 63, 6454-6455. 
(112) Matsumura, K.; Hashiguchi, S.; Ikariya, T.; Noyori, R. Asymmetric Transfer 
Hydrogenation of α,β-Acetylenic Ketones. J. Am. Chem. Soc. 1997, 119, 
8738-8739. 
(113) Reddy, Y. K.; Falck, J. R. Asymmetric Total Synthesis of (+)-Fostriecin. Org. 
Lett. 2002, 4, 969-971. 
(114) Esumi, T.; Okamoto, N.; Hatakeyama, S. Versatile enantiocontrolled synthesis 
of (+)-fostriecin. Chem. Commun. 2002, 3042-3043. 
 93 
 
(115) Taniguchi, M.; Kobayashi, S.; Nakagawa, M.; Hino, T.; Kishi, T. β-Halovinyl 
ketones: Synthesis from acetylenic ketones. Tetrahedron Lett. 1986, 27, 4763-
4766. 
(116) Evans, D. A.; Chapman, T.; Carreira, E. M. Directed Reduction of β-Hydroxy 
Ketones Employing Tetramethylammonium Triacetoxyborohydride. J. Am. 
Chem. Soc. 1988, 110, 3560-3578. 
(117) Miyashita, K.; Ikejiri, M.; Kawasaki, H.; Maemura, S.; Imanishi, T. Total 
Synthesis of an Antitumor Antibiotic, Fostriecin (CI-920). J. Am. Chem. Soc. 
2003, 125, 8238-8243. 
(118) Wittig reactions of ylides conjugated with E-olefins to produce Z-olefinic 
bonds had been reported previously: (a) Corey, E. J.; Marfat, A.; Goto, G.; 
Brion, F. Leukotriene B. Total Synthesis and Assignment of Stereochemistry. 
J. Am. Chem. Soc. 1980, 102, 7984-7985. (b) Niwa, H.; Watanabe, M.; 
Inagaki, H.; Yamada, K. Didemnilactones A and B and neodidemnilactone 
three new fatty acid metabolites isolated from the tunicate Didemnum 
moseleyi (Herdman). Tetrahedron 1994, 50, 7385-7400. 
(119)  For examples of other P(III)/P(V)-based tethers, see: (a) Rubinstenn, G.; 
Esnault, J.; Mallet, J.-M.; Sinay, P. Radical-mediated synthesis of N-acetyl-D-
galactosamine containing C-disaccharides via a temporary phosphoramidic 
connection. Tetrahedron: Asymmetry 1997, 8, 1327-1336. (b) Sprott, K. T.; 
McReynolds, M. D.; Hanson, P. R. A Temporary Phosphorus Tether/Ring-
Closing Metathesis Strategy to Functionalized 1,4-Diamines. Org. Lett. 2001, 










Phosphate Tethers in Synthesis: 




We have reported the use of tripodal-phosphate tethers for coupling of both 
simple and complex allylic alcohols using ring-closing metathesis (RCM).1  This 
method highlights the ability of a phosphate tether to bestow multivalent activation 
throughout phosphate ester appendages, thereby providing latent leaving group ability 
yet possessing orthogonal stability.  This wetted our interest in developing a new 
strategy employing phosphate tethers, in which a phosphate ester serves a dual role as 
both a tether for coupling two allylic alcohols via ring-closing metathesis (RCM) and 
as a subsequent leaving group in selective anti-SN2’ displacement reactions with 
organocuprate nucleophiles.   
An underlying principle of this approach utilizes the well-documented 
superiority of phosphates as leaving groups in copper mediated anti-SN2’ 
displacement reactions, initially highlighted by Yamamoto and coworkers.2  This 
feature, where the stereochemistry of an allylic phosphate is inverted in an anti-SN2’ 
displacement, has been successfully employed in previous strategies that exploit high 
stereospecificity for chirality transfer.3  Further advances in this area have recently 
uncovered enantioselective anti-SN2’ displacements with chiral Schiff base cuprates 
as a viable means of desymmetrizing meso-1,3-syn allylic phosphates,4 as well as 
reagent-controlled asymmetric allylic phosphate displacements catalyzed by copper.5  
The method we report herein initially focuses on the use of symmetry breaking 
cuprate additions to readily prepared pseudo-C2-symmetric monocyclic phosphate 
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(S,S)-1.1 (Scheme 1).  To the best of our knowledge, this system is the first of its kind 
where a central phosphate tether imparts divalent activation to the unique doubly 
allylic phosphate subunit.  In the discussion that follows, intriguing conformational 
effects led us to extend the study into unsymmetric phosphates, ultimately providing 
experimental insight into the Corey mechanism of cuprate displacements. 
2.2 Reactivity of the pseudo-C2-Symmetric Monocyclic Phosphate 
Our study began with the generation of (S,S)-monocyclic phosphate 1.1, 
which was readily achieved in three steps and in good overall yields (Scheme 1).  
Allylic alcohol (S)-1.3 is readily generated on multi-gram scale using the 
Mioskowski-Christie protocol6 with commercially available glycidol ether (S)-1.2.  
Upon condensation of the alkoxide of 1.3 with (MeO)POCl2, the phosphate triester 
tether mediates coupling of two olefins via RCM in good yield using 
(IMesH2)(PCy3)(Cl)2Ru=CHPh (Grubbs II; cat.-B);7 use of catalyst 
(PCy3)2(Cl)2Ru=CHPh (Grubbs I; cat.-A) gave poor yields of 1.1.  Optimized RCM 








2. RCM, cat.-B, 











-30 oC to rt
95-99%  
 We first examined a number of conditions as part of our initial probe into 
orthogonal reactivity patterns within cyclic phosphates containing multiple allylic 
phosphate positions.  Attempts to cleave out the phosphate tether using the LiAlH4 
 97 
reduction protocol of Bartlett’s9 successfully generated the C2-symmetric Z-
configured-1,2,5,6-tetraol subunit 2.1 (Scheme 2).  Alternatively, post-RCM 
hydrogenation of 1.1 via the Louie-Grubbs procedure10 led cleanly to formation of 
saturated cyclic phosphate 2.2.  Wilkinson’s catalyst was also found to be a suitable 
hydrogenation partner, but other typical hydrogenation catalysts (Pd/C) lead to 
complete decomposition of starting material.  As anticipated, cleavage of saturated 



























 We then shifted focus towards anti-SN2'-allylic displacement studies using 
soft organocuprate nucleophiles.  A prerequisite for this reaction requires the leaving 
group to be orthogonal to the π system, i.e. co-planar alignment of the σ* and π* 
orbitals.  Monocyclic phosphate (S,S)-1.1 possesses the ability to align the phosphate 
moiety in two requisite anti-periplanar relationships outlined in Scheme 3.  In both 
conformers it was initially anticipated that energies related to the orthogonally-
aligned phosphate leaving group would be roughly equal in energy, since both are 
secondary allylic phosphates.  When considering only electronic factors, this would 
imply transition states of equal energy as described by the original Corey 
mechanism2b which invokes a bidentate coordination of incoming cuprate to both π* 
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and σ* orbitals, vide infra.  Attack of cuprate nucleophiles on 1.1 can potentially 
occur through any of four diastereotopic olefinic orbitals.  Symmetry, however, 
presents two (not four) stereodivergent pathways for anti-SN2'-allylic displacement, 
ultimately leading to only two possible diastereomeric products.11  Pathway A occurs 
through conformer A with addition anti to the vicinal CH2OBn group generating anti-
(Z) diastereomer 3.2, while pathway B occurs via conformer B with addition syn to 















































 Pleasingly, anti-SN2’ displacement of allylic phosphate 1.1 using 
Et2Zn/CuCN•2LiCl, and after acid workup, led to formation of phosphate acid 3.1b as 


























treatment with Red-Al led to good yields of homoallylic alcohol 4.1b.  Initial 
tentative assignment of the relative stereochemistry within phosphate acid 3.1b was 
made based on the proposed model for cuprate addition and the observed olefinic 
coupling constant consistent with an (E)-configured olefin (J = 15.7 Hz).  
Unambiguous determination of relative stereochemical relationship at C(2,3) within 
4.1b was ultimately achieved using Karplus-analysis of vicinal protons contained 
within the six-membered ring derived from reductive ozonolysis/acetonide formation 
of 4.1 (Scheme 5).12  Analysis of JAC, JBC, JCD coupling constants provided small 
coupling values (1.4-2.6 Hz) consistent with the assigned structure.  These values 










1. - 78 oC, O3, MeOH 













 The remarkable selectivity for this transformation can be rationalized using 
Corey’s proposed concerted, asynchronous mechanism2b for cuprate additions as 
highlighted in Figure 1.  In this mechanism, Corey surmises that the reacting cuprate 
simultaneously coordinates both the π* orbital of the olefin and σ* orbital of the 
phosphate ester leaving group.  The asynchronous nature of the transformation 
predicts a transition state in which substantial bond-lengthening occurs with respect 
to the σ* bonding orbital.  When applied to conformers A and B in (S,S)-1.1, it is 
anticipated the σ* orbitals are roughly equal in energy, since both are secondary 
allylic phosphates.  Therefore, the stereoselectivity displayed in the cuprate reaction 
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with 1.1 must ultimately be dictated by the lower steric requirements of conformer B 
to attain the requisite coplanar alignment of π* and σ* orbitals with the cuprate d-
orbital; the greater allylic 1,3-strain (A1,3 strain) within conformer A due to the 





















Figure 1: Corey Model for Rationalizing Stereoselectivity 
 Additional reactions of 1.1 with an array of zinc-based organocuprates gave 
similar high yields and selectivities when using 4-5 equivalents of dialkylzinc-derived 
organocuprates (entries 1-3, Table 1).  Treatment of 1.1 with 8-9 equivalents of the 
mixed zinc-copper reagents using alkyl halide-derived, functionalized organozinc 
reagents (entries 4-8, Table 1) provided similar yields and diastereoselectivities.  The 
specified excess reagents were used in all cases to ensure complete consumption of 
starting materials and overall provided cleaner post-workup mixtures.15  Following 
acidic workup, the phosphate acids were directly subjected to Red-Al to afford             














































































































 While cleavage of the phosphate acid using Red-Al® afforded the majority of 
products 4.1 in good yields, lower yields were observed for reductions in which 
substrates 3.1 contained functionally-sensitive R1 groups.  To circumvent this 
problem, in situ methylation of the crude phosphate acid using TMSCHN2 produced 









4.1f = 83%, R1 = (CH2)3CN















2.3 Cuprate Additions to Unsymmetric Monocyclic Phosphates 
 We next turned our attention to the construction of unsymmetric monocyclic 
phosphates containing similar steric environments with regards to the incoming 
cuprate, but disparate electronic energies at the σ* orbitals of the leaving phosphate 
ester (i.e., primary versus secondary allylic phosphate ester leaving groups).  In 
contrast to phosphate 1.1, an energetic bias for the corresponding allylic phosphates 
was thus anticipated.  Dioxaphosphacycle 7.1 was generated via the coupling of one 
equivalent of allylic alcohol 1.3 with allyldiphenyl phosphate, followed by RCM to 
afford 7.1 in good yields over two steps (Scheme 7).  Treatment of 7.1 with 3.0 
equivalents of diethyl zinc-derived organocuprates, and subsequent phosphate 
cleavage, led to formation of a single product 7.2 produced via cuprate displacement 
at the secondary allylic phosphate position.  In contrast to (S,S)-1.1, no dominant 
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conformational preferences exist between the two described reactive conformations 
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Conformer C Conformer D
Cu(I)NC RCu(I)R CN
 
 This intriguing result led us to explore yet a third paradigm, the unsymmetric 
cyclic phosphate 8.2, containing both secondary and tertiary allylic phosphate 
positions (Scheme 8).  Phosphate 8.2 was assembled via differential coupling of 
secondary allylic alcohol 1.3 and 2-methylbut-3-en-2-ol (8.1) with dichloromethyl 
phosphate.  The resulting labile acyclic phosphate was immediately subjected to 







1.  BuLi, 1.3, -40 oC
(Cl)2P(O)OMe, 80%
2. BuLi, 8.1 -40 oC to 0 oC;
cat.-B, CH2Cl2























































Treatment of 8.2 with 3.0 equivalents of diethyl zinc-derived organocuprate at -40 ºC, 
and subsequent phosphate cleavage, led to formation of a single product 8.3.  Using 
the aforementioned Karplus analysis of the resulting acetonide of 8.3, unambiguous 







1. - 78 oC, O3, MeOH 














 The regioselectivity of cuprate displacement in 8.2 is most surprising in that 
the requisite conformer F leading to product 8.3 (Scheme 8) contains an unfavorable 
A1,3 interaction generated by the gem-dimethyl moiety.  However, the observed 
selectivity is consistent with the results obtained with 7.1 in which the cuprate 
displaces the more substituted phosphate leaving group.  Since the Corey model for 
cuprate addition predicts significant bond breakage through σ*, the lower energy σ* 
(i.e. the most substituted carbon) in the asynchronous concerted transition state 
dictates the reaction pathway over substantial A1,3 steric interactions. 
 In rationalizing and summarizing regio- and diastereoselective cuprate 
additions with symmetric (S,S)-1.1 and unsymmetric phosphates 7.1 and 8.2, both 
steric and stereoelectronic effects appear to play major roles.  In the case of 7.1 and 
8.2, cuprate displacements proceeded via the more substituted σ* positions, secondary 
and tertiary, respectively.  When σ* energies are equivalent as in (S,S)-1.1, allylic 
































Corey Model for Allylic Cuprate Displacements:
Overlap of Cu d-orbitals with !* and #* orbitals,
more overlap with !* orbital
Empircally, we have shown selectivity is
governed exclusively by lower !* energy
Reactivity: 3o > 2o > 1o C-O > C-N
Pseudo-C2-Symmetric Phosphacycles:
When !* energies are equivalent,
A1,3 strain governs selectivity
 
 In conclusion, monocyclic phosphates undergo a highly selective anti-SN2’ 
allylic phosphate displacement.  Subsequent cleavage affords an array of syn-(E)-
homoallylic alcohols when pseudo-C2-symmetric monocyclic phosphates are 
employed.  In extending this method to unsymmetric phosphates, cuprate addition 
proceeded through the more substituted allylic phosphate position (lower σ* energy) 
with the general reactivity pattern being 1º < 2º < 3º, allowing access to anti-
configured homoallylic alcohols, in which the resulting stereochemistry is exclusively 
produced via chirality transfer from a remote stereogenic center.  In probing these 
systems, the Corey mechanism for allylic organocuprate displacements was examined 
and further substantiated, although testing systems with additional dissymmetric 
substitution on the olefin is necessary to rule out nucleophilic avoidance of steric 
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Phosphate Tethers in Synthesis: 
Generation of the Central Core of Fostriecin Towards Library Development 
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3.1 Introduction 
While the use of phosphates in chemical synthesis is limited, they are 
ubiquitous in nature and provide structural and chemical keystones in dynamic 
biological systems making them ideal targets for both pharmaceutical and agricultural 
applications.1  The ability of phosphates to exist with defined tetrahedral geometry 
and stable anionic charge, present it as a well-suited pharmacophore.  Consequently, 
organophosphates and their analogs have served as surrogates for carboxylic acids, 
amino acids, and anomeric carbons in carbohydrates, to name a few.  Furthermore, 
direct application of the phosphate moiety towards kinase and phosphatase regulation 
is evident and realized in several naturally occurring inhibitors.   
Investigation of phosphatase inhibitors as pharmacologically viable targets is 
relatively new compared to investigations on kinase inhibitors.2  While initially 
phosphatases were regarded as enzymes that “clean-up” after more essential 
regulatory kinases, a large body of evidence dismisses this misconception in light of 
the pivotal role of phosphatases in the body.3  In particular, protein phosphatase 2A 
(PP2A) regulates myriad cellular processes, including: metabolism, transcription, 
translation, cell cycle, signal transduction, differentiation, and oncogenic 
transformation.4  Moreover, recent research has linked PP2A and other phosphatases 
with the mechanism associated with motor learning.5  Given this wide range of 
regulation it is not surprising to find that particular naturally occurring phosphatase 
inhibitors are involved in certain diseases, such as hepatocarcinoma and HIV-1.4  Yet, 
it has also been shown that other phosphatase inhibitors (particularly, selective 
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inhibitors of PP2A)6 can be used to disrupt cancerous cells, thus paving the way 
towards development of this class of inhibitors as viable drug targets.2 
The leustroducsins (1.2) are a class of phosphate-containing molecules that 
were isolated from the culture broth of Streptomyces platensis SANK 60191 
belonging to the phoslactomycin group of antibiotics.7  In particular, leustroducsin B 
has been shown to exhibit an array of biological activities.  The in vitro induction of 
cytokine production through transcriptional and posttranscriptional activation of NF-
kΒ8 and significant in vivo thrombopoietic, anti-infective, and anti-metastatic 















































The most selective inhibitor of PP2A to date is the molecule fostriecin (1.1, 
aka CI-920, NSC 339638, and PD 110,161) with an IC50 value of 1.5-3.0 nM.3,9 
Boger and coworkers determined that the unsaturated α β-unsaturated lactone, 
completely unprotected phosphate and C(11) hydroxyl moieties are essential for 
activity.10  The terminal hydroxyl group on the triene tail was found to play no role in 
the activity of the molecule. 
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Cytostatin (1.3) is yet another phosphate-containing compound and a member 
of the fostriecin family.  It has been shown to prevent metastasis, inhibit tumor cell 
growth, inhibit cell adhesion and cause apoptosis in certain cell lines due to its 
exquisitely selective inhibition of PP2A.6  Analogous to fostriecin, it was found that 
the αβ-unsaturated lactone ring, completely unprotected phosphate and C(11) 
hydroxyl moieties are essential for activity in cytostatin, while the triene was merely 
beneficial for binding but did not drastically effect activity.11  The activity granted by 
the unsaturated lactone ring in cytostatin (as well as fostriecin) is believed to come 
from a nucleophilic conjugate addition in the enzyme,12 while the deprotected 
phosphate ensures a very tight, yet non-covalent, interaction.  The triene, while 
proven to be non-essential, seems to help substrate binding and thereby enhance 
activity.  Indeed, it was shown that the triene moiety could be replaced with a vinyl 
iodide to yield an analog nearly as potent (IC50 39 nM at pH = 8.1) as cytostatin itself 
(IC50 33 nM at pH = 8.1; IC50 210 nM at pH = 7.5).11 
 While the essential features of leustroducsin B, fostriecin, and cytostatin are 
well evidenced, these structurally similar compounds differ in placement of groups 
and functionality on C(6), C(8) and C(10).  In particular, while Boger surmised that 
the C(8) stereocenter of fostriecin might serve to mimic the PP2A substrate 
stereocenter, no systematic study of this center has been performed.  However, in 
Kanai and Shibasaki’s synthesis of fostriecin and 8-epi-fostriecin, they deduced the 
epimer was a more selective PP2A inhibitor.13  The high specificity of cytostatin, 
which bears no C(8) stereocenter but a stereocenter at C(10), begs study of differing 
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substitution in these regions.  The proposed methods towards leustroducsin B, 
fostriecin, and cytostatin allow for developing analogs with differing substitution in 
these areas, particularly at the C(8) position in fostriecin and leustroducsin B, and the 
C(10) position in cytostatin.  The method also allows for substitution of the triene tail 
with groups of similar lipophilicity and geometric disposition.  It has been postulated 
that the triene tail is the culprit for degradation in the storage of fostriecin and 
cytostatin.3,11 
The architecture and SAR of the above molecules have prompted our 
investigation of fostriecin, leustroducsin B, and analogs thereof, starting with our 
bicyclic phosphate system (R,R,PS)-2.1 (Scheme 2). The key feature in these planned 
syntheses revolved around a pivotal terminus differentiation strategy of the C2-
symmetric anti-diol (R,R)-2.2 using a phosphate tether and RCM to derive (R,R,PS)-

























































C(12)/C(13) Z-olefin, the C(7) terminal olefin armed for regioselective oxidation, and 
triol protection at the C(9), C(11), and C(14) carbinol centers.  We deemed the 
potential fruits of such a synthetic investigation to be too enticing to overlook. 
3.2 Selective Oxidation of the Exocyclic Olefin 
Generation of the bicyclic phosphate required has been reported previously in 
our group.14,15 Construction of P-chiral bicyclic[4.3.1]-phosphate triester (R,R,PS)-2.1 
began with coupling of C2-symmetric diene 1,3-diol (R,R)-2.216 with phosphoryl 
trichloride producing the pseudo-C2-symmetric compound 3.1 possessing 
interchangeable, homotopic Cl and P=O groups.  Concurrent addition of lithium 
allyloxide into phosphoryl monochloride 3.1 yields phosphate triester triene 3.2.  
Ring-closing metathesis (RCM) using Grubbs second-generation catalyst17 afforded 
desired phosphate (R,R,PS)-2.1 in good yield. 











































Key to the formation of fostriecin and fostriecin-based libraries was the 
realization of an oxidation of the exocyclic olefin in bicyclic phosphate (R,R,PS)-2.1.  
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Reactions under standard Wacker conditions,18 however, for up to 12-16 hours 
resulted in complete recovery of starting material in 80-90% yield.  This is turns out 
to be unsurprising, as protected allylic alcohols are known to be problematic,19 if not 
completely unreactive, towards Wacker oxidation.  Indeed, the electron withdrawing 
nature of the phosphate may prevent the necessary ligation of PdII.  Upon rigorous 
investigation, it was found that employing modified-Wacker conditions20,21,22 with 
bicyclic phosphate (S,S,PR)-2.1 provided initial yields of 40% of desired ketone 
(S,S,PR)-4.1, whereby structural confirmation was achieved using X-ray 
crystallographic analysis. (Scheme 4).  Optimization of this protocol utilizing 


































The reaction was extremely time-dependent, where erring on either side of the 
optimal time23 even slightly resulted in drastic losses in yield.  It was also notable that 
while most transformations utilized warming of the mixture after PdCl2 addition to 
achieve desirable yields, the oxidation of phosphate (R,R,PS)-2.1 was poor at 
temperatures above 40 ºC.  A putative mechanism invoked24 in this process involves 
oxymercuration of the substrate, followed by addition of cupric chloride and PdCl2 
 115 
(traditional reagents utilized for the standard Wacker oxidation) whereby 
transmetallation allows for oxidation to the ketone.  As the reaction is performed 
under strictly anaerobic conditions, cupric chloride is the terminal oxidant for the Pd0 
formed during oxidation of substrate.  This same transient Pd0 species is what we 
postulate to be the detrimental species in the formation of ketone (R,R,PS)-4.1 from 
(R,R,PS)-2.1 (Scheme 5); the intermediacy of Pd-allyl species formed from bicyclic 
phosphate (R,R,PS)-2.1 has been utilized in this lab in the generation of the northern 












It was hypothesized that if a Pd0 species could be avoided, several problems 
could be circumvented, namely: strict time dependence, large quantities of palladium, 
and starting material/product degradation.  Investigation into several alternatives 
proved to be fruitless.  Recently, however, hope for a catalytic process was 
resurrected by a Sigman group publication that described the conversion of protected 
allylic alcohols into acyloin products via a catalytic Pd complex24 (Scheme 6).  Not 
only did the catalyst avoid the use of mercuric salts altogether and involvement of a 
Pd0 intermediate, the reaction proceeded with good yields on electron deficient 

























17 h, 89% 17 h, 60% 4.5 h, 77% 35 min, 92%  
We enthusiastically employed the requisite conditions on our bicyclic 
phosphate (R,R,PS)-2.1 only to quantitatively recover starting material (Scheme 7).  
Attempts to attenuate the conditions to afford oxidized product, including heating the 
solution, yielded the same initial result. Comparison of the relative pKa’s of acetic 
acid and phosphoric acid is illustrative, as the greater electron withdrawing nature of 
the phosphate appears to provide an inadequate alkene ligand for the Pd(quinox)Cl2 
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pKa = 2.12  
While the use of mercury salts has not been circumvented as of yet, bypassing 
the use of large amounts of palladium was heralded by the observation that cupric 
chloride was demercurating the intermediate generated in the oxymercuration 
reaction.  Initial attempts to perform the classical NaBH4 demercuration led to 
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extensive degradation of the intermediate, thus leading to a reinterpretation of the 
mechanism of the modified Wacker oxidation.  Rather than the transmetallation of 
mercury by palladium, simple addition of cupric chloride to the oxymercuration 
mixture could allow for rapid protonation, followed by slower PdII oxidation of the 
alcohol.  The PdII oxidation of alcohols26 utilizes similar conditions to the those 
utilized in the modified Wacker.  This interpretation was bolstered by performing the 
experiment with the omission of PdCl2, as depicted in Scheme 8, to provide a 

















Noting this, the oxidation of alcohol 8.1 was screened using several different 
oxidation conditions detailed in Scheme 13.  Initial attempts at using Swern oxidation 
conditions lead to exclusive dehydration to regenerate (R,R,PS)-2.1. Dess-Martin 
periodinane with pyridine curiously also formed the dehydration adduct as the major 
product.  Upon comparing pyridinium dichromate and pyridinium chlorochromate, 
the desired ketone was generated to a larger extent with PCC.  These observations 
were the basis of the speculation that acidic media is more favorable so as to prevent 
elimination.  Thusly, employing Jones reagent afforded the desired ketone (R,R,PS)-
4.1 without an observable trace (by 1H-NMR) of elimination product.  It should also 
be noted that TPAP oxidation in acetonitrile also provided clean conversion to the 



































Currently, the most optimized conditions employ oxymercuration followed by 
addition of CuCl2 to relinquish alcohol 8.1, after which the solvent is removed and the 
crude alcohol is directly oxidized via Jones oxidation to provide (R,R,PS)-4.1 in gram 
scale affording yields of 80-95% (Scheme 10).  Not only is the oxidation rapid, but 
purification involves simply passage of the crude mixture through a short silica plug 
to remove any associated metal ions.  This protocol, while more robust than the 
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phosphate system. As illustrated in Figure 1, lack of anti-periplanar (app) lone pairs 
in phosphate (R,R,PS)-2.1 imparts increased acid stability.14,27 When oxygen lone 
pairs occupy trans-app to an adjacent polar bond (P-OR), they donate electron 
density from their lone pair orbital, n, to the antibonding P-O σ*, thus weakening the 
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P=O bond and increasing the basicity at O; conversely, lack of app lone pairs imparts 
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Figure 1: Stereoelectronic effects within an acyclic phosphate vs. (S,S, PR)-2.1 
3.3 Probing a Diastereoselective Grignard Addition with the α-Ketophosphate 
Realization of the exocyclic olefin oxidation of (R,R,PS)-2.1 allowed for 
investigation into a diastereoselective Grignard addition of vinyl magnesium bromide 
to yield tertiary alcohol 11.1 (Scheme 11). Previous models of analogous systems 
employing 1,2-stereoinduction under chelating conditions28,29 provided strong 
precedent for such a selective addition.  The vinyl group was chosen as both a handle 
for library development as well as possible employment in the total synthesis of 
fostriecin, where such a handle was anticipated to readily lend itself available to 
incorporation of diverse moieties via cross-metathesis.  Initial attempts employing 5 
equivalents of commercially available vinyl magnesium bromide at -30 ºC pleasingly 
provided the desired addition product 11.1, where tentative assignment of the 
stereochemistry of alcohol 11.1 was made based upon the aforementioned precedent, 
































Optimization of this key C8 stereocenter generation entailed investigating 
temperature, equivalents, and chelating additives to potentially enhance 
diastereoselectivity.  The new, commercially obtained vinyl magnesium bromide 
appeared to perform best at -45 ºC in THF, as at lower temperatures the addition 
appeared to occur very sluggishly and at temperatures higher than -30 ºC attack at 
phosphorous appeared to compete.  Illustrative to the screening of additives is the 
investigation of additional MgBr2•OEt2, detailed in Scheme 16. It was observed that 
increasing the equivalents of the chelation reagent appeared to decrease yields by 


























Fortunately, based upon the difference in reactivity with certain substrates of 
commercial vinyl magnesium bromide versus freshly prepared vinyl magnesium 
bromide, we reinvestigated the addition utilizing freshly prepared vinyl magnesium 
bromide.  A very different reactivity was observed; one of the first observations was 
that -45 ºC was too high of a temperature and that -78 ºC was optimal.  This allowed 
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for diastereoselectivities of 15:1 (based on 31P-NMR) and a greater recovery of 
unreacted starting material.  While the yield was not significantly different, the 
presence of MgBr2•OEt2 did not prove to be detrimental unlike with commercial 
vinyl Grignard.  Therefore, utilizing 3 equivalents of freshly prepared vinyl Grignard 



















3.4 Generating the Fostriecin Core: Library Proof of Concept 
The next task towards forming the fostriecin core was to engage the newly 
installed olefin of 11.1 in the aforementioned selective cross-metathesis.  The reactive 
nature of the olefin generated, however, was in question, as previous explorations on 
the reactive nature of the exocyclic olefin in (R,R,PS)-2.1 had concluded (R,R,PS)-2.1 
exhibited Type III olefin behavior.15,30 While unprotected tertiary allylic alcohols are 
typified as exhibiting Type II reactivity, protected allylic alcohols are also classed as 
Type II olefins.31  Given that the exocyclic olefin of (R,R,PS)-2.1 is a protected allylic 
alcohol, it’s Type III reactivity profile seems to deviate from a blanket assessment.  
The role the phosphate played in attenuating the reactivity of the unprotected tertiary 
alcohol of 11.1 was also at issue, an assessment that is elaborated upon in Chapter 4 
(vide infra).  At this stage of the investigation the olefin was believed to be Type III 
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given the electron withdrawing nature of the phosphate bearing carbinol in 
combination with the steric interactions presented by the bicyclic system. 
Nevertheless, employing 5 equivalents of glycidol-derived allylic alcohol 14.1 
with phosphate 11.1 in the presence of 10 mol % Hoveyda-Grubbs II catalyst 














































Subsequent attack of lithium thiophenol, as precedented by our earlier work,14 
exploits the orthogonal leaving group ability of the phosphate to reveal the requisite 
stereo-tetrad of fostriecin 14.3 in quantitative yield with a malleable C(14) handle.  
These results also solidify our proposed method in generation of a fostriecin-like 














































































An approach towards fostriecin and fostriecin-like libraries utilizing rapid 
functionalization of bicyclic phosphate (R,R,PS)-2.1 was investigated. This compact, 
multifaceted core coupled with an array of selective reactive pathways begged the 
synthetic queries enacted.  Key to unraveling and expanding upon this central core of 
the molecule was realization of an exocyclic olefin oxidation to generate (R,R,PS)-4.1.  
Diastereoselective Grignard addition yields 11.1, where the source of Grignard used 
was found to play a non-trivial role.  Selective cross-metathesis of the olefin of 11.1 
with glycidol-derived allylic alcohol 14.1 generates diol 14.2 with exquisite E/Z 
selectivity in good yield.  Subsequent attack of lithium thiophenol exploits the 
orthogonal leaving group ability of the phosphate to reveal the requisite stereo-tetrad 
of fostriecin 14.3 in quantitative yield.  Not only does this sequence serve as a proof 
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of concept approach for the total synthesis of fostriecin, it also serves as an archetype 
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Routes Towards Fostriecin through Cross Metathesis Investigations 
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4.1 Introduction 
Fostriecin (1.1, CI-920, Scheme 1) is a biologically potent metabolite first 
isolated from Streptomyces pulveraceus in 1983 by workers at Warner Lambert-Parke 
Davis.1  It displays in vitro activity against a broad range of cancerous cell lines 
including lung cancer, breast cancer, and ovarian cancer,2 as well as in vivo antitumor 
activity.  In addition, fostriecin has demonstrated activity against leukemia (L1210, 
IC50 0.46 µM and P338).3  Its mode of action appears to operate via an inhibitory 
pathway of the mitotic entry checkpoint. Evidence of this pathway is shown in 
fostriecin's potent and selective inhibition of a number of protein phosphatases.4,5  In 
1997, Boger and coworkers determined the relative and absolute stereochemistry in 
fostriecin that confirmed previous assignments in a family of biologically active and 
structurally related natural products, including leustroducsin B (LSN-B, 1.2), 
phospholine (1.3), and phosphazomycin C (1.4).6   




























































Leustroducsin B (LSN-B) was originally purified as a colony-stimulating 
factor inducer from the broth of Streptomyces platensis by Sankyo in 1993 and has 
been shown to exhibit a variety of biological activities.7  Shibata and coworkers 
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determined the absolute configuration of leustroducsin H (LSN-H) in 1995,8 which 
allowed Matsuhashi in 2002 to confirm the absolute configuration of LSN-B via the 
chemical transformation of LSN-H.9 In vivo, leustroducsin B has been found to 
increase host resistance against Escherichia coli in addition to inducing 
thrombocytosis in mice.  In vitro activity has been shown to induce granulocyte-CSF 
and granulocyte-macrophage-CSF production by KM-102 cells.  Recent studies have 
suggested that LSN-B induces cytokine production via NF-κB activation at the 
transcriptional and post-transcriptional levels.10 In 2003, Fukuyama and coworkers 
reported the first total synthesis of leustroducsin B, achieving this pioneering 
synthesis in 46-linear steps.10  More recently, Imanishi and coworkers achieved the 
total synthesis of leustroducsin B in 2008.11 
Since the first total synthesis by Boger and coworkers in 2001,12 several total 
syntheses13 and synthetic studies14 have been reported for fostriecin.  In 2001 
Jacobsen completed the total synthesis of fostriecin in 17 steps, highlighted by the use 
of a Cr-catalyzed hetero-Diels-Alder followed by a zirconium mediated addition to a 
chiral epoxy aldehyde to set three of the four stereocenters in >99% ee.13a  Imanishi’s 
2002 synthesis utilized Horner-Wadsworth-Emmons chemistry and Stille coupling to 
complete the total synthesis in 24 linear steps.13c,e  More recently in 2005, Trost 
completed dephospho-fostriecin in 14 linear steps employing a direct asymmetric Zn-
catalyzed aldol reaction,15 while Shibasaki’s formal synthesis utilized four 
asymmetric catalysts to set the four stereogenic centers.16,17 
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Key structural features in this class include a C(1)-C(5) α,β-unsaturated δ-
lactone, a central anti-1,3-diol moiety at C(9)/C(11), a C(8) tertiary carbinol 
stereocenter, a C(9) phosphate, a Z,Z,E-triene subunit extending from C(12)-C(17) in 
fostriecin (1.1), and the corresponding Z,Z-diene subunit extending from C(12)-C(15) 
in LSN-B (1.2), 1.3, and 1.4.  In addition, a C(8)-β-ethyl amine functionality and 
added complexity of a C(16)-1,3-disubstituted cyclohexyl system in LSN-B pose 
formidable synthetic challenges.  We are proposing the utilization of versatile bicyclic 
phosphate (R,R,PS)-2.1 for the total syntheses of leustroducsin B (1.2), fostriecin (1.1) 
and potential analogs (Scheme 2). 
4.2 Retrosynthetic Analysis of Fostriecin and Leustroducsin B 
The key feature in these highly convergent syntheses revolves around a 
pivotal terminus differentiation strategy of the C2-symmetric anti-diol (3R,5R)-hepta-
1,6-diene-3,5-diol using a phosphate tether and RCM to derive (R,R,PS)-2.1.  This 
desymmetrization step serves to assemble in a single step the requisite C(12)/C(13) Z-
olefin, the C(7) terminal olefin armed for regioselective oxidation, and triol protection 
at the C(9), C(11), and C(14) carbinol centers. Additional features include a late-stage 
installation of the α,β−unsaturated δ-lactone moiety and setting the C(6)/C(7) E-
configured olefin utilizing a critical CM coupling between the central 1,3-anti-diol 
subunits in 2.5 and 2.10 (assessed as Type III CM partners)18 and 2.4 and 2.11 
(assessed as Type II CM partners).  Wittig olefination of the aldehyde 2.5 with the 
ylide of 2.6, or of 2.10 with the ylide of phosphonium salt 2.9, would install the 
eastern side-chains, respectively.  A key diastereoselective vinyl Grignard addition 
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into ketophosphates 2.2 and 2.7 using literature precedence will set the C(8) tertiary 
carbinol center and insert a “vinyl linchpin” residing in 2.3 or 2.10 for subsequent 
CM.  This addition is preceded by C(8) sidechain installation relying on 
regioselective oxidation of (R,R,PS)-2.1 using a oxidation/enolization/CM sequence to 
derive ketone 2.7.  Overall, this highly convergent pathway (Plan A) encompasses an 
16 linear-step sequence to fostriecin and 19 linear-step sequence to leustroducsin B, 
applicable to other members in this family and unnatural analogs. 


































































Another possible route (Plan B) involved installation of the lactone at an 
earlier stage via a diastereoselective Grignard addition of isopropyl-protected lactols 
3.1 and 3.2 (Scheme 3).  The most notable change in the synthetic sequence would be 
generation of the lactone via the lactol in the latter part of the synthesis versus cross-
metathesis installation of the intact lactone.  Such a secondary route was envisioned 
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to circumvent promiscuous reactivity of the lactone if such a phenomena was 
witnessed.  The drawback to such a route appeared to be twofold: 1) the operational 
manner of the oxidation, as deprotection to the lactol prior to oxidation or direct 
oxidation of the protected lactol could potentially suffer from functional/protecting 
group compatibility issues that the cross-metathesis route avoids, and 2) the linearity 
of a route utilizing a protected lactol Grignard.  As such, the former synthetic route 










4.3 Generation of the Lactone Precursor and Organometallic Addition Studies 
Generation of the western lactone portion of fostriecin was initially planned 
through use of the chiral, non-racemic glycidol ethers, with the lactone of 
leustroducsin B arriving from an analogous route (Scheme 4). Starting from (R)-THP-
protected glycidol 4.1, Grignard addition in the presence of CuI and acryloylation 
would derive diene 4.2.  Ring-closing metathesis, deprotection, Dess-Martin 
oxidation, and Wittig methylenation would afford lactone 2.4.  In a similar manner, 
asymmetric allylboration with (S,S)-tartrate-derived Z-crotylboronate19 (S,S)-4.3 
would set the requisite C(4)/C(5) syn stereorelationship in lactone 2.11.  Coupling 
with acryloyl chloride presents diene 4.4 which could be followed by subsequent 
RCM as demonstrated by Cossy.14a  Deprotection with DDQ, Dess-Martin oxidation, 
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and Wittig olefination would then afford 2.11 in a concise 6-step sequence.  In 
practice, the proposed route toward lactone 2.4 proceeded well prior to the 
oxidation/methylenation sequence, where the fugacious aldehyde formed via Dess-
Martin oxidation provided a variety of products upon treatment with phosphonium 












































 Initial attempts at generation of a protected lactol available for organometallic 
addition to the ketone were likewise problematic.  Attempts to generate iodide 3.1 
(Scheme 5) from Trost’s (R,E)-1-iodohexa-1,5-dien-3-ol15 (5.1) were set aside upon 
observation of reluctant ring-closing metathesis of the lactone in the presence of the 
vinyl iodide, where the solution turned black upon addition of Hoveyda-Grubbs II 
catalyst with apparent catalyst inactivation shortly thereafter.  This inactivation and 
decomposition of starting material may be due to initial metathesis of the vinyl iodide 



































 Reassessing the situation we saw an opportunity to capitalize on Jacobsen’s 
hetero-Diels-Alder methodology13,21 towards generating the desired cross metathesis 
and Grignard addition precursors for fostriecin.22  Initiation of the synthetic sequence 
relied upon generation of the precatalyst, a process previously reported by the 
Jacobsen group.21bc Precatalyst preparation commenced through Friedel-Crafts 
adamantylation of p-cresol (Scheme 6).  The 2-adamantyl-1-p-cresol (6.1) is then 
subjected to a net formylation via electrophilic addition of formaldehyde presumably 
with subsequent oxidation by excess formaldehyde through a Oppenauer-type 
oxidation.23  The resulting aldehyde (6.2) is immediately condensed with (1R, 2S)-
(+)-cis-1-amino-2-indanol to form ligand 6.3.  The active precatalyst 6.4 is formed by 



































With the necessary precatalyst 6.4 in hand, formation of the desired lactol 
precursor24 proceeded with a formal hetero-Diels-Alder annulation of diene 7.125 and 
aldehyde 7.226 (Scheme 7) to provide benzylated lactol 7.3 in high enantiomeric 
excess.  Subsequent deprotection and epimerization of the anomer leads to terminal 









4 Å M. S., 90%
94% ee, d.r. 95:5
1. TBAF, THF, 0 ºC
2. 1 mol % TsOH, 2 h
3. recrystallization













Not only was 7.5 posited to be a versatile precursor for our studies towards the 
proposed synthesis of fostriecin, but application of the model for catalyst 
enantioselectivity with diene 8.128 (Scheme 8) and aldehyde 7.2 foresaw application 
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towards leustroducsin B, hence discoveries made with lactol 7.5 were anticipated to 
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 Investigations into organometallic addition thus started by attempting a 
similar direct hydrometallation of the terminal alkyne as performed by the Jacobsen 
group.  This approach was predicated on Wipf’s hydrozirconation29/zinc 
transmetallation protocol30 for addition to aldehydes, where the Jacobsen group 
posited that the enhanced electrophilicity of the α-oxy ketone could exhibit enhanced 
reactivity in contrast to a typical ketone's unreactive nature.  The Jacobsen group 
found that employing equimolar quantities of Schwartz’s reagent, alkyne 7.5, and 
Me2Zn with 1.5 equivalents α-epoxyketone 9.1 at 25 ºC provided 9.2 in >30:1 
diastereoselectivity and 45% yield (Scheme 9).13a,24 
Prompted by the elegance of this direct approach and encouraged by the 
inertness of our monocyclic phosphates to dialkyl zinc species, we set forth to assess 
this method with regards to our exocyclic ketone 2.2.  We expected the α-phosphoryl 
oxygen of ketone 2.2 to exhibit a greater inductive withdrawing effect on the ketone, 
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if indeed such a rational was operative for this addition on our substrate.  Attempts at 
applying this method to our bicyclic α-phosphoryl ketone 2.2 at a variety of 
temperatures and equivalents of hydrometallated alkyne 7.5 proved fruitless.  At 
lower temperatures (< 0 ºC) no reaction was observed on the ketone, while 
temperatures above 0 ºC proceeded with attack of the organometallate on 
phosphorous without engaging the ketone.31  While the phosphoryl oxygen may 
exhibit a greater inductive withdrawing effect on the ketone, the enhanced 
electrophilicity of the bicyclic phosphate (versus acyclic and our monocyclic systems) 
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 Undaunted, the generation of a hydrometallated version of alkyne 7.5 was 
attempted via a stepwise approach.  Initial trials utilized a hydroboration/iodination 
sequence to provide a species, iodide 3.1, capable of lithium-halogen exchange in 
generating a more reactive hydrometallated variant as originally planned in 
retrosynthetic plan B (Scheme 10).32  Hydroboration was attempted with 
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catecholborane, the Arase system employing catalytic dicyclohexylborane with 
catecholborane,33 and with dicyclohexylborane34 as the sole hydroboration reagent.  It 
was found that the use of dicyclohexylborane exclusively provided the best yield 
following iodination, whereby subsequent iodination with either I2 or N-













Overall, the moderate selectivity of hydroboration on alkyne 7.5 and 
lackluster yield provided motivation for a different approach, where 
hydrostannylation could provide the necessary intermediate.  Utilization of both 
radical35 and Pd-mediated hydrostannylation36 hydrostannylation protocols found that 
radical hydrostannylation provided the E-alkene 11.1 with the highest selectivity as a 
single observable geometric isomer (Scheme 11).  Iodine/stannane exchange via NIS 
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7.5 11.1 3.1  
Both E-stannylalkene 11.1 and E-iodoalkene 3.1 were tested for their potential 
vinyl metal congeners to affect selective addition with ketone (R,R)-2.2.  Direct 
lithiation of E-stannylalkene 11.1 by n-BuLi38 provided poor metal exchange, an 
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uninspiring result especially when it was observed that the lithiated species derived 
reacted poorly (Scheme 12).  In contrast, transmetallation of E-iodoalkene 3.1 
proceeded smoothly when 2.2 equivalents of t-BuLi were employed.39  The resulting 
vinyl lithium species, however, exhibited poor chemo- and diastereoselectivity.  
Utilizing a protocol developed by the Oshima group to generate a vinylmagnesium 
ate complex40 for addition into ketones, E-iodoalkene 11.1 was transformed into 
magnesiate via addition of E-iodoalkene 11.1 to a mixture of 1 equivalent 
isopropylmagnesium chloride and 2 equivalents of s-BuLi in THF at 0 ºC.  After 
exchange was assured, this solution was cooled to -78 ºC and subsequently 
cannulated into ketone (R,R,PS)-2.2 preincubated with freshly prepared MgBr2.41  
While this produced the desired addition product 12.1 with excellent 
diastereoselectivity, significant problems associated with the solubility of ketone 
(R,R,PS)-2.2 with MgBr2 and preferential addition of the magnesiate with the 
phosphate of 2.2 made this route unattractive.  Indeed, the problems encountered 
utilizing commercial isopropylmagnesium chloride were almost identical to those 
observed when utilizing commercial vinylmagnesium bromide with ketone (R,R,PS)-
2.2, with the added detrimental phosphate addition attributed to the higher reactivity 



























































1. i-PrMgCl (1 equiv)
s-BuLi (2 equiv), 0 ºC
MgBr2 (3 equiv.)





Organometallic addition was achieved by conversion of E-iodoalkene 11.1 to 
the Grignard in a two-step process (Scheme 13).  Lithium-halogen exchange with t-
BuLi was followed by cannulation of the organolithium into MgBr2•OEt2 to form the 
corresponding Grignard. Subsequent cannulation into ketone 2.2 at -45 ºC provided 
addition adduct 12.1 as a single observable diastereomer in 69% yield.  Bicyclic 
phosphate 12.1 presented a synthon with the correct stereotetrad and the carbocyclic 
skeleton of the lactone core in place.  While this provided the necessary plausibility 
for retrosynthetic plan B, it was decided the coupling of the intact lactone core late 
stage as planned in retrosynthetic plan A was more convergent, easily amenable to 
modifications for advanced library development and leustroducsin B synthetic efforts, 
and would potentially avoid problems associated with lactone oxidation on an 
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advanced intermediate.  It was this rational that initiated studies investigating the 


















4.4 Investigation of Lactone Installation Through Cross Metathesis 
Formation of a lactone primed for cross metathesis (Plan A) began with 
conversion of the alkyne of 7.5 to an alkene.  Preparation of the desired alkene was 
thought to be easily performed by a Lindlar hydrogenation of alkyne 7.5, where Pd-
CaCO3 in the presence of freshly distilled quinoline in EtOAc under H2 readily 
reduced the alkyne to alkene 14.1 in 80% yield on gram scale (Scheme 14).  It is 
worth noting that allowing the reaction to proceed longer than 2 hours led to over 
hydrogenation of the exocyclic portion while the endocyclic olefin remained intact.  
At scales smaller than 1 gram poorer yields were obtained, with mixtures of over 
hydrogenated product, remaining starting material, and product necessitating tedious 
separation of the chromatographically similar compounds.  In an attempt to access 
14.1 on smaller scales and to avoid this dilemma, a separate protocol was developed 
where stannane 11.1 was protodemetallated with TFA at 0 ºC in THF to cleanly 
generate alkene 14.1, however with modest yields.  Nevertheless, the investigation 
proved fruitful toward the siphoning of material from retrosynthetic route B to route 
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Cross metathesis of the protected lactol 14.1 with tertiary alcohol 15.1 was 
performed to assess the viability of the coupling, where protected lactol 14.1 was 
added in five-fold excess to tertiary alcohol 15.1 with 10 mol % Hoveyda-Grubbs II 
catalyst (Scheme 15).  Phosphate 12.1 was pleasingly provided in 77% yield with 
excellent selectivity for the E-isomer.  Based on this unoptimized success, generation 
of the central segment of fostriecin was probed with concurrent investigations into the 

























Formation of the central segment of fostriecin proceeded from phosphate 15.1, 
which itself arrives from selective manipulation of bicyclic phosphate (R,R,PS)-2.1 as 
described in Chapter 3.  The tertiary alcohol of phosphate 15.1 was protected as the 
TES ether generating 2.3 prior to phosphate tether removal42 to provide 
monoprotected tetraol 16.1 (Scheme 16).  Utilizing precedent set by Hatakeyama,13d 
the monoprotected tetraol 16.1 was selectively bis-protected at -78 ºC to afford 
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alcohol 16.2, whereby the C9 alcohol was left untouched.  From this differentiated 
synthon, phosphate 16.3 was generated by employing dibenzyl N,N-diisopropyl 
phosphoramidite and subsequent tert-butyl hydroperoxide oxidation.  This sequence 
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We concurrently generated the unprotected tertiary alcohol variant of alcohol 
16.2 through an analogous route, where phosphate 15.1 was directly subjected to 
LiAlH4-mediated phosphate tether cleavage to afford tetraol 17.1 (Scheme 17).  
Utilizing the same bis-protection protocol developed in the previous reaction series, 
selectively bis-protected tetraol 17.2 was produced to examine reactivity differences 



















15.1 17.1 17.2  
The investigation of the C9 DMB protected alcohol was also envisioned, as 
the DMB group could serve a role in late stage installation of the phosphate should 
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unforeseen modifications to the planned route prohibit early inclusion.  Investigations 
were halted due to two observations: 1) attempts to protect the alcohol with the DMB 
group either yielded no reaction or extensive migration of the silyl groups under basic 
conditions, and 2) attempts to utilize the DMB and PMB groups in previous 
routes13a,15 curiously converted the protecting group to another species without 
comment (adding steps) or removed it prior to triene formation.  While the DMB 
group had been utilized by Yamada to avoid degradation of the α,β,γ,δ-unsaturated 
lactone upon deprotection in the synthesis of aplyronines A, B, and C, 43 the unwritten 
prose of previous synthetic efforts indicated that the deprotection conditions were 
detrimental to the triene of fostriecin. 
Synthesis of the necessary cross metathesis partner involved exploring routes 
towards the oxidation of the protected lactol.  Initially, it was believed deprotection of 
alkene 14.1 to lactol 18.1a would allow for facile oxidation to lactone 2.4 (Scheme 
18).  Acidic deprotection of the isopropyl group provided deprotected 18.1a and a 
mixture of acyclic E (18.1c) and Z (18.1b) isomers at the internal olefin.44 It was 
posited that Lewis and/or Bronsted acids should help interconvert the olefin, with 
generation of the Z-isomer allowing conversion of the acyclic aldehyde 18.1b to 
lactol 18.1a whereby oxidation to desired lactone 2.4 would shift the overall 
equilibrium, ultimately allowing for reclamation of the E-isomer to generate desirable 
yields of lactone 2.4.  In practice, mildly Lewis acidic (Fétizon’s reagent, MnO2) and 
Bronsted acidic (PCC) oxidizing agents failed to appreciably convert the E-isomer 
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into lactone 2.4.  Employing Jones reagent, however, allowed for interconversion and 




4:1 acetone: 0.5 M HCl
PCC, CH2Cl2
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Avoiding the generation of lactol 18.1a allowed for PCC to directly oxidize 
isopropyl protected lactol 14.1 (Scheme 19) in similarly good yields with some 
acyclic E-isomeric products present,45 but direct oxidation of protected lactol 14.1 to 
lactone 2.4 by Jones reagent was clearly the desired route, affording product in 93% 
yield with very facile purification.  In addition, it was found that vinyl stannane 11.1 
could also be directly converted to lactone 2.4 through the Jones oxidation in 80% 
yield when additional p-toluenesulfonic acid was present, thereby presenting a route 





















acetone, 0 ºC, 93%
2.411.1  
With lactone 2.4 in hand, attention turned to the desired direct cross 
metathesis with the central fostriecin core to append the western segment (Scheme 
20).  Cross metathesis of the assessed Type II lactone 2.4 with assigned Type III 
phosphate 16.3 utilizing 10 mol % Hoveyda-Grubbs II catalyst provided the desired 
coupling product 20.1 in good selectivity for the E-olefin isomer but in very dismal 
yield, a result that could not be improved despite changes in solvent, concentration 
and catalyst.  While phosphate 16.3 was readily reclaimed, only scant traces of 
dimerized lactone were noticed.  Given the conditions employed, if lactone 2.4 was a 
Type II olefin such as glycidol-derived allylic alcohol 20.2 or alkene 14.1,46 then 
large amounts of dimerized product should be observed.47  Thusly, lactone 2.4 was 
concluded to be a sluggish Type II olefin as it ultimately did cross-metathesize and 

































 It was suspected that the highly electron withdrawing nature of the α-
phosphate of 16.3 may be reducing the reactivity of the olefin, providing our 
uninspiring yields.  To test this, alcohol 16.2 was subjected to metathesis with lactone 
2.4, however at this stage no desired reaction product (21.1) was observed.  
Additionally, reclamation of alcohol 16.2 was poor as the substrate appeared to 
undergo olefin migration and elimination reactions to yield a convoluted variety of 
degradation products.  It appeared the phosphate was not the problem, but rather was 
protecting the alcohol from participating in deleterious side reactions with the catalyst 


















Enhanced reactivity was surmised to occur by changing most proximal 
environment to the olefin by utilizing diol 17.2.  The unprotected tertiary allylic 
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alcohol 17.2 is a Type II olefin, and it was postulated reaction of 17.2 with excess 
lactone 2.4 should provide us with a better coupling of the western and central 
segments (Scheme 22).  Empirically, however, it was found that only a slightly better 
coupling product 22.1 was observed, with the notable disadvantage that 22.1 co-elutes 
with lactone 2.4.  While dimerized 17.2 was initially thought to be recyclable, re-
investigation of Grubbs seminal publication18 on cross metathesis types found that 
tertiary allylic alcohols, while Type II, are unique in that the dimers are Type IV and 
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 The newly acquired data previously outlined necessitated a reassessment of 
lactone 2.4 and the coupling method.  At the outset of the investigations, we were 
apprehensive of the lactone, concerned with potentially promiscuous reactivity.  On 
the contrary, the lactone was very stable to storage and appeared to show reluctant 
reactivity in cross metathesis, likely a result of the inductively withdrawing 
endocyclic α-oxygen of the lactone on the alkene.  The reactivity starkly contrasted 
isopropyl protected lactol 14.2 in metathesis, a classical Type II olefin, such that the 
lactone was a near Type III olefin.  Forming the necessary alkylidene seemed to be 
the issue; if initiation of metathesis on either the reluctant Type II lactone 2.4 or the 
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Type III terminal olefin in 16.3 (or potentially 16.2) could be realized, an effective 
coupling could be affected. 
4.5 Investigation of Lactone Installation via Relay Cross Metathesis 
 Relay metathesis appeared to be a plausible route towards resolving this 
predicament. While the majority of relay metathesis cases providing enhanced 
reactivity/product formation involve intramolecular cyclizations,48 reports on relay 
cross metathesis are extremely sparse.49  In Lee’s investigation, conjugated enynes 
such as 23.1 efficiently underwent cross-metathesis with (Z)-but-2-ene-1,4-diyl 
diacetate (Scheme 23).  Application of the same concept to afford a formal 
methacrylate cross-metathesis, though, found exclusive cross metathesis at the 
terminal olefin to produce 23.4 without catalyst delivery to form the enoate 
alkylidene.  Performing the same reaction without external alkene allowed for the 
formation of methacrylate, thus indicating the cross-metathesis with (Z)-1,4-
bis(benzyloxy)but-2-ene occurred at a significantly greater rate than the 
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 The quandary of deciding upon either the modification of lactone 2.4 or 
phosphate 16.3 by a catalyst delivery vehicle was left to an empirical resolution.  
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Lactone 2.4 was first to be tested, as we postulated that a Fu sp2-sp3 coupling50 
between vinyl stannane 11.1 and 5-iodopentene could readily modify the western 
segment towards formation of the desired relay lactone 24.1 (Scheme 24). 
Implementation of this protocol readily afforded lactone 24.1, which was initially 
tested with phosphate (R,R,PS)-2.1 (a Type III olefin) to determine if our supposition 
had merit.  The relay cross metathesis exceeded our expectations when the 
unoptimized reaction returned phosphate 24.2 quantitatively in a respectable ratio of 
geometric isomers, a pleasing contrast to attempting the reaction without the 
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We then attempted the cross metathesis of our fostriecin core segment 16.3 with the 
relay-primed lactone 24.1, were optimal conditions involved slow introduction of 
lactone 24.1 over the course of 6 hours (Scheme 25).  While this method did provide 
an increased yield of product, the increase was disappointingly slight and certainly 
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 As the previous investigation indicated the sluggish reactivity of the exocyclic 
olefin in phosphate 16.3 may play a more significant role in the cross metathesis, 
construction of the relay analog proceeded with formation of (E)-1-bromo-1,6-
heptadiene (26.1) from 1-hepten-6-yne by slightly modifying a Wolfe group 
procedure (Scheme 26).51  Generation of the Grignard of 26.1 followed by addition 
into ketophosphate 2.2 provided relay analog 26.2, which could be easily protected 




















3 CH2Cl2, 0 ºC, 2 h
96%
TESOTf, 2,6-lut.
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phosphate 26.3 to refluxing lactone 2.4 in DCE provided none of the desired relay 
cross product (Scheme 27).  Instead, cross metathesis proceeded at the terminal olefin 
of the relay linker to afford the extended chain variant (27.1).  Modification of the 
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exocyclic olefin of phosphate 16.3 to the relay variant 26.3 appears to have produced 
a Type IV olefin, or at the very least a Type III olefin so inhibited towards metathesis 
that intermolecular coupling outcompetes the intramolecular reaction even under the 
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 To circumvent this, the unprotected tertiary alcohol relay variant 26.2 was 
tested for coupling (Scheme 28).  Unfortunately, the desired coupling product 28.1 
was only obtained in 17% yield, with 20% recovery of phosphate 15.1 a testament to 
the sluggish reactivity of lactone 2.4 and with the remainder of material appearing to 
undergo isomerization/elimination reactions to generate a complex mixture of 
degradation products, indicating the unprotected tertiary alcohol alkylidene is 
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present.  Attempted coupling of phosphate 15.1 with lactone 2.4 provided dimerized 
bis-phosphate as the exclusive product, as irreversible self-coupling appeared to be 
the most facile reaction pathway. 
Given these results it appears cross metathesis, either utilizing a catalyst 
delivery vehicle (relay cross-metathesis) or direct coupling, is not a viable option for 
appending the intact lactone 2.4 in realizing a facile route from our compact 
functional synthon (R,R,PS)-2.1. The cross metathesis investigations, however, were 
able to provide enough material to achieve the penultimate intermediate in the 
proposed synthesis (on microgram scale), and therefore allowed the establishment of 
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While cross-metathesis is a viable route toward library development, the 
research presented indicates that installation of the carbocyclic skeleton of the 
essential lactone of fostriecin in a high yielding, efficient manner may rely on 
implementing retrosynthetic plan B.  The efficient and diastereoselective addition of 
isopropyl lactol 3.1 to ketone (R,R,PS)-2.2 has been demonstrated, thus paving the 
way for implementation.  In addition, upon perusal of the oxidation conditions 
utilized for lactone generation,52 prohibitive protecting group incompatibilities are no 


































































Exploration of two synthetic approaches from (R,R,PS)-2.1 towards fostriecin 
were embarked upon simultaneously.  Due to the anticipated elegant introduction of 
the western lactone of fostriecin, initial focus of our investigative energies centered 
upon realizing a cross metathesis of the lactone subunit with the central segment of 
fostriecin.  Intensive studies found the deactivating nature of the carboxylate oxygen 
on the alkene of lactone 2.4 in conjunction with the lethargic protected tertiary allylic 
alcohol 16.3 provided unacceptable conversion upon metathesis, despite installation 
of catalyst delivery vehicles (lactone 24.1).  Attempts to utilize the unprotected 
variant 15.1 displayed preferential dimerization of allylic tertiary alcohol 15.1, while 
the relay primed analog 26.2 was frustrated by competing elimination pathways.  
Analysis of Grignard addition of the lactone core 3.1 to ketone 2.2, however, 
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propitiously heralds retrosynthetic plan B’s viability.  Future work in the total 
synthesis of fostriecin is expected to be enabled by application of this synthetic 
option, as well as guide the efforts in the total synthesis of leustroducsin B and other 
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5.1 General Experimental Methods 
All air and moisture sensitive reactions were carried out in flame- or oven-dried 
glassware under argon atmosphere using standard gastight syringes, cannulaes, and 
septa.  Stirring was achieved with oven-dried magnetic stir bars.   Et2O, toluene, THF 
and CH2Cl2 were purified by passage through the Solv-Tek purification system 
employing activated Al2O3 (Grubbs, R.H.; Rosen, R.K.;  Timmers, F.J.; 
Organometallics 1996, 15, 1518-1520).  Et3N was purified by passage over basic 
alumina and stored over KOH.  Butyl Lithium was purchased from Aldrich and 
titrated prior to use.  Dialkyl zinc and alkyl zinc halide reagents were purchased from 
Aldrich and were used at the reported molarities.  Grubb’s second-generation olefin 
metathesis catalyst was acquired from Materia and used without further purification.  
Flash column chromatography was performed with Merck silica gel (EM-9385-9, 
230-400 mesh).  Thin layer chromatography was performed on silica gel 60F254 plates 
(EM-5717, Merck).  Deuterated solvents were purchased from Cambridge Isotope 
laboratories.  1H, 13C and 31P NMR spectra were recorded on a Bruker DRX-400 
spectrometer operating at 400 MHz, 100 MHz, and 162 MHz respectively or a Bruker 
Avance operating at 500 MHz and 125 MHz respectively.  High-resolution mass 
spectrometry (HRMS) and FAB spectra were obtained on a VG Instrument ZAB 
double-focusing mass spectrometer.  
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5.2 Experimental Data: Chapter 2 







A solution of allylic alcohol 1.3 (2.05 g, 11.54 mmol) in THF (58 mL) was 
cooled to –30 ˚C.  BuLi (2.47M, 11.02 mmol) was slowly added, followed by ten 
minutes of stirring.  A solution of dichloromethyl phosphate (781 mg, 5.25 mmol) in 
THF (10.5 mL) was slowly cannulated into the reaction vessel containing the 
alkoxide.  The reaction continued to stir at –30 ˚C for 30 minutes, the cold bath was 
removed and the solution was warmed to room temperature and stirred for an 
additional two hours.  Upon completion (monitored by TLC), the reaction was 
quenched with 20 mL of NH4Cl (sat’d aq).  The separated aqueous layer was 
extracted with Et2O (3x) and the combined organic layers washed with brine then 
dried (MgSO4).  Flash chromatography (2:1 hexanes/EtOAc) provided 1.96 g (87% 
yield) of the diene product as a faint yellow oil.  
[α]D = +0.54 (c = 0.37, CH2Cl2) 
IR (neat) 2930, 1452, 1266, 1016, 734, 698 cm-1 
1H NMR (500 MHz, CDCl3) δ 7.4-7.3 (m, 10H), 5.91 (ddd, J = 17.2, 10.6, 6.4 Hz, 
1H), 5.91 (ddd, J = 17.2, 10.6, 6.4 Hz, 1H), 5.45 (d, J = 17.2, 1H), 5.39 (d, J = 17.2, 
1H), 5.30 (d, J = 10.5, 1H), 5.30 (d, J = 10.5, 1H), 4.98-5.09 (m, 2H), 4.59 (dd, J = 
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12.2, 5.1 Hz, 2H), 4.54 (dd, J = 12, 1.4 Hz, 2H), 3.72 (d, J = 11.4 Hz, 3H), 3.62 (dd, J 
= 10.6, 6.3 Hz, 2H), 3.57 (m, 2H) 
13C NMR (125 MHz, CDCl3) δ 138.11, 134.05, 134.02, 133.99, 128.56, 127.89, 
118.84, 118.65, 78.13, 78.10, 78.09, 78.05, 73.44, 73.41, 72.47(d, JCP = 0.8 Hz), 
72.42 (d, JCP = 1.5 Hz), 54.48, 54.44 
31P NMR (162 MHz, CDCl3) δ 0.29 
HRMS calculated for C23H29O6P (M+H)+ 433.1780; found 433.1757 (FAB).  
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A flask containing the (S,S)-diene phosphate triester (1.45 g, 3.36 mmol) was 
charged with toluene (670 mL) that had been degassed for 20 minutes with argon.  
The solution was brought to reflux while continually sparging with argon, and 
(ImesH2)(PCy3)(Cl2)Ru=CHPh was added (200 mg, 0.235 mmol).  The reaction was 
maintained at reflux under argon sparging for 30 minutes.  Upon completion 
(monitored by TLC) the reaction was cooled to room temperature and concentrated 
under reduced pressure.  Purification via flash chromatography (1:1 hexanes/EtOAc) 
supplied 927 mg (68% yield) of monocylic phosphate 1.1. 
[α]D –52.6 (c = 1.6, CH2Cl2) 
FTIR (neat) 3029, 1454, 1365, 1282, 1027 cm-1 
1H NMR (400 MHz, CDCl3) δ 7.28-7.39 (m, 10H), 5.76 (ddd, J = 12.0, 1.8, 1.6 Hz,  
1H), 5.72 (ddd, J = 12.0, 1.8, 1.6 Hz, 1H), 5.26-5.32 (m, 1H), 5.07-5.14 (m, 1H), 
4.56-4.64 (m, 4H), 3.87 (d, JHP = 11.1 Hz, 3H), 3.67 (dddd, J = 6.4, 5.5, 5.1, 0.9 Hz, 
2H), 3.59 (dddd, J = 5.3, 5.1, 2.1, 0.5 Hz, 2H) 
13C NMR (100 MHz, CDCl3) δ 137.56, 137.48, 129.49, 128.42, 128.09, 127.83, 
127.81, 127.69, 127.63, 73.91, (d, JCP = 7.0), 73.62 (d, JCP = 4.5), 73.49, 73.33, 71.60 
(d, JCP = 11.9), 71.21 (JCP = 12.1), 54.62 (d, JCP = 5.1) 
31P NMR (162 MHz, CDCl3) δ 3.61 
HRMS calculated for C21H25O6P (M+H)+ 405.1467; found 405.1437 (FAB).  
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Phosphate 1.1 (30 mg, 0.074 mmol) was taken up in THF (0.20 mL) and 
cooled to 0 ˚C while stirring under argon.  LiAlH4 (0.010 mg, 0.24 mmol) was added 
slowly, and upon complete addition stirring continued for an additional 2 hours while 
warming to room temperature.  The mixture was then cooled to 0 ˚C and slowly 
quenched with H2O (0.1 mL) followed by 10% NaOH aq (0.2 mL).  The layers were 
separated and the aqueous layer extracted with EtOAc (5x).  The combined organic 
layers were concentrated under reduced pressure and dried (Na2SO4).  Column 
chromatography (5:1 heptane:EtOAc) provided 4 (18.3 mg, 75%) as a clear oil. 
[α]D = + 21.7 (c = 1.7, CH2Cl2) 
FTIR (neat) 3417, 3025, 2902, 1493, 1465, 1101, 1075, 737, 698 cm-1 
1H NMR (400 MHz, CDCl3) δ 7.28-7.37 (m, 10H), 5.58-5.64 (m, 2H), 4.63-4.68 (m, 
2H), 4.57 (s, 2H), 3.53 (dd, J = 9.4, 4.4 Hz 2H), 3.46 (dd, J = 9.5, 7.4 Hz, 1H), 2.65 
(bs, 2H) 
13C NMR (100 MHz, CDCl3) δ 137.62, 132.08, 128.47, 127.87, 127.84, 73.48, 73.42, 
67.21.  
HRMS calculated for C20H24O4 (M+Na)+ 351.1572; found 351.1582 (FAB).  
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Post ring-closing metathesis (50 mg, 0.123 mmol) with 
(ImesH2)(PCy3)(Cl2)Ru=CHPh (33 mg, 0.040 mmol), the reaction was a concentrated 
under reduced pressure and the resulting brown oil was taken up in dry CH2Cl2 (10 
mL).  The reaction was cannulated to a hydrogen Parr bomb apparatus, followed by 
implementing three quick cycles of evacuation and hydrogen purging.  The bomb was 
capped and charged with H2 (300 psi) while heating at 80 ˚C.  After stirring for two 
hours, the reaction mixture was concentrated under reduced pressure and immediately 
subjected to column chromatography (1:1 heptane:EtOAc) providing 45.4 mg of 2.2 
(90 % yield) as a light brown oil (small ruthenium contamination estimated to be < 
1%). 
[α]D = -2.15 (c = 0.33, CH2Cl2) 
FTIR (neat) 2917, 1279, 1098, 1000, 737, 698 cm-1 
1H NMR (400 MHz, CDCl3) δ 7.25-7.37 (m, 10H), 4.52-4.61 (m, 5H), 4.31-4.35 (m, 
1H), 3.82 (d, JHP = 11.1 Hz, 3H), 3.43-3.65 (m, 4H), 2.06 (dd, J = 11.9, 4.3 Hz, 1H), 
1.98 (dd, J = 10.6, 3.8 Hz, 1H), 1.73-1.82 (m, 2H) 
13C NMR (100 MHz, CDCl3) δ 137.67 (d, JCP = 2.6 Hz), 128.35, 127.72, 127.65, 
127.55, 77.94 (d, JCP = 6.4 Hz), 76.38 (d, JCP = 3.7 Hz), 73.32 (d, JCP = 10.6 Hz), 
72.59 (d, JCP = 11.1 Hz), 72.08 (d, JCP = 11.1 Hz), 54.26 (d, JCP = 4.9 Hz), 30.78, 
30.51 
 173 
31P NMR (162 MHz, CDCl3) δ 3.02 
HRMS calculated for C21H27O6P (M+H)+ 407.1624; found 407.1649 (FAB).  
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Phosphate 2.2 (30 mg, 0.074 mmol) was dissolved in THF (1.2 mL) and 
cooled to 0 ˚C while stirring under argon.  LiAlH4 (0.0084 mg, 0.22 mmol) was 
added slowly, and upon complete addition stirring continued for an additional 2 hours 
while warming to room temperature.  An additional amount of LiAlH4 was added, 
and the solution stirred for an additional hour.  The mixture was then cooled to 0 ˚C 
and slowly quenched with H2O (0.1 mL) followed by 10% NaOH aq (0.2 mL), and 
then H2O (0.1 mL).  The layers were separated and the aqueous layer extracted with 
EtOAc (5x).  The combined organic layers were concentrated under reduced pressure 
and dried (Na2SO4).  Column chromatography (5:1 heptane:EtOAc) provided 6 (21.9 
mg, 90%) as a clear oil. 
[α]D = +7.06 (c = 0.09, CH2Cl2) 
FTIR (neat) 3436, 1096, 737, 698 cm-1 
1H NMR (500 MHz, CDCl3) δ 7.28-7.37 (m, 10H), 4.55 (s, 2H), 3.82-3.88 (m, 2H), 
3.49 (dd, J = 9.0, 3.5 Hz, 2H), 3.49 (dd, J = 9.0, 7.5 Hz, 2H), 2.25 (bs, 2H), 1.56-1.65 
(m, 4H) 
13C NMR (125 MHz, CDCl3) δ 137.93, 128.46, 127.79, 127.75, 74.41, 73.34, 70.38, 
29.53. 
HRMS calculated for C20H24O4 (M+Na)+ 351.1572; found 351.1582 (FAB).  
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General Procedure A for Diakyl Zincate Derived Cuprates:  To a solution of 
CuCN•2LiCl (1 mmol, 1M in THF) cooled to -30 ˚C was added dropwise the dialkyl 
zinc reagent as a solution in THF (1 mmol).  After stirring 30-45 min (Me2Zn 
required longer stirring times) at -25 ˚C  to -30 ˚C, a solution of phosphate 1.1 (0.20 
mmol) in THF (2 mL) was added.  The reaction progress was monitored by TLC 
(products are baseline in EtOAc), and upon completion were quenched with 10% HCl 
aq. (1 mL) and stirred for 30 – 60 min.  The aqueous layer was extracted was 
extracted with EtO2 (4 x 1 mL) and the combined organic layers were subsequently 
washed with H2O (1 x 1 mL) and filtered of the resulting white solids.  The aqueous 
layer was removed and the organic layer was concentrated under reduced pressure.  
The crude acids were used without further purification.   
 
General Procedure B for Alkyl Zinc halide Derived Cuprates:  To a solution of 
CuCN•2LiCl (1 mmol, 1M in THF) cooled to -30 ˚C was added dropwise the alkyl 
zinc halide reagent as a solution in THF (1 mmol, 1.0M).  After stirring for one hour 
at -25 ˚C  to -30 ˚C, a solution of phosphate 1.1 (0.11 mmol) in THF (1.1 mL) was 
added.  The reaction progress was monitored by TLC (products are baseline in 
EtOAc), and upon completion (~ 2 hours) were quenched with 10% HCl aq. (1 mL) 
and stirred for 30-60 min.  The layers were separated and the aqueous layer extracted 
with CH2Cl2 (4 x 1 mL) and the combined organic layers were subsequently washed 
with H2O (1 x 1mL) and the resulting white solids were filtered off.  The aqueous 
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layer was removed and the organic layer was concentrated under reduced pressure.  
The crude acids were used without further purification.  
 
General Procedure for  Making  Alkyl Zinc Iodides (Cy-Zn-I): 
To a heterogeneous mixture of activated Zn dust (288 mg, 4.4 mmol) in THF (330 
µL) under argon was added dibromoethane (15 µL, 0.176 mmol), which was heated 
to 65 ˚C for one minute and then cooled to room temperature.  Trimethylsilyl chloride 
was then added (16 µL, 0.132 mmol) and the mixture was allowed to stir for 15 
minutes, upon which time the appropriate alkyl iodide (4 mmol) in THF (1.6 mL) was 
added and the reaction heated to 40 ˚C with stirring.  Upon completion (monitored by 
GC or Zn disappearance), the reagent was used immediately.  
 
General Procedure for Red-Al® of Phosphate Acids:  A stirring solution of the 
phosphate acid (0.124 mmol) in toluene (1.24 mL) was cooled to 0 ˚C and Red-Al 
(151 µL, 0.495 mmol) was added dropwise.  The reaction was allowed to proceed for 
30 minutes and monitored by TLC.  If necessary, an additional 1 equivalent of Red-
Al was added to ensure completion.  Reaction was quenched with H2O (1 mL) 
followed by slow addition of 10% HCl aq. (1 mL) at 0 ˚C. The layers were separated 
and the aqueous layer extracted with CH2Cl2 (4 x) and the combined organic layers 
were subsequently washed with brine and dried (MgSO4).  
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Following procedure A (100 mg of 1.1) and phosphate acid removal, column 
chromatography (heptane:EtOAc 4:1) afforded 4.1a (67 mg, 83 %) as a clear oil over 
two steps. 
[α]D = +30.4 (c = 1.0, CH2Cl2) 
FTIR (neat) 3461, 2358, 1456, 1361, 1249, 1027 cm-1 
1H NMR (400 MHz, CDCl3) δ 7.35-7.26 (m, 10H), 5.58-5.79 (m, 2H), 4.53 (d, J = 
1.8 Hz, 2H), 4.48 (s, 2H), 3.96-3.97 (m, 2H), 3.64 (ddd, J = 7.2, 7.2, 3.0 Hz, 1H), 
3.55 (dd, J = 9.5, 3.1, 1H), 3.39 (dd, J = 9.7, 7.7, 1H), 2.32-2.39 (m, 1H), 1.09 (d, J = 
6.8 Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ 138.26, 137.90, 135.62, 128.44, 127.77, 127.71, 
127.59, 127.05, 73.53, 73.34, 72.66, 71.98, 70.60, 39.80, 15.9. 
HRMS calculated for C21H26O3 (M+Na)+ 349.1780; found 349.1817 (FAB).  
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Following procedure A (50 mg of 1.1) and phosphate acid removal, column 
chromatography (heptane:EtOAc 4:1) afforded 4.1b (38 mg, 90%) as a clear oil over 
two steps. 
[α]D = +4.87 (c = 0.58, CH2Cl2) 
FTIR (neat) 3420, 2914, 1457, 1269, 1101, 1073, 737, 699 cm-1 
1H NMR (400 MHz, CDCl3) δ 7.35-7.26 (m, 10H), 5.62 (dt, J = 15.4, 6 Hz, 1H), 5.44 
(dd, J = 15.4, 9.3 Hz, 1H), 4.53 (d, J = 4.4 Hz, 2H), 4.49 (s, 2H), 3.99 (d, J = 5.9 Hz, 
2H), 3.7-3.66 (m, 1H), 3.57 (d, J = 9.5 Hz, 1H), 3.38 (t, J = 9.3 Hz, 1H), 2.48 (s, 1H), 
2.14-2.06 (m, 1H), 1.32-1.21 (m, 2H), 0.88 (t, J = 7.5 Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ 138.26, 137.89, 133.60, 129.01, 128.51, 128.41, 
128.36, 127.75, 127.72, 127.69, 127.57, 126.94, 73.32, 72.94, 72.49, 71.77, 70.50, 
47.92, 23.32, 11.56. 
HRMS calculated for C22H28O3 (M+NH4)+ 358.2382; found 358.2381 (FAB).  
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Following procedure A (50 mg of 1.1) and phosphate acid removal, column 
chromatography (heptane:EtOAc 5:1) afforded 4.1c (44.5 mg, 89 %) as a clear oil 
over two steps. 
[α]D = +17.5, (c , 2.1 CH2Cl2) 
FTIR (neat)  3446, 2348, 1101 cm-1 
1H NMR (400 MHz, CDCl3) δ 7.38-7.27 (m, 10H), 5.59 (ddd, J = 15.6, 6.0, 6.0 Hz, 
1H), 5.43 (dd, J = 15.4, 10.0 Hz, 1H), 4.53 (dd, J = 23.0,11.7 Hz, 2H), 4.48 (dd, J = 
12.2, 8.0 Hz, 2H) 3.92 (dd, J = 5.9, 1.0 Hz, 2H), 3.78-3.84 (m, 1H), 3.57 (dd, J = 9.5, 
2.6 Hz, 1H), 3.33 (dd, J = 9.4, 7.6 Hz, 1H), 2.39 (bs, 1H), 2.13-2.21 (m, 1H), 2.07 
(ddd, J = 9.6, 9.6, 3.1 Hz, 1H), 0.88 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ 138.28, 137.90, 130.41, 130.11, 128.42, 128.37, 
127.75, 127.72, 127.70, 127.58, 73.49, 73.34, 71.70, 70.46, 70.04, 51.79, 26.66, 
21.38, 16.82. 







Following procedure B (100 mg of 1.1) and phosphate acid removal, column 
chromatography (heptane:EtOAc 5:1) afforded 4.1d (68 mg, 70 %) as a clear oil. 
[α]D = +9.84 (c = 1.58, CH2Cl2) 
FTIR (neat) 3453, 3031, 2922, 2850, 1496, 1450, 1098, 737, 698 cm-1 
1H NMR (500 MHz, CDCl3) δ 7.37-7.28 (m, 10H), 5.57 (dt, J = 15.4, 5.9 Hz, 1H), 
5.44 (dd, J = 15.4, 10 Hz, 1H), 4.53 (dd, J = 11.8, 10.6 Hz, 2H), 4.49 (s, 2H), 3.98 (d, 
J = 5.9 Hz, 2H), 3.86 (td, J = 8.4, 2.5 Hz, 1H), 3.57 (dd, J = 9.5, 2.6 Hz, 1H), 3.32 
(dd, J = 9.4, 7.8 Hz, 1H), 2.42 (d, J = 4 Hz, 1H), 2.07 (td, J = 9.6, 3.9 Hz, 1H), 1.80-
1.70 (m, 4H), 1.65 (d, J = 12.7 Hz, 1H), 1.50 (d, J = 12.8 Hz, 1H), 1.33-1.20 (m, 2H), 
1.14-1.06 (m, 2H), 0.94 (ddd, J = 13, 12.8, 3.1 Hz, 1H) 
13C NMR (125 MHz, CDCl3) δ 138.57, 138.19, 131.42, 130.15, 128.66, 128.62, 
127.99, 127.95, 127.93, 127.83, 73.30, 73.58, 72.01, 70.73, 69.68, 52.07, 37.37, 
32.16, 28.09, 26.90, 26.84, 26.75 
HRMS calculated for C26H34O3 (M+Li)+ 401.2668; found 401.2678 (FAB).  
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Following procedure B (100 mg 1.1) and phosphate acid removal, column 
chromatography (heptane:EtOAc 4:1) afforded 4.1e (81.0 mg, 82%) as a clear oil 
over two steps. 
[α]D = –6.2 (c 1.4, CH2Cl2) 
FTIR (neat) 3444, 1494, 1452, 1097 cm-1 
1H NMR (400 MHz, CDCl3) δ 7.38-7.15 (m, 15H), 5.48 (dd, J = 15.7, 8.1 Hz, 1H), 
5.43 (ddd, J = 15.7, 10.6, 5.3 Hz, 1H), 4.56 (dd, J = 11.9, 7.3 Hz 2H), 4.31 (dd, J = 
12.0, 0.1 Hz, 2H), 3.91 (dd, J = 12.8, 4.1 Hz, 1H), 3.87 (dd, J = 12.3, 5.0 Hz, 1H), 
3.78-3.73 (m, 1H), 3.65-3.57 (m, 1H), 3.50-3.43 (m, 1H), 3.12 (dd, J = 13.4, 4.0 Hz, 
1H), 2.68 (dd, J = 13.5, 9.3 Hz, 1H), 2.62-2.52 (m, 2H) 
13C NMR (100 MHz, CDCl3) δ 139.79, 138.31, 137.00, 132.81, 129.52, 129.38, 
128.45, 128.31, 128.07, 127.82, 127.76, 127.67, 127.51, 125.85, 73.37, 72.68, 71.81, 
71.37, 70.27, 47.82, 37.27. 
HRMS calculated for C37H30O3 (M+Na)+ 425.2093; found 425.2083 (FAB).  
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Following procedure B (100 mg of 1.1) and methylation/phosphate removal, 
column chromatography (heptane:EtOAc 4:1) afforded 4.1f (78.0 mg, 83%) as a clear 
oil. 
[α]D = -12.0 (c = 1.5, CH2Cl2) 
FTIR (neat) 3463, 3031, 2927, 2246, 742, 702 cm-1 
1H NMR (400 MHz, CDCl3) δ 7.36-7.28 (m, 10H), 5.63 (ddd, J = 15.5, 5.7, 5.7 Hz, 
1H), 5.43 (dd, J = 15.5, 9.5 Hz, 1H), 4.52 (dd, J = 11.8, 7.7 Hz, 2H), 4.48 (dd, J = 
9.1, 0.1 Hz, 2H), 3.97 (d, J = 5.6 Hz, 2H), 3.62 (ddd, J = 7.4, 5.4, 2.3 Hz, 1H), 3.55 
(dd, J = 9.5, 9.4 Hz, 1H), 3.36 (dd, J = 9.4, 7.6 Hz, 1H), 2.47 (bs, 1H), 2.32 (dddd, J = 
14.3, 7.3, 7.0, 2.6 Hz 2H), 2.18 (ddd, J = 18.2, 10.1, 3.3 Hz, 1H), 1.96-1.86 (m, 1H), 
1.78-1.67 (m, 1H), 1.55 (ddd, J = 6.9, 6.0, 4.8 Hz, 1H), 1.34-1.45 (m, 1H) 
13C NMR (100 MHz, CDCl3) δ 138.17, 137.78, 132.42, 129.90, 128.51, 128.46, 
127.91, 127.80, 127.75, 127.72, 119.72, 73.44, 72.71, 72.49, 72.23, 70.30, 45.91, 
29.76, 23.31, 17.27. 








Following procedure B (100 mg of 1.1) and methylation/phosphate removal, 
column chromatography (heptane:EtOAc 5:1) afforded 4.1g (84.7 mg, 85 %) as a 
clear oil. 
[α]D = +5.8 (c = 0.625, CH2Cl2) 
FTIR (neat) 3442, 3031, 2921, 2856, 1494, 1452, 1361, 1099, 736, 698 cm-1 
1H NMR (400 MHz, CDCl3) δ 7.32-7.11 (m, 10H), 5.67-5.59 (m, 1H), 5.46 (dd, J = 
15.5, 9.4 Hz, 1H), 4.54 (dd, J = 17.4, 11.9 Hz, 2H), 4.49 (app s, 2H), 3.99 (dd, J = 
5.9, 1.1 Hz, 2H), 3.66 (ddd, J = 7.8, 7.8, 2.9 Hz,  1H), 3.57 (dd, J = 9.5, 2.9 Hz, 1H), 
3.57-3.52 (m, 2H), 3.39 (dd,  J = 9.5, 7.5 Hz, 1H), 2.22-1.88 (m, 3H), 1.84-1.69 (m, 
3H), 1.48-1.24 (m, 4H) 
13C NMR (100 MHz, CDCl3) δ 138.27, 137.86, 133.35, 129.24, 128.45, 128.38, 
127.73, 127.70, 127.61, 73.38, 72.71, 72.85, 72.62, 71.90, 70.34, 46.24, 45.00, 35.59, 
29.70, 24.43. 
HRMS calculated for C24H31ClO3 (M+NH4)+ 420.2305; found 420.2310 (FAB).  
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Following procedure B and phosphate acid removal, column chromatography 
(heptane:EtOAc 4:1) afforded 4.1h (61 mg, 65%) as a clear oil. 
[α]D = +3.53 (c = 0.17, CH2Cl2) 
FTIR (neat) 3422, 1274, 750, 699 cm-1 
1H NMR (500 MHz, CDCl3) δ 7.36-7.30 (m, 10H), 5.80 (ddt, J = 17, 10.2, 6.6 Hz, 
1H), 5.62 (dt, J = 15.5, 6 Hz, 1H), 5.46 (dd, J = 15.5, 9.4 Hz, 1H), 5.00 (dd, J = 17.1, 
1.4 Hz, 1H), 4.94 (dd, J = 10.2, 1 Hz, 1H), 4.54 (dd, 18.3, 11.7, 2H), 4.49 (s, 2H), 
3.99 (d, J = 6 Hz, 2H), 3.66 (td, J = 7.7, 3 Hz, 1H), 3.57 (dd, J = 9.5, 3 Hz, 1H), 3.38 
(dd, JHH = 9.3, 7.7 Hz, 1H), 2.40 (d, J = 4.2 Hz, 1H), 2.19 (ddd, J = 9.4, 7.9, 3.6 Hz, 
1H), 2.09-2.00 (m, 2H), 1.77-1.73 (m, 1H), 1.49-1.45 (m, 1H), 1.31-1.27 (m, 2H) 
13C NMR (125 MHz, CDCl3) δ 139.07, 138.53, 138.15, 133.98, 129.20, 128.67, 
128.61, 128.01, 127.95, 127.94, 127.82, 114.65, 73.59, 73.10, 72.94, 72.06, 70.72, 
46.50, 34.03, 30.19, 26.73 
HRMS calculated for C25H32O3 (M+NH4)+ 398.2695; found 398.2696 (FAB).  
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Using procedure A (50 mg of 1.1) afforded 3.1a (51.5 mg, 99%) as a clear 
viscous oil (compound was processed without further purification). 
[α]D = +15.6 (c = 4.5, CH2Cl2) 
FTIR (neat) 2331, 1496, 1454, 1232 cm-1 
1H NMR (400 MHz, CDCl3) δ 10.16 (bs, 1H), 7.37-7.26 (m, 10H), 5.71-5.62 (m, 
2H), 4.58-4.49 (m, 2H), 4.48 (s, 2H), 4.36-4.32 (m, 1H), 3.96 (s, 2H), 3.71-3.53 (m, 
5H), 2.73-2.61 (m, 1H), 1.11 (d, J = 6.7 Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ 138.67, 138.30, 134.72, 128.81, 128.80,  128.25, 
128.22, 128.11, 128.05, 81.45, 73.71, 72.44, 71.02, 70.45, 54.61, 38.80, 15.87 
31P NMR (162 MHz, CDCl3) δ 2.67 
HRMS calculated for C22H29O6P (M+Na)+ 443.1599; found 443.1600 (FAB). 
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General Methylation procedure:  
To a stirring solution of phosphate acid (0.295 mmol) in MeOH (0.6 mL) was slowly 
added (trimethylsilyl)diazomethane (2.0M, 1.48 mmol).  Upon addition, the reaction 
was allowed to run for 20 minutes at room temperature with stirring to ensure 
completion (monitored by TLC), then quenched by dropwise addition of acetic acid 
until effervescence ceases.  The reaction was concentrated under reduced pressure 
and pushed through a small plug of silica (4:1 hexanes/EtOAc) to supply the desired 
methyl phosphate ester.  
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Using procedure A, methylation followed by column chromatography 
(EtOAc:heptane 2:1) afforded 6.1a (50 mg, 95%) as a clear oil over two steps. 
[α]D = -27.0 (c = 2.0, CH2Cl2) 
FTIR (neat) 3062, 2952, 1454, 1363, 1278, 1041 cm-1 
1H NMR (400 MHz, CDCl3) δ  7.36-7.24 (m, 10H), 5.69-5.62 (m, 2H), 4.58-4.40 (m, 
5H), 3.97-3.94 (m, 2H), 3.73 (d, JHP = 11.2, 2H), 3.69 (d, JHP = 11.2, 2H), 3.64-3.56 
(m, 2H), 2.73-2.64 (m, 1H), 1.10 (d, J = 6.9 Hz, 3H) 
13C NMR (125 MHz, CDCl3) δ 138.19, 137.79, 134.00, 128.34, 128.31,  127.89, 
127.71, 127.69, 127.65, 127.57, 80.95 (d, JCP = 6.3), 73.16, 71.99, 70.55, 70.07 (d, 
JCP = 1.3), 54.28 (d, JCP = 6.3), 54.23 (d, JCP = 6.3), 38.44 (d, JCP = 5.0), 15.43 
31P NMR (162 MHz, CDCl3) δ 2.06 
HRMS calculated for C23H32O6P (M+H)+ 435.1937; found 435.1967 (FAB).  
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A flask containing allylic alcohol 1.3 (0.680 g, 3.83 mmol) was diluted up in 
THF (0.2 M, 20 mL) and cooled to -40 ˚C, followed by dropwise addition of BuLi 
(1.53, 2.5M).  After 10 minutes of stirring, allyldiphenyl phosphate (1.45 g, 5 mmol) 
in THF (1M, 5 mL) was cannulated to the flask containing the alkoxide.  The solution 
was stirred for eight hours while slowly warming to room temperature.  The reaction 
was quenched with sat’d aq. NH4Cl- and the layers were separated and the aqueous 
layer extracted with Et2O (2x).  The combined organic layers were concentrated 
under reduced pressure and dried (Na2SO4).  Column chromatography (1:1 
Hex:EtOAc) afforded the acyclic phosphate ester (1.03 g, 71%) as an oil.  To a flask 
containing the phosphate precursor was added degassed CH2Cl2 (0.05 M, 22.6 mL) 
and was subsequently fitted with a reflux condenser and needle, through which a slow 
steady stream of Ar flowed.  Grubbs catalyst (ImesH2)(PCy3)(Cl2)Ru=CHPh (0.034 
mg, 0.04 mmol) was added and the reaction lowered into an oil bath warmed to 50 
˚C.  The reaction was monitored by TLC and after 1.0-1.5 hrs was deemed complete.  
Following cooling to room temperature, the reaction was concentrated and purified 
via column chromatograpy (2:1 hexanes:EtOAc), to yield cyclic phosphate 7.1 as a 
1:1 mixture of diastereomers at phosphorus (0.301 g, 76%). 
1H NMR (400 MHz, CDCl3) δ 7.40-7.17 (m, 10H), 5.89-5.74 (m, 2H), 5.41-5.23 (m, 
1H), 5.14-4.89 (m, 1H), 4.71-4.51 (m, 3H), 3.79-3.62 (m, 2H) 
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13C NMR (100 MHz, CDCl3) δ 150.38 (d, JCP = 16.1), 150.22 (d, JCP = 16.1), 137.44, 
129.68 (d, JCP = 4.0), 128.61, 128.38, 128.23, 127.78, 127.67 (d, JCP = 7.0), 127.42, 
127.08, 125.22, (d, JCP = 6.0), 120.11 (d, JCP = 5.0), 119.87 (d, JCP = 4.0), 74.35 (d, 
JCP = 7.0), 74.01 (d, JCP = 4.0), 73.47, 73.28, 71.58 (d, JCP = 9.1), 71.15 (d, JCP = 
11.1), 64.87 (d, JCP = 7.0), 64.80 (d, JCP = 8.0) 
31P NMR (162 MHz, CDCl3) δ -3.61 and -2.87 




O OH  
Following procedure A (90 mg of 7.1) and methylation/phosphate removal, 
column chromatography (heptane:EtOAc 3:1) afforded 7.2 (42.1 mg, 81%) as a clear 
oil. 
[α]D = + 6.2 (c = 1.6, CH2Cl2) 
FTIR (neat) 3389, 2958, 1454, 1307, 1089, 1049 cm-1 
1H NMR (400 MHz, CDCl3) δ 7.22-7.19 (m, 5H), 5.63 (dt, J = 15.4, 6.0 Hz, 1H), 
5.43 (dd, J = 15.5, 8.7 Hz, 1H), 4.45 (s, 2H), 3.49 (dd, J = 10.6, 5.2 Hz, 1H), 3.36 (dd, 
J = 10.6, 8.0 Hz, 1H) 2.12-2.03 (m, 1H), 1.71 (bs, 1H), 1.45-1.34 (m, 1H), 1.26-1.15 
(m, 1H), 0.83 (t, J = 7.5 Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ 138.24, 135.15, 129.18, 128.43, 127.68, 127.58, 
72.11, 70.67, 65.60, 47.26, 23.78, 11.67 
HRMS calculated for C14H20O2 (M+Na)+ 243.1361; found 243.1361 (FAB). 
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A flask containing allylic alcohol 1.3 (0.239 g, 1.34 mmol) was diluted up in 
THF (0.2 M, 6.7 mL) and cooled to –30 ˚C, followed by dropwise addition of BuLi 
(0.537 mL, 2.5M).  After 10 minutes of stirring, dichloromethyl phosphate (0.147, 
1.47 mmol) was added to the flask containing the alkoxide.  The solution was stirred 
for one hour while slowly warming to room temperature.  The reaction was quenched 
with sat’d aq. NH4Cl- and the layers were separated and the aqueous layer extracted 
with Et2O (2x).  The combined organic layers were concentrated under reduced 
pressure and dried (Na2SO4).  Column chromatography (4:1 Hex:EtOAc) afforded the 
monochloride phosphate ester (0.311 g, 80%) as an oil.  The chloride was 
immediately used.  A flask containing alcohol 8.1 (0.074 mg, 0.861 mmol) was 
charged with THF (0.2 M, 4.31 mL) and cooled to -30 ˚C, followed by dropwise 
addition of BuLi (0.346 mL, 2.4 M).  After 10 minutes of stirring, a solution of the 
previously generated monochloride phosphate ester (0.200 g, 0.688 mmol) in THF 
(0.7 M, 1 mL) was cannulated to the flask containing the alkoxide.  The solution was 
stirred for 1.5 hrs while slowly warming to room temperature.  The reaction was 
quenched with sat’d aq. NH4+Cl- and the layers were separated and the aqueous layer 
extracted with Et2O (2x).  The combined organic layers were concentrated under 
reduced pressure and dried (Na2SO4).  Due to the instability of the acyclic phosphate, 
the reaction mixture was carried on without chromatography.  To a flask containing 
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the crude phosphate ester (assumed to be 0.688 mmol) was added degassed toluene 
(0.02 M, 34 mL) and was subsequently fitted with a reflux condenser, and needle 
through which a slow steady stream of Ar flowed.  Grubbs catalyst 
(ImesH2)(PCy3)(Cl2)Ru=CHPh (0.029 mg, 0.034 mmol) was added and the reaction 
lowered into an oil bath warmed to 90 οC.  The reaction was monitored by TLC and 
after 1.0 hr was deemed complete.  Following cooling to room temperature, the 
reaction was concentrated and purified via column chromatograpy (2:1 
hexanes:EtOAc), to yield cyclic phosphate 8.2 as a 1:1 mixture of diastereomers at 
phosphorus (0.100 g, 47 %).  One diastereomer could be purified, and was used for 
characterization. 
FTIR (neat) 3029, 2966, 1101, 737, 698 cm-1 
1H NMR (500 MHz, CDCl3) δ 7.35-7.27 (m, 5H), 5.63 (dd, J = 12.1 Hz, JHP = 2.3 
Hz, 1H), 5.53 (dd, J = 12.1 Hz, JHP = 3.1 Hz, 1H), 4.61 (dd, J = 12, 4.1 Hz, 2H), 3.81 
(d, JHP = 11.2 Hz, 3H), 3.67 (dd, J = 10.2, 6.9 Hz, 1H), 3.57 (ddd, J = 10.2, 5.2, 1.9 
Hz, 1H), 1.75 (s, 3H), 1.48 (d, JHP = 2.5 Hz, 3H) 
13C NMR (125 MHz, CDCl3) δ 137.90, 137.66, 128.46, 127.68, 124.16, 82.10 (d, JCP 
= 5.0 Hz), 73.55, 72.79 (d, JCP = 6.3 Hz), 71.86 (d, JCP = 10.1 Hz), 54.13 (d, JCP = 5.0 
Hz), 30.53 (d, JCP = 11.3 Hz), 29.32 








Following procedure A (90 mg of 8.2) and methylation/phosphate removal, 
column chromatography (heptane:EtOAc 3:1) afforded 8.3 (58.0 mg, 81%) as a clear 
oil. 
[α]D = +13.1, (c = 1.5, CH2Cl2) 
FTIR (neat) 3431, 3029, 2966, 1101 cm-1 
1H NMR (400 MHz, CDCl3) δ 7.31-7.22 (m, 5H), 5.02 (d, J = 8.9 Hz, 1H), 4.50 (s, 
2H), 3.81-3.74 (m, 1H), 3.54 (dd, J = 9.6, 3.1 Hz, 1H), 3.45 (dd, J = 9.6, 7.8, 1H), 
2.37-2.28 (m, 1H), 2.24 (bs, 1H), 1.78 (s, 3H), 1.65, (s, 3H), 1.61-1.51 (m, 1H), 1.34-
1.24 (m, 1H), 0.86, (t, J = 7.3, 3H) 
13C NMR (100 MHz, CDCl3) δ 138.15, 134.65, 129.61, 128.44, 127.76, 124.40, 












2. - 78 oC, O3, MeOH 













1H NMR (400 MHz, CDCl3) δ 7.37-7.28 (m, 5H), 4.62 (d, J = 12.1 Hz, 1H), 4.48 (d, 
J = 12.1 Hz, 1H), 4.26  (ddd, J = 6.2, 6.2, 2.4 Hz, 1H), 3.97  (ddd, J = 11.9, 2.6, 1.11 
Hz, 1H), 3.82  (dd, J = 11.9, 1.4 Hz, 1H), 3.49  (dd, J = 9.6, 6.6 Hz, 1H), 3.43  (dd, J 
= 9.7, 5.9 Hz, 1H), 1.77-1.65 (m, 1H), 1.46 (s, 3H), 1.38 (s, 3H), 1.35-1.27 (m, 2H), 
0.92 (t, J = 7.2 Hz). 






2. - 78 oC, O3, MeOH 













(4S,5S)-4-(benzyloxymethyl)-5-ethyl-2,2-dimethyl-1,3-dioxane:   
1H NMR (400 MHz, CDCl3) δ 7.36-7.22 (m, 5H), 4.63 (d, J = 12.3 Hz, 1H), 4.52 (d, 
J = 12.3 Hz, 1H), 3.87 (dd, J = 11.7, 5.4 Hz, 1H), 3.74 (ddd, J = 10.3, 5.0, 2.8 Hz, 
1H),85 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 138.42, 128.33, 127.73, 
127.56, 98.19, 73.58, 73.38, 71.50, 63.65, 37.02, 29.38, 21.08, 19.38, 10.05.  HRMS 
calculated for C16H24O3 (M+Na)+ 287.1623; found 287.1628 (FAB).  
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Celite, acetone, 0 ºC







 To a 250 mL round bottom flask under Ar (g) equipped with large stir bar was 
added 8.91 g (27.95 mmol, 2 equiv.) mercuric acetate followed by 35 mL degassed 
deionized H2O.  To this stirring mixture was cannulated a solution of 2.82 g (13.98 
mmol) phosphate 2.11,2 in 105 mL of degassed THF.  The mixture was stirred 
vigorously until completion (24-48 h, monitored by TLC, 100% EtOAc).  A mixture 
of 2.35 g (27.95 mmol, 2 equiv.) solid NaHCO3 and 2.86 g (16.77 mmol, 1.2 equiv.) 
CuCl2•2H2O was then added and the ensuing mixture allowed to stir for 15 minutes. 
100 mL EtOAc was then added, mixed, and the layers separated.  The small aqueous 
layer was extracted 3 more times with 100 mL EtOAc to ensure recovery of the very 
polar product, followed by combination of the organic extracts which were washed 
with brine and dried with Na2SO4.  Filtration into a 250 mL round bottom flask 
followed by solvent removal in vacuo provided 3.09 g of alcohol 8.1, which was used 
immediately in the next reaction. 
 The 250 mL round bottom flask is equipped a stir bar and 140 mL of acetone 
is added to generate a 0.1 M solution followed by 21 g of Celite® (1.5 g/mmol).  The 
stirring solution is cooled to 0 ºC, at which time 6.28 mL of Jones reagent (16.77 
mmol, 1.2 equiv.) is added dropwise.  The reaction is allowed to proceed with stirring 
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at 0 ºC until completion (TLC 20% acetone in ethyl acetate; ~ 2 h).  Upon indication 
of reaction completion, 0.5 mL isopropyl alcohol is added to consume any leftover 
Jones reagent, followed by filtration.  The filtrate is then concentrated to 40 mL, 
followed by addition of 100 mL ethyl acetate and careful addition of 10 mL NaHCO3 
(aq).  The solution is mixed and the layers separated, followed by 3 x 100 mL 
extractions of the aqueous layer.  The combined organic layers are washed with brine, 
dried with Na2SO4, filtered and silica added.  The solvent is then removed and the 
product laden silica added to a very short silica gel column.  Eluting the column with 
100% ethyl acetate (1 column volume) removes any less polar constituents, followed 
by elution with 20% acetone in ethyl acetate to elute product.  Solvent removal 
provides 3.05 g (80% yield) of phosphate 4.1. 
[α]D: -21 (c = 0.63, acetone, 25.6 ºC) 
FTIR: (neat) 2970, 2924, 2893, 2850, 1724, 1292, 1259, 1091, 1058, 991, 946, 921, 
885, 770 cm-1 
1H NMR (500 MHz, CHCl3-d) δ ppm 6.11 (dddd, J = 11.9, 6.5, 3.0, 2.2 Hz, 1H), 
5.65 (ddd, J = 11.9, 4.0, 2.7 Hz, 1H), 5.31 (dddd, J = 24.6, 3.9, 2.1, 1.9 Hz, 1H), 5.05 
(dddd, J = 14.8, 11.2, 5.0, 2.7 Hz, 1H), 4.97 (dt, J = 12.1, 2.3 Hz, 1H), 4.43 (ddd, J = 
28.3, 14.8, 6.7 Hz, 1H), 2.37 (s, 3H), 2.26 (ddddd, J = 14.8, 6.5, 5.2, 3.8, 2.5 Hz, 1H), 
2.15 (dddd, J = 14.8, 2.6, 2.5, 1.5 Hz, 1H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 205.8 (d, JCP = 12.0 Hz), 129.3, 128.7, 79.6 
(d, JCP = 7.2 Hz), 77.4 (d, JCP = 7.1 Hz), 63.5 (d, JCP = 6.4 Hz), 31.3 (d, JCP = 6.0 
Hz), 26.2 
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31P NMR (162 MHz, CHCl3-d) δ ppm -3.64 













To a 10 mL round bottom flask under Ar (g) equipped with stir bar was added 
312 mg (0.98 mmol, 2 equiv.) mercuric acetate followed by 1.25 mL degassed 
deionized H2O.  To this stirring mixture was cannulated a solution of 100 mg (0.49 
mmol) phosphate 2.1 in 3.75 mL of degassed THF.  The mixture was stirred 
vigorously until completion (24-48 h, monitored by TLC, 100% EtOAc).  A mixture 
of 82 mg (0.98 mmol, 2 equiv.) solid NaHCO3 and 100 mg (0.59 mmol, 1.2 equiv.) 
CuCl2•2H2O was then added and the ensuing mixture allowed to stir for 15 minutes. 
20 mL EtOAc was then added, mixed, and the layers separated.  The small aqueous 
layer was extracted 3 more times with 20 mL EtOAc to ensure recovery of the very 
polar product, followed by combination of the organic extracts which were washed 
with brine and dried with Na2SO4 and filtered.  Silica was added followed by solvent 
removal, whereupon the impregnated silica was placed on a silica gel column and the 
product eluted with 20% acetone in EtOAc, which after solvent removal provided 107 
mg (99% yield) of alcohol 8.1. 
FTIR: (neat) 3387, 2928, 1280, 1105, 1068, 1036, 978, 931, 769 cm-1 
1H NMR (500 MHz, acetone-d6) δ ppm 6.09 (dddd, J = 11.9, 5.2, 4.3, 2.2 Hz, 1H), 
5.76 (ddd, J = 11.9, 3.8, 2.6 Hz, 1H), 5.33 (app d, J = 24.7 Hz, 1H), 4.89 (dddd, J = 
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14.1, 6.2, 5.6, 2.7 Hz, 1H), 4.69 (d, J = 5.5 Hz, 1H), 4.45-4.31 (m, 2H), 4.16 (dddd, J 
= 6.3, 5.9, 5.9, 5.8 Hz, 1H), 2.24-2.12 (m, 3H), 2.09 (br s, 2H) 
13C NMR (126 MHz, acetone-d6) δ ppm 131.2, 128.3, 82.0 (d, JCP = 6.9 Hz), 78.6 (d, 
JCP = 6.7 Hz), 72.5 (d, JCP = 10.4 Hz), 63.6 (d, JCP = 6.3 Hz), 34.9, 31.6 (JCP = 5.9 
Hz) 
31P NMR (162 MHz, acetone-d6) δ ppm -4.20 (t, JPH = 25.0 Hz) 
HRMS Exact Mass: calculate for C10H16HgO7P (M+HgOAc)+ 481.0340; 


















A 25 mL flask containing 280 mg (1.28 mmol) of ketone 4.1 was placed under 
argon atmosphere and 13 mL of THF were added to generate a 0.1 M solution. The 
solution was then cooled to -78 ºC and freshly prepared vinyl magnesium bromide 
(3.86 mL, 1.0M in THF, 3 equiv.) was added slowly along the side of the flask.  The 
reaction mixture was maintained in a cooling bath at -78 ºC for 7 h, after which time 
13 mL of saturated aqueous NH4Cl was added, the flask removed from the cooling 
bath, and the mixture allowed to reach room temperature.   The reaction mixture was 
extracted with 3 x 30 mL EtOAc and the organic layers collected.  The organic layers 
were then washed with 20 mL brine, dried with Na2SO4, filtered, SiO2 added and the 
solvent removed in vacuo.  The substrate impregnated SiO2 was then placed on a 
short column, eluted with 2 column volumes of ethyl acetate, and then eluted with 
10% acetone in EtOAc.  Solvent removal afforded 230 mg (73% yield) of the desired 
tertiary alcohol 11.1. 
 
[α]D: -68.6 (c = 3.45, acetone, 27 ºC)  
FTIR: (neat) 3406, 2981, 2935, 1263, 1224, 1161, 1072, 1031, 983, 921, 883, 771 
cm-1 
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1H NMR (500 MHz, CHCl3-d) δ ppm 6.03 (dddd, J = 6.9, 6.6, 3.7, 1.4 Hz, 1H), 5.80 
(dd, J = 17.3, 10.9 Hz, 1H), 5.58 (ddd, J = 11.85, 3.9, 2.7 Hz, 1H), 5.39 (dd, J = 17.3, 
1.2 Hz, 1H), 5.23 (dddd, J = 25.0, 2.2, 2.0, 1.0 Hz, 1H), 5.21 (dd, J = 10.9, 1.2 Hz, 
1H), 5.00 (dddd, 14.7, 5.6, 5.6, 2.7 Hz, 1H), 4.39 (ddddd, 14.9, 10.3, 6.9, 1.8, 0.8 Hz, 
2H), 2.37 (ddd, J = 14.9, 12.2, 6.4 Hz, 1H), 2.24 (br s, 1H), 1.75 (ddd, 14.8, 3.6, 2 Hz, 
1H), 1.38 (s, 3H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 139.3, 130.1, 128.1, 115.7, 81.6 (d, JCP = 7.2 
Hz), 77.4 (d, JCP = 6.9 Hz), 74.1 (d, JCP = 9.1 Hz), 63.3 (d, JCP = 6.4 Hz), 29.3 (d, JCP 
= 5.5 Hz), 24.6  
31P NMR (162 MHz, CHCl3-d) δ ppm -2.88 (t, JPH = 25.0 Hz) 

























A solution of 11 mg (0.0446 mmol) of phosphate 11.1 and 40 mg (0.223 
mmol, 5 equiv.) of allylic alcohol 14.1 in 1 mL of degassed CH2Cl2 is prepared, thus 
generating a 0.05M solution with respect to phosphate 11.1.  The solution is added to 
a small, flame dried pressure tube containing a stir bar and 3 mg (0.0045 mmol, 0.1 
equiv.) Hoveyda-Grubbs II catalyst, which is immediately flushed with argon, 
capped, and placed in a 48 ºC silicon oil bath.  The reaction is allowed to stir for 12 
hours at 48 ºC and then removed from heat to cool to room temperature.  Addition of 
a slight amount of SiO2 followed by solvent removal provides the impregnated SiO2, 
which is placed on a column and eluted with 10% acetone in ethyl acetate to provide 
12 mg (70% yield) of the desired cross-metathesis product as a single observable 
isomer. 
 
[α]D: -60 (c = 0.10, acetone, 23.8 ºC) 
FTIR: (neat) 3340, 2978, 2860, 1286, 1072, 1035, 987, 923, 742 cm-1 
1H NMR (500 MHz, CHCl3-d) δ ppm 7.34 (m, 5H), 5.99 (dddd, J = 11.9, 5.3, 4.5, 2.2 
Hz, 1H), 5.85 (dd, J = 15.6, 5.1 Hz, 1H), 5.71 (dd, J = 15.6, 1.2 Hz, 1H), 5.45 (ddd, J 
= 11.9, 3.9, 2.5 Hz, 1H), 5.14 (ddd, J = 21.0, 2.1, 1.7 Hz, 1H), 4.99 (dddd, J = 11.9, 
8.4, 5.6, 2.7 Hz, 1H), 4.56 (s, 2H), 4.39 (br s, 1H), 4.36 (ddd, J = 27.5, 12.1, 7.9, 2.0 
 203 
Hz, 2H), 3.58 (dd, J = 9.6, 3.4 Hz, 1H), 3.38 (dd, J = 9.5, 7.6 Hz, 1H), 2.50 (d, J = 3.3 
Hz, 1H), 2.31 (ddd, J = 14.9, 12.2, 6.4 Hz, 1H), 2.21 (s, 1H), 1.69 (ddd, J = 14.9, 3.3, 
2.2 Hz, 1H), 1.37 (s, 3H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 137.9, 132.5, 130.2, 129.5, 128.7, 128.2, 
128.1, 128.0, 81.5 (d, JCP = 7.3 Hz), 77.4 (d, JCP = 6.8 Hz), 74.2, 73.8 (d, JCP = 9.1 
Hz), 73.7, 70.7, 63.4 (d, JCP = 6.4 Hz), 29.3 (d, JCP = 5.5 Hz), 25.2 
31P NMR (162 MHz, CHCl3-d) δ ppm -2.88 (t, JPH = 21.1 Hz) 
























THF, 23 ºC, 10 min
> 99%  
To a dry 5 mL round bottom flask under argon containing a stir bar and 5 mg 
(0.0126 mmol) of phosphate 14.2 was added 130 µL of THF to generate a 0.1M 
solution.  13 µL (0.013 mmol, 1 equiv.) of a 1.0M solution of LiSPh in THF was 
added dropwise, noting TLC (20% acetone in EtOAc solvent system) to determine 
the endpoint of the reaction via disappearance of starting material. An appropriately 
titrated reaction as described lends to a facile workup: addition of 10 µL of 1.25M 
HCl-methanol followed by solvent removal produces 6.4 mg (>99% yield) of 
phosphate acid 14.3. 
 
[α]D: -13 (c = 0.10, MeOH, 24.4 ºC) 
FTIR: (neat) 3628, 3340, 2978, 2860, 1286, 1072, 1035, 987, 923, 742, 681 cm-1 
1H NMR (500 MHz, MeOH-d4) δ ppm 7.30 (m, 10H), 5.78 (app s, 1H), 5.77 (app s, 
1H), 5.75 (t, J = 9.4 Hz, 1H), 5.56 (dd, J = 18.4, 7.8 Hz, 1H), 4.53 (dd, J = 9.9, 3.0 
Hz, 2H), 4.27 (dd, J = 10.9, 4.3 Hz, 1H), 4.12 (d, J = 5.9 Hz, 1H), 3.65 (dd, J = 13.8, 
8.2 Hz, 1H), 3.56 (dd, J = 13.8, 7.4 Hz, 1H), 3.42 (ddd, J = 9.0, 4.5, 2.9 Hz, 2H), 1.99 
(ddd, J = 12.7, 8.9, 4.9 Hz, 1H), 1.59 (ddd, J = 11.9, 10.2, 3.2 Hz, 1H), 1.31 (s, 3H), 
1.29 (dd, J = 16.6, 10.4 Hz, 1H) 
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13C NMR (126 MHz, MeOH-d4) δ ppm 139.8, 137.4, 136.2, 131.3, 130.6, 130.2, 
130.0, 129.5, 129.0, 128.8, 128.7, 127.6, 80.1, 75.6, 74.4, 72.1, 69.2, 40.3, 32.9, 32.1, 
25.1 
31P NMR (162 MHz, MeOH-d4) δ ppm -2.53 
HRMS Exact Mass: calculate for C25H30O7PS (M-H)– 505.1455; found 505.1446 
(ESI) 
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acetone, 0 ºC to r.t.
16 h, 80%  
To a 50 mL round bottom flask equipped with comparably large stir bar is 
added 800 mg of stannane 11.1 (1.74 mmol), 2.62g Celite (1.5g/mmol) and 17.5 mL 
of acetone (0.1M with respect to 11.1). The stirring mixture was brought to 0 ºC and 
1.44 mL of Jones reagent (2.67M, 3.84 mmol, 2.2 equiv.) added dropwise, followed 
by addition of 1.99g of TsOH•H2O (10.4 mmol, 6 equiv.).  After 1 hour the reaction 
was allowed to stir at room temperature for 15 hours before the reaction was filtered 
and the solid washed with 10 mL of acetone.  The filtrate was concentrated, 30 mL of 
EtOAc and 10 mL of brine added, and the mixture agitated.  Separation of the organic 
layer followed by extraction of the aqueous layer with 3x 10ml portions of EtOAc 
preceeded combination of all organic layers, to which SiO2 was added and the slurry 
concentrated to dryness.  The impregnated SiO2 was placed on a SiO2 column, 
flushed with 1:1 petroleum ether: diethyl ether to remove more nonpolar components, 
followed by elution with 100% diethyl ether to elute 173 mg (80% yield) of desired 
lactone 2.4. 
 
[α]D: +93 (c = 0.55, CH2Cl2, 26.3 ºC) 
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FTIR: (neat) 2957, 2924, 2854, 1722, 1420, 1385, 1246, 1034, 987, 935, 816, 669 
cm-1 
1H NMR (500 MHz, CHCl3-d) δ ppm 6.88 (ddd, J = 9.8, 5.4, 3.1 Hz, 1H), 6.06 (ddd, 
J = 9.8, 2.3, 1.3 Hz, 1H), 5.95 (ddd, J = 16.5, 10.6, 5.7 Hz, 1H), 5.41 (dd, J = 16.5, 
0.9 Hz, 1H), 5.30 (dd, J = 10.6, 0.8 Hz, 1H), 4.93 (ddd, J = 10.3, 5.4, 5.3 Hz, 1H), 
2.47 (ttd, J = 18.5, 5.1, 1.3 Hz, 1H), 2.45 (dddt, J = 18.5, 12.8, 10.0, 2.55 Hz, 1H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 164.0, 144.6, 135.0, 121.9, 118.1, 78.0, 29.6 














To a flame dried 100 mL round botton flask under argon containing a stir bar 
is placed 1.99 g stannane 11.1 (4.34 mmol) and 62 mL of CH2Cl2 to generate a 0.07M 
solution.  The mixture is placed in a cold bath and lowered to -45 ºC, at which time 
1.17 g N-iodosuccinimide (5.21 mmol, 1.2 equiv.) is added to the stirring solution in 
the dark.  The reaction is allowed to proceed in the dark until complete by TLC (30:1 
hexane: diethyl ether; about 2 hours), at which time 50 mL 10% NaS2O3 (aq) is added 
and the mixture allowed to achieve room temperature while continuing to protect the 
vessel from light.  The organic layer is separated and the aqueous layer extracted with 
3x 15 mL diethyl ether.  The combined organic layers are dried with MgSO4, filtered, 
and the solvent removed.  The crude mixture is then purified by flash column 
chromatography, initially using 100% petroleum ether to remove any stannane, 
followed by elution with 30:1 petroleum ether: diethyl ether to provide 995 mg (78% 
yield) of the vinyl iodide. 
 
[α]D: +36 (c = 4.46, CH2Cl2, 26.0 ºC) 
FTIR: (neat) 3043, 2968, 2924, 2895, 1464, 1380, 1315, 1180, 1124, 1099, 1059, 
1026, 1002, 947, 783, 717 cm-1 
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1H NMR (500 MHz, CHCl3-d) δ ppm 5.95 (ddt, J = 10.2, 5.7, 1.4 Hz, 1H), 5.70 (dtd, 
J = 10.2, 2.9, 1.3 Hz, 1H), 5.12 (d, J = 0.9Hz, 1H), 4.68 (ddd, J = 11.3, 2.9, 2.3 Hz, 
1H), 4.05 (hept., J = 6.2 Hz, 1H), 2.45 (d, J = 4.5 Hz, 1H), 2.41 (dddt, J = 17.8, 7.7, 
2.8, 1.8 Hz, 1H), 2.21 (dddd, J = 17.8, 5.7, 3.7, 1.3 Hz, 1H), 1.27 (d, J = 6.2 Hz, 3H), 
1.18 (d, J = 6.2 Hz, 3H), 1.05 (s, 1H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 127.8, 126.1, 93.1, 83.0, 72.9, 70.1, 57.1, 31.4, 
24.0, 22.2 
HRMS Exact Mass: calculate for C10H15INaO2 (M+Na)+ 317.0014; found 317.0015 
(ESI) 
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 To a 10 mL flame dried flask was added 200 mg (0.85 mmol) of alcohol 5.1,3 
253 µL (1.45 mmol, 1.7 equiv.) i-Pr2NEt, and 4.3 mL of CH2Cl2 (0.2 M w/r 5.1).  The 
solution was cooled to 0 ºC with stirring, at which time 83 µL (1.03 mmol, 1.2 equiv.) 
acryloyl chloride was added dropwise.  The reaction was allowed to stir at 0 ºC until 
completion, typically about 1.5 h.  Upon completion, sat. NH4Cl (aq) was added and 
the mixture extracted with 3 x 10 mL diethyl ether.  The combined organic layers 
were washed with brine, dried with MgSO4, and filtered.  The solvent was removed 
under reduced pressure and the crude material filtered through a silica plug with 20:1 
hexanes: diethyl ether.  Solvent removal provided 199 mg of the ester (0.71 mmol, 84 
% yield), which was used immediately to prevent potential polymerization. 
 The ester was placed in a 100 mL flame dried flask equipped with reflux 
condenser under Ar atmosphere followed by 71 mL dry, degassed dichloroethane to 
generate a 0.01 M solution.  The condenser was fitted with a vent and a long needle 
through which Ar was slowly introduced into the stirring mixture.  The solution was 
heated to 90 ºC before 89 mg (0.14 mmol) Hoveyda-Grubbs II catalyst was 
introduced.  Stirring was continued at 90 ºC until completion of the reaction by TLC 
(20:1 hexane: diethyl ether).  Upon completion, the reaction was cooled and the 
solvent removed under reduced pressure.  The crude material was purified by 
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chromatography (2:1 hexane: diethyl ether) to produce 71 mg (40% yield) of lactone 
5.2 as a faint yellow oil. 
  
[α]D: +68 (c = 0.40, CH2Cl2, 23.6 ºC) 
FTIR: (neat) 2957, 2930, 2857, 1722, 1420, 1386, 1246, 1035cm-1 
1H NMR (500 MHz, CHCl3-d) δ ppm 6.87 (ddd, J = 9.8, 5.4, 3.1 Hz, 1H), 6.51 (br s, 
2H), 6.06 (ddd, J = 9.8, 2.4, 1.3 Hz, 1H), 4.89 (dt, J = 10.3, 4.3 Hz, 1H), 2.53-2.40 
(m, 2H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 163.2, 144.2, 141.9, 121.9, 81.4, 78.8, 29.1 
HRMS Exact Mass: calculate for C7H7INaO2 (M+Na)+ 272.9388; 











PhH, 90 ºC, 2h
65%  
To a flame dried 100 mL round bottom flask equipped with stir bar, water-
jacketed reflux condenser and under argon was placed 3.76g (22.6 mmol) of alkyne 
7.5,4 12.2 mL of Bu3SnH (45.2 mmol, 2 equiv.) and 23 mL of benzene (1M with 
respect to alkyne 7.5).  To this stirring mixture was added 370 mg (2.26 mmol, 10 
mol %) of AIBN, brought to 90 ºC, and allowed to proceed at this temperature for 2 
hours.  After this duration of time, the reaction was allowed to cool to room 
temperature, the solvent removed, and the mixture placed on a pretreated SiO2 
column (pretreatment involves mixing 1mL Et3N per 100g SiO2), flushed with 100% 
hexanes to remove excess Bu3SnH.  After removal of excess Bu3SnH, the product is 
eluted with a 1% Et3N/ 1:1 hexane:CH2Cl2 system to afford 6.74g (65% yield) of the 
stannane. 
 
[α]D: +25.9 (c = 2.90, CH2Cl2, 26.0 ºC) 
FTIR: (neat) 3043, 2956, 2921, 2871, 2854, 1464, 1420, 1400, 1377, 1315, 1180, 
1126, 974, 959, 946, 864, 717, 690, 665, 594, 501 cm-1 
1H NMR (500 MHz, CHCl3-d) δ ppm 6.22 (dd, J = 19.2, 1.3 Hz, 1H), 6.04 (dd, J = 
19.2, 5.1 Hz, 1H), 6.01 (m, 1H), 5.72 (dddd, J = 10.1, 4.4, 2.8, 1.6 Hz, 1H), 5.13 (dd, 
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J = 1.5, 1.1 Hz, 1H), 4.40 (ddd, J = 9.4, 5.4, 4.3 Hz, 1H), 4.02 (hept., J = 6.2 Hz, 1H), 
2.08 (ddd, J = 10.4, 2.5, 1.4 Hz, 1H), 2.07 (ddd, J = 5.1, 4.7, 1.4 Hz, 1H), 1.49 (dddd, 
J = 8.1, 7.4, 1.9, 1.7 Hz, 6H), 1.30 (dddd, J = 7.4, 7.3, 4.1, 3.3 Hz, 6H), 1.24 (d, J = 
6.2 Hz, 3H), 1.18 (d, J = 6.2 Hz, 3H), 0.89 (q, J = 8.2 Hz, 9H), 0.88 (t, J = 7.3 Hz, 
6H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 148.0, 129.3, 128.9, 126.3, 93.6, 69.9, 69.2, 
30.6, 29.3, 24.0, 22.4, 13.9, 9.6 















 To a 5 mL flame dried round bottom flask flushed with Ar (g) and equipped 
with stir bar was added 40 mg (0.138 mmol, 3 equiv.) of iodide 3.1 and 0.34 mL of 
Et2O (0.4 M with respect to 3.1).  This solution was cooled to -78 ºC with stirring, at 
which time 178 µL of t-BuLi (1.7 M in pentanes, 0.303 mmol, 2.2 equiv. with respect 
to 3.1) was added and the reaction warmed to 0 ºC to stir for 30 minutes.  The mixture 
was then cannulated into a -78 ºC solution of 36 mg MgBr2•OEt2 (0.138 mmol, 3 
equiv.) in 0.46 mL of THF (0.3 M with respect to MgBr2•OEt2), warmed to 0 ºC and 
allowed to stir for 30 minutes.   This solution was then slowly cannulated along the 
internal side of the reaction flask into a -45 ºC solution of 10 mg ketone 2.2  (0.046 
mmol) in 0.16 mL of THF (0.3 M with respect to 2.2).  The reaction was allowed to 
stir at -45 ºC for 3 hours, at which time the reaction was quenched at -45 ºC by 
addition of 2 mL sat. NH4Cl (aq) and allowed to warm to room temperature.  The 
mixture was then added to 10 mL EtOAc in a separatory funnel and the layers 
separated, followed by extraction of the aqueous layer with 3 x 10 mL portions of 
EtOAc.  The organic layers were then combined, washed with brine, dried (Na2SO4), 
filtered, and SiO2 added.  The solvent was then removed and the SiO2-bound 
substrate added to a silica gel column, which was subjected to 2 CVs of 3:1 
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hexane:EtOAc followed by elution of the product with 100% EtOAc.  Removal of the 
solvent provided 12 mg (69% yield) of phosphate 12.1 as a single observable 
diastereomer.  [Note: Running the ketone addition reaction at -78 ºC rather than -45 
ºC requires ~7 h reaction time.] 
 
[α]D: –26 (c = 0.10, CH2Cl2, 24.9 ºC) 
FTIR: (neat) 3381, 2970, 2924, 1292, 1180, 1126, 1072, 1031, 997, 924 cm-1 
1H NMR (500 MHz, CHCl3-d) δ ppm 5.99-5.92 (m, 3H), 5.86 (dd, J = 15.7, 5.1 Hz, 
1H), 5.67 (ddd, J = 10.1, 4.9, 2.0 Hz, 1H), 5.61 (d, J = 15.8 Hz, 1H), 5.51 (tdd, J = 
11.9, 3.9, 2.7 Hz, 1H), 5.16 (app d, 24.0 Hz, 1H), 5.04 (d, J = 2.3 Hz, 1H), 4.94 
(dddd, J = 14.8, 5.6, 5.5, 2.9 Hz, 1H), 4.40 (ddd, J = 12.4, 5.7, 1.2 Hz, 1H), 4.32 
(ddddd, J = 14.8, 12.3, 6.7, 2.0, 1.8 Hz, 2H), 3.90 (sept., J = 6.2 Hz, 1H), 2.30 (ddd, 
J= 13.0, 8.5, 5.8 Hz, 1H), 2.10 (d, 12.0 Hz, 1H), 1.98 (tt, J = 4.0, 2.1 Hz, 1H), 1.68 
(dddd, J = 12.8, 11.6, 2.1, 1.8 Hz, 1H), 1.33 (s, 3H), 1.14 (d, J = 6.2 Hz, 3H), 1.11 (d, 
J = 6.2 Hz, 3H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 139.3, 131.3, 130.1, 128.5, 128.1, 126.4, 93.8, 
81.6 (d, JCP = 7.2 Hz), 77.3 (d, JCP = 2.9 Hz), 73.7 (d, JCP = 9.1 Hz), 70.3, 65.9, 63.4 
(d, JCP = 6.3 Hz), 30.8, 29.4 (d, JCP = 5.5 Hz), 25.1, 24.0, 22.5 
31P NMR (162 MHz, CHCl3-d) δ ppm -2.89 (t, JPH = 23.8 Hz) 
HRMS Exact Mass: calculate for C18H27NaO7P (M+Na)+ 409.1392; 













 To a small dried Pyrex pressure tube under argon was placed 27 mg (0.16 
mmol, 5 equiv.) of alkene 14.1 , 2.0 mg Hoveyda-Grubbs II catalyst (0.003 mmol, 10 
mol %) and a stir bar.  To this was added 7.8 mg (0.03 mmol) of phosphate 15.1 in 
0.6 mL of degassed CH2Cl2 (0.05M with respect to phosphate 15.1) and the solution 
immediately placed in a 46 ºC oil bath with stirring.  After 12 h, the tube was 
removed from heat to cool, SiO2 added and the solvent removed. Placement of the 
substrate impregnated silica on a column allowed for elution with 100% EtOAc to 












To a dried 50 mL round bottom flask under argon equipped with stir bar is 
placed 700 mg stannane 11.1 (1.53 mmol) followed by 15 mL THF to generate a 
0.1M solution.  This solution is lowered in temperature to 0 ºC via cold bath, after 
which time 3.06 mL of a 5.0M TFA solution in THF (15.28 mmol, 10 equiv.) is 
added dropwise.  The reaction is allowed to proceed at 0 ºC for 1.5 h with stirring, 
after which time the reaction is quenced by slow addition of sat. aq. NaCO3 (15 mL) 
and 15 mL diethyl ether added.  The layers are separated, the aqueous layers extracted 
with Et2O (3 x 5 mL), and the combined organic layers washed with brine.  The 
organic layers were then dried with MgSO4, filtered, solvent carefully removed via 
reduced pressure over a 0 ºC bath, and the product purified via column 
chromatography (50:1 petroleum ether: diethyl ether) to provide 146 mg (57% yield) 
of alkene 14.1. 
 
[α]D: +59 (c = 0.37, CH2Cl2, 24.8 ºC) 
FTIR: (neat) 3080, 3045, 2970, 2924, 2894, 1647, 1458, 1423, 1398, 1381, 1182, 
1126, 1101, 1034, 1009, 993, 962, 943, 924, 860, 719, 783 cm-1 
1H NMR (500 MHz, CHCl3-d) δ ppm 6.01 (m, 1H), 5.91 (ddd, J = 17.3, 10.6, 5.6 Hz, 
1H), 5.73 (dtd, J = 10.0, 2.8, 1.5 Hz, 1H), 5.30 (dt, J = 17.3, 1.6 Hz, 1H), 5.16 (dt, J = 
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10.6, 1.6 Hz, 1H), 5.12 (ddd, J = 5.7, 1.5, 1.2 Hz, 1H), 4.43 (dddd, J = 10.0, 4.8, 4.6, 
0.6 Hz, 1H), 4.01 (dq, J = 6.3, 6.2 Hz, 1H), 2.08 (dddd, J = 10.8, 4.2, 2.5, 0.9 Hz, 
1H), 2.03 (dddd, J = 17.7, 5.6, 4.2, 1.4 Hz, 1H), 1.23 (d, J = 6.3 Hz, 3H), 1.18 (d, 6.2 
Hz, 3H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 138.5, 128.6, 126.4, 115.6, 93.4, 69.9, 67.0, 
30.5, 24.0, 22.3 
HRMS Exact Mass: calculate for C10H16NaO2 (M+Na)+ 191.1048; 






0.01 equiv. 5% Pd-CaCO3
0.05 equiv. qunoline





A 100 mL round bottom flask equipped with stir bar is charged with 1.10 g (6.53 
mmol) of alkyne 7.5, 42 mg (0.327 mmol, 0.05 equiv.) freshly distilled quinoline, and 
65 mL degassed EtOAc (0.1M with respect to 7.5) and is placed under a H2 
atmosphere via balloon. To this stirring mixture is added 139 mg 5% Pd-CaCO3 
(0.065 mmol Pd, 0.01 equiv.). The reaction was allowed to proceed for 2 h 
(monitored by GC) at which time the mixture was filtered through Celite and the 
solvent removed gently.  The crude product was passed through a short SiO2 plug, 
eluting with 20:1 petroleum ether: diethyl ether to provide 877 mg (80% yield) of the 



















A flame dried 25 mL round bottom flask was charged with 320 mg phosphate 
15.1 (1.3 mmol) and 13 mL of CH2Cl2 to generate a 0.1M solution, followed by 197 
µL of 2,6-lutidine (1.69 mmol, 1.3 equiv.).  The solution was then cooled to 0 ºC and 
323 µL of TESOTf (1.43 mmol, 1.1 equiv.) was added dropwise to the solution with 
stirring.  The solution was allowed to stir at 0 ºC until completion (about 1 hour).  The 
reaction was quenched with 13 mL of saturated aqueous NH4Cl, separated, and the 
aqueous layer re-extracted 3 more times.  The combined organic layers were then 
washed with brine, dried with MgSO4, and filtered.  Addition of SiO2 preceded 
removal of solvent, following which the impregnated SiO2 was loaded onto a short 
column and the desired product eluted with 1:2 hexane: ethyl acetate to provide 468 
mg (99% yield) of the silyl protected phosphate. 
 
[α]D: -36.4 (c = 1.05, CH2Cl2, 26.5 ºC) 
FTIR: (neat) 2955, 2914, 2876, 1294, 1263, 1236, 1220, 1134, 1074, 1061, 1042, 
993, 978, 781, 737, 727, 694, 611, 433 cm-1 
1H NMR (500 MHz, CHCl3-d) δ ppm 6.00 (dddd, J = 11.9, 6.7, 3.6, 2.4 Hz, 1H), 
5.80 (dd, J = 17.3, 10.7 Hz, 1H), 5.56 (ddd, 11.9, 3.9, 2.6 Hz, 1H), 5.30 (dd, J = 17.3, 
1.1 Hz, 1H), 5.21 (dddd, J = 25.0, 2.5, 1.9, 1.7 Hz, 1H), 5.17 (dd, J = 10.7, 1.1 Hz, 
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1H), 4.99 (dddd, J = 14.7, 5.6, 5.5, 2.7 Hz, 1H), 4.34 (ddd, J =  27.7, 14.2, 6.8 Hz, 
1H), 4.24 (ddd, J = 11.9, 1.8, 1.7 Hz, 1H), 2.31 (ddd, J = 14.7, 11.9, 6.4 Hz, 1H), 1.79 
(ddd, J = 13.1, 2.4, 1.8 Hz, 1H), 1.40 (s, 3H), 0.95 (t, J = 8.0 Hz, 9H), 0.61 (qd, J = 
7.2, 1.6 Hz, 6H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 142.0, 130.3, 128.0, 115.7, 81.5 (d, JCP = 7.6 
Hz), 77.4 (d, JCP = 6.6 Hz), 76.4 (d, JCP = 10.0 Hz), 63.2 (d, JCP = 6.4 Hz), 29.0 (d, 
JCP = 5.4 Hz), 22.7, 7.3, 6.9 
31P NMR (162 MHz, CHCl3-d) δ ppm -2.86 (t, JPH = 27.0 Hz) 
HRMS Exact Mass: calculate for C16H29NaO5PSi (M+Na)+ 383.1420; 




















68 %  
A 0.06M solution of phosphate (250 mg, 0.70 mmol) in diethyl ether (12 mL) 
is prepared under argon atmosphere and subsequently cooled to 0 ºC with stirring.  To 
this is slowly added LiAlH4 (79 mg, 2.09 mmol, 3 equiv.) and to reaction allowed to 
continue stirring at 0 ºC.  The reaction is monitored by TLC (1:2 hexane: ethyl 
acetate) until substrate appears to be consumed and allowed to continue for 15 more 
minutes at 0 ºC (total reaction time typically about 1 hour).  The reaction is quenched 
by slow, dropwise addition of 79 mg of H2O, followed by slow, dropwise addtion of 
79 mg of 15 % NaOH (aq), and finishing with an addition of 237 mg of H2O.  At this 
point, the mixture is allowed to reach room temperature until all salts appear to have 
become a white color.  SiO2 is then added and the solvent removed, at which point the 
silica complexed product is placed on a short silica gel plug and eluted with a 1:4 
hexane: ethyl acetate mixture, producing 150 mg (68% yield) of mono-protected 
tetraol 16.1. 
 
[α]D: +17.4 (c = 2.20, CH2Cl2, 27.6 ºC) 
FTIR: (neat) 3342, 2955, 2912, 2877, 1458, 1413, 1238, 1099, 1049, 1010, 977, 921, 
873, 740, 727 cm-1 
1H NMR (500 MHz, CHCl3-d) δ ppm 5.93 (dd, J = 17.4, 10.9 Hz, 1H), 5.69 (dddd, J 
= 6.3, 5.0, 1.2, 1.1 Hz, 1H), 5.57 (ddt, J = 11.2, 7.8, 1.3 Hz, 1H), 5.31 (dd, J = 17.4, 
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1.4 Hz, 1H), 5.13 (dd, J = 10.9, 1.4 Hz, 1H), 4.67 (dd, J = 8.4, 8.3 Hz, 1H), 4.28 (ddd, 
J = 7.0, 6.7, 6.1 Hz, 1H), 4.18 (ddd, J = 8.6, 7.1, 5.9 Hz, 1H), 3.82 (dd, J = 7.1, 3.9 
Hz, 1H), 3.77 (br s, 1H),1.80 (ddd, J = 14.8, 6.7, 3.8 Hz, 1H), 1.58 (br s, 2H), 1.54 
(ddd, J = 14.8, 7.0, 2.7 Hz, 1H), 1.27 (s, 3H), 0.99 (t, J = 8.0 Hz, 9H), 0.69 (q, J = 8.0 
Hz, 6H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 142.0, 135.7, 130.0, 113.5, 76.2, 75.7, 65.3, 
59.0, 40.6, 25.0, 7.2, 5.4 
HRMS Exact Mass: calculate for C16H32NaO4Si (M+Na)+ 339.1968; 














A 0.1M solution of triol 16.1 (44 mg, 0.138 mmol) in CH2Cl2 (1.4 mL) is 
generated in a flame dried 5mL flask under Ar atmosphere, followed by addition of 
2,6-lutidine (72 µL, 0.620 mmol, 4.5 equiv.).  The solution is then submerged in a dry 
ice-acetone bath to bring the temperature to -78 ºC, at which time a slow addition of 
TBSOTf (70 µL, 0.303 mmol, 2.2 equiv.) is affected.  The reaction is monitored by 
TLC to ensure the selective bis-protected product is produced, where the mono-
protected species is visualized in a 2:1 hexane: diethyl ether system (Rf = 0.15) to 
note disappearance while the bis-protected species is visible through a 20:1 hexane: 
diethyl ether system (Rf = 0.21).  After disappearance of the mono-protected species 
by TLC, the reaction is allowed to continue for 15 minutes more (total reaction time 
is about 45 minutes). Saturated aqueous NH4Cl is then added and the reaction allowed 
to achieve room temperature, whereby the layers are then separated and the aqueous 
layer extracted with 3x 5mL portions of diethyl ether, the combined organic layers 
washed with brine, and then dried with MgSO4.  Filtration followed by solvent 
removal allows for purification via flash column chromatography utilizing a 20:1 




[α]D: +4.4 (c = 3.34, CH2Cl2, 25.7 ºC) 
FTIR: (neat) 3464, 3016, 2954, 2929, 2879, 2858, 1471, 1462, 1411, 1362, 1254, 
1080, 1005, 923, 835, 775, 741, 727 cm-1 
1H NMR (500 MHz, CHCl3-d) δ ppm 5.93 (dd, J = 17.4, 10.8 Hz, 1H), 5.48 (ddd, J = 
10.8, 5.1, 5.0 Hz, 1H), 5.37 (ddd, J = 11.2, 6.2, 1.6 Hz, 1H), 5.28 (dd, J = 17.4, 1.6 
Hz, 1H), 5.10 (dd, J = 10.8, 1.6 Hz, 1H), 4.48 (ddd, J = 9.4, 3.8, 3.6 Hz, 1H), 4.29 
(ddd, J = 13.1, 7.0, 1.6 Hz, 1H), 4.13 (ddd, J = 13.1, 5.3, 1.7 Hz, 1H), 3.68 (dd, J = 
5.8, 3.8 Hz, 1H), 2.59 (s, 1H), 1.90 (ddd, J = 14.5, 9.7, 3.8 Hz, 1H), 1.31 (dddd, J = 
9.8, 5.8, 4.9, 3.9 Hz, 1H), 1.21 (s, 3H), 0.98 (t, J = 8.0 Hz, 9H), 0.90 (s, 9H), 0.88 (s, 
9H), 0.66 (qd, J = 8.0,1.9 Hz, 6H), 0.07 (s, 6H), 0.06 (s, 3H), 0.05 (s, 3H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 142.3, 134.0, 129.7, 113.3, 75.9, 75.5, 66.8, 
59.6, 43.0, 26.1, 24.0, 18.5, 18.3, 7.3, 5.7, -3.1, -4.3 
HRMS Exact Mass: calculate for C28H60NaO4Si3 (M+Na)+ 567.3697; 










CH2Cl2, 0 ºC, 3 h










A flame dried 5 mL round bottom flask equipped with stir bar is charged with 
63 mg of tris-protected tetraol 16.2 (0.116 mmol), 49 mg of 1H-tetrazole (0.699 
mmol, 6 equiv.), and 1.2 mL of CH2Cl2 (0.1M with respect to 16.2).  The stirring 
mixture is cooled to 0 ºC at which time 127 µL of dibenzyl N,N-diisopropyl 
phosphoramidite (0.349 mmol, 3 equiv.) was added and allowed to continue stirring 
at 0 ºC.  After completion as indicated by TLC using 20:1 hexane: diethyl ether 
(phosphite Rf = 0.8 vs. alcohol Rf = 0.21), the cloudy reaction mixture was allowed to 
stir for 30 minutes more (total time 3 h) before 70 µL of a 5.0M t-BuOOH in decane 
solution (0.349 mmol, 3 equiv.) was added at 0 ºC generating a clear solution and the 
reaction allowed to stir at 0 ºC for 1.5 h.  The reaction was quenched by addition of 1 
mL of 10% Na2S2O3 (aq.) and allowed to stir for 30 min., at which time it was diluted 
with 5 mL of NaHCO3, extracted with 3x 10 ml portions of CH2Cl2, dried with 
MgSO4, filtered and concentrated.  Purification by column chromatography 
proceeded by elution with 5:1 hexane: diethyl ether to remove more non-polar 
impurities, followed by elution with 2:1 hexane: diethyl ether to provide 73 mg (78% 
yield) of phosphate 16.3. 
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[α]D: +11.8 (c = 0.88, CH2Cl2, 25.6 ºC) 
FTIR: (neat) 2954, 2930, 2881, 2856, 1458, 1411, 1379, 1362, 1254, 1080, 1001, 
835, 775, 735, 696, 598 cm-1 
1H NMR (500 MHz, CHCl3-d) δ ppm 7.32 (m, 10H), 6.09 (dd, J = 17.6, 11.0 Hz, 
1H), 5.45 (ddd, J = 11.8, 6.6, 5.2 Hz, 1H), 5.35 (dddd, J = 11.2, 9.1, 4.1, 1.6 Hz, 1H), 
5.30 (dd, J = 17.6, 0.6 Hz, 1H), 5.26 (dd, J = 11.0, 0.5 Hz, 1H), 4.99 (d, J = 2.6 Hz, 
2H), 4.97 (d, J = 2.7 Hz, 2H), 4.46 (td, J = 9.7, 1.7 Hz, 1H), 4.30 (ddd, J = 13.2, 6.9, 
1.6 Hz, 1H), 4.13 (ddd, J = 13.2, 5.1, 1.7 Hz, 1H), 3.89 (dd, J = 8.3, 1.3 Hz, 1H), 1.72 
(ddd, J = 11.8, 10.4, 1.4 Hz, 1H), 1.46 (ddd, J = 16.5, 3.5, 3.4 Hz, 1H), 1.22 (s, 3H), 
0.94 (t, J = 8.0 Hz, 9H), 0.89 (s, 9H), 0.86 (s, 9H), 0.65 (q, J = 8.0 Hz, 6H), 0.06 (s, 
6H), 0.05 (s, 3H), 0.04 (s, 3H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 138.5, 136.5, 136.4, 134.0, 129.8, 128.62, 
128.6, 128.4, 128.37, 128.0, 117.2, 87.6 (d, JCP = 7.9 Hz), 75.2 (d, JCP = 10.8 Hz), 
69.0 (d, JCP = 5.4 Hz), 68.8 (d, JCP = 5.3 Hz), 66.0, 59.6, 42.8, 30.5, 26.1 (d, JCP = 6.4 
Hz), 19.9, 18.5, 18.3, 7.3, 5.8, -2.8, -4.2, -5.0 
31P NMR (162 MHz, CHCl3-d) δ ppm -4.02 (t, JPH = 8.0 Hz) 
HRMS Exact Mass: calculate for C42H73NaO7PSi3 (M+Na)+ 827.4299; 
found 827.4328 (ESI) 
Note: On larger scales, the minor diastereomer generated during the generation of 
tertiary alcohol 15.1 is separable and can be faintly observed and isolated at this point 
in the 5:1 hexane: diethyl ether elution (Rf = 0.25 in 5:1 hexane: diethyl ether).  It is 
easily distinguishable by 13C NMR from the major isomer: (126 MHz, CHCl3-d) δ 
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ppm 143.2, 136.22, 136.16, 134.3, 129.6, 128.7, 128.64, 128.58, 128.4, 127.9, 125.7, 
114.9, 82.5 (d, JCP = 15.4 Hz), 77.2 (d, JCP = 6.1 Hz), 69.26 (d, JCP = 6.0 Hz), 69.22 
(d, JCP = 9.1 Hz), 65.6, 59.6, 40.2, 30.5, 26.1, 22.5, 18.4, 18.2, 7.3, 6.8, -3.6, -4.5, -4.9 
 229 











64 %  
A 0.06M solution of phosphate 15.1 (38 mg, 0.154 mmol) in THF (2.6 mL) is 
prepared under argon atmosphere and subsequently cooled to 0 ºC with stirring.  To 
this is slowly added LiAlH4 (18 mg, 0.463 mmol, 3 equiv.) and the reaction allowed 
to continue stirring at 0 ºC.  The reaction is monitored by TLC (1:1 EtOAc: acetone) 
until substrate appears to be consumed and allowed to continue for 15 more minutes 
at 0 ºC (total reaction time typically about 1 h).  The reaction is quenched by slow, 
dropwise addition of 18 mg of H2O, followed by slow, dropwise addtion of 18 mg of 
15 % NaOH (aq), and finishing with an addition of 54 mg of H2O.  At this point, the 
mixture is allowed to reach room temperature until all salts appear to have become a 
white color.  SiO2 is then added and the solvent removed, at which point the silica 
complexed product is placed on a short silica gel plug and eluted with a 1:1 EtOAc: 
acetone mixture, producing 20.2 mg (64% yield) of tetraol 17.1. 
 
[α]D: +46 (c = 0.05, acetone, 24.6 ºC) 
FTIR: (neat) 3339, 2951, 2910, 2877, 1458, 1410, 1238, 1099 cm-1 
1H NMR (500 MHz, acetone-d6) δ ppm 5.96 (dd, J = 17.4, 10.9 Hz, 1H), 5.50 (m, 
2H), 5.28 (dd, J = 17.4, 2.0 Hz, 1H), 5.02 (dd, J = 10.8, 2.0 Hz, 1H), 4.68 (dddd, J = 
6.6, 4.6, 2.6, 2.3 Hz, 1H), 4.19 (ddd, J = 12.4, 5.4, 1.7 Hz, 1H), 4.10 (ddd, J = 12.6, 
4.2, 3.8 Hz, 1H), 3.91 (d, J = 4.8 Hz, 1H), 3.73 (d, J = 5.5 Hz, 1H), 3.71 (s, 1H), 3.69 
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(dd, J = 5.7, 1.9 Hz, 1H), 3.54 (s, 1H), 1.67 (ddd, J = 15.0, 9.3, 1.9 Hz, 1H), 1.44 
(ddd, J = 15.0, 7.8, 2.6 Hz, 1H), 1.22 (s, 3H) 
13C NMR (126 MHz, acetone-d6) δ ppm 144.2, 135.9, 130.4, 112.7, 75.6, 74.6, 65.5, 
58.7, 40.3, 24.7 
HRMS Exact Mass: calculate for C10H18NaO4 (M+Na)+ 225.1103; 














A 0.1M solution of tetraol 17.1 (19 mg, 0.093 mmol) in CH2Cl2 (1 mL) is 
generated in a flame dried 5 mL flask under Ar atmosphere, followed by addition of 
2,6-lutidine (49 µL, 0.421 mmol, 4.5 equiv.).  The solution is then submerged in a dry 
ice-acetone bath to bring the temperature to -78 ºC, at which time a slow addition of 
TBSOTf (47 µL, 0.206 mmol, 2.2 equiv.) is affected.  The reaction is monitored by 
TLC to ensure the selective bis-protected product is produced (4:1 hexane: diethyl 
ether, Rf = 0.21), although no mono-protected species was observed during the course 
of the reaction with this substrate After disappearance of the starting material is 
observed by TLC (1:1 EtOAc: acetone), the reaction is allowed to continue for 15 
minutes more (total reaction time is about 45 minutes). 1 mL of sat. aq. NH4Cl  is 
then added and the reaction allowed to achieve room temperature.  The layers are 
then separated and the aqueous layer extracted with 3x 5mL portions of diethyl ether, 
the combined organic layers washed with brine, and then dried with MgSO4.  
Filtration followed by solvent removal allows for purification via flash column 
chromatography utilizing a 4:1 hexane: diethyl ether solvent system to afford 31 mg 
(77% yield) of the desired product. 
 
[α]D: +17 (c = 0.25, CH2Cl2, 25.3 ºC) 
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FTIR: (neat) 3459, 3010, 2954, 2929, 2879, 2858, 1079, 1009, 923 cm-1 
1H NMR (500 MHz, CHCl3-d) δ ppm 5.82 (dd, J = 17.4, 10.9 Hz, 1H), 5.59 (ddt, J = 
11.4, 8.5, 1.5 Hz, 1H), 5.51 (ddd, J = 11.6, 6.2, 0.8 Hz, 1H), 5.29 (dd, J = 17.4, 1.6 
Hz, 1H), 5.12 (dd, J = 10.9, 1.6 Hz, 1H), 4.83 (dt, J = 8.1, 4.4 Hz, 1H), 4.21 (ddd, J = 
11.2, 6.5, 1.3 Hz, 1H), 4.13 (ddd, J = 13.4, 5.2, 1.7 Hz, 1H), 3.78 (ddt, J = 12.1, 8.4, 
2.9 Hz, 1H), 3.77 (br s, 1H), 2.49 (br s, 1H), 1.64 (dd, J = 4.3, 4.2 Hz, 2H), 1.27 (s, 
3H), 0.89 (s, 9H), 0.88 (s, 9H), 0.08 (s, 3H), 0.061 (s, 3H), 0.059 (s, 3H), 0.05 (s, 3H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 141.1, 133.7, 129.1, 114.0, 75.2, 74.6, 68.3, 
59.6, 38.7, 26.1, 26.0, 24.9, 18.5, 18.2, -4.3, -4.98, -5.04, -5.06 
HRMS Exact Mass: calculate for C22H46NaO4Si2 (M+Na)+ 453.2832; 



























 To a small dried Pyrex pressure tube under argon was placed 10 mg (0.012 
mmol) of phosphate 16.3 , 0.6 mg Hoveyda-Grubbs II catalyst (0.001 mmol, 10 mol 
%) and a stir bar.  To this was added 8 mg (0.06 mmol) of lactone 2.4 in 0.12 mL of 
degassed dichloroethane (0.1 M with respect to phosphate 16.3) and the solution 
immediately placed in a 90 ºC oil bath with stirring.  After 12 hours, the tube was 
removed from heat to cool, SiO2 added and the solvent removed. Placement of the 
substrate impregnated silica on a column allowed for elution with 2:1 hexane: diethyl 
ether to provide 0.8 mg (7% yield) of phosphate 20.1. 
[α]D: +9.6 (c = 0.01, CH2Cl2, 24.8 ºC) 
1H NMR (500 MHz, CHCl3-d) δ ppm 7.44-7.20 (m, 5H), 6.93-6.87 (m, 5H), 6.90 
(app dd, J = 5.6, 1.3 Hz, 1H), 6.07 (ddt, J = 16.0, 9.8, 1.9 Hz, 1H), 6.06 (ddd, J = 9.9, 
2.5,1.4 Hz, 1H), 5.96 (ddd, J = 16.5, 10.6, 5.7 Hz, 1H), 5.61 (ddd, J =10.2, 6.9, 1.6 
Hz, 1H), 5.30 (dt, J = 10.6, 1.2 Hz, 1H), 5.10 (ddd, J = 8.1, 7.2, 1.2 Hz, 1H), 4.94 (m, 
[PhCH2O-]2 + C5-H, 5H), 4.87 (dd, J = 7.3, 7.4 Hz, 1H), 4.56 (ddd, J = 6.1, 6.0, 5.9 
Hz, 1H), 4.21 (dt, J = 4.1, 1.4 Hz, 1H), 2.55 (ddd, J = 6.1, 4.2, 1.8 Hz, 1H), 2.49-2.41 
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(m, 2H), 1.75 (ddd, J = 6.6, 1.6, 0.6 Hz, 1H), 1.43 (s, 3H), 0.91 (s, 18H), 0.89 (t, J = 
8.0 Hz, 9H), 0.65 (q, J = 8.0 Hz, 6H), 0.07 (s, 6H), 0.04 (s, 3H), 0.036 (s, 3H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 164.1, 145.0, 144.7, 135.0, 133.7, 129.5, 
129.2, 127.5, 126.0, 125.9, 125.7, 121.88, 121.85, 120.8, 79.2, 78.1, 77.7, 74.2 (d, JCP 
= 6.9 Hz), 71.0, 66.1, 62.8, 42.9, 30.2, 29.9, 29.6, 26.1, 22.40, 22.36, 15.5, 14.3, 7.4, 
5.9, -4.2, -5.1 
31P NMR (162 MHz, CHCl3-d) δ ppm -4.13 (t, JPH = 8.1 Hz) 
HRMS Exact Mass: calculate for C47H77NaO9PSi3 (M+Na)+ 923.4511; 



















10 mol % cat-C, DCE




To a small dried Pyrex pressure tube bearing a cap with Teflon septa and 
under argon was placed 6.3 mg (0.008 mmol) phosphate 16.3, 0.5 mg Hoveyda-
Grubbs II catalyst (0.0008 mmol, 10 mol %), 0.25 mL degassed dichloroethane and a 
stir bar. The solution is placed in a 90 ºC silicon oil bath and allowed to stir for 10 
minutes.  Another solution containing 3.0 mg of lactone 24.1 (0.016 mmol) in 500 µL 
of degassed dichloroethane is placed in a syringe and the needle of the syringe placed 
through the septa of the Pyrex tube.  The syringe is then injected via syringe pump at 
a rate of 100 µL per hour and the reaction allowed to proceed overnight.  The pressure 
tube is then removed from heat, SiO2 added, and the solvent removed.  The product 
bearing silica gel is then placed on a column for purification utilizing 2:1 hexane: 
diethyl ether to provide 1.1 mg (16% yield) of phosphate 20.1. 
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 In a glove box under Ar (g), 107 mg (0.03 mmol, 0.15 equiv.) of 
PCy(pyrrolidinyl)25 and 39 mg (0.41 mmol, 1.9 equiv.) Me4NF are added to a 5 mL 
round bottom flask containing 2 mg (0.005 mmol, 0.025 equiv.) of [(π-allyl)PdCl]2 in 
1.1 mL THF.  This mixture is allowed to stir for 5 minutes at 25 ºC.  1.28 g (2.81 
mmol) of stannane 11.1, 1.40 g of freshly dried 3Å molecular sieves (500 mg/mmol 
11.1), and 660 mg of 5-iodo-1-pentene (3.37 mmol, 1.2 equiv.) was then added in that 
particular order.  The vessel was capped with a Teflon lined cap and removed from 
the glove box.  The mixture then stirred vigorously at 25 ºC for 24 h in the absence of 
light.  After 24 h had passed, 1 mL 10% KF (aq) was added and the mixture allowed 
to stir for 30 minutes.  The layers were separated and the aqueous layer extracted 3 
more times with 5 mL diethyl ether.  The combined organic layers were then washed 
with brine, dried with MgSO4, filtered and solvent removed in vacuo.  The residue 
was then placed on a silica gel column, eluted with 80:1 petroleum ether: diethyl 
ether to remove more non-polar species followed by elution with 30:1 petroleum 
ether: diethyl ether to elute the impure coupling product.  The semi-pure product was 
used in the subsequent reaction. 
 To a 50 mL round bottom flask equipped with comparably large stir bar is 
added the semi-pure coupling product, 4.2 g Celite (1.5g/mmol) and 28 mL of 
acetone (0.1M with respect to 11.1). The stirring mixture was brought to 0 ºC and 
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2.32 mL of Jones reagent (2.67M, 6.18 mmol, 2.2 equiv.) added dropwise. The 
reaction is allowed to proceed with stirring at 0 ºC until completion (TLC 2:1 hexane: 
diethyl ether; ~ 2 h).  Upon indication of reaction completion, 0.5 mL isopropyl 
alcohol is added to consume any leftover Jones reagent, followed by filtration, 
addition of silica, and solvent removal.  Placing the product saturated silica on a silica 
column allowed for elution of the desired product with 2:1 petroleum ether: diethyl 
ether, where solvent removal provided 361 mg (67% yield) of lactone 24.1 as a light 
colorless oil. 
[α]D: +65 (c = 0.15, CH2Cl2, 25.7 ºC) 
FTIR: (neat) 2909, 2872, 1722, 1420, 1385, 1294, 1237 cm-1 
1H NMR (500 MHz, CHCl3-d) δ ppm 6.89 (ddd, J = 9.8, 5.7, 2.7 Hz, 1H), 6.05 (ddd, 
J = 9.8, 2.5, 1.1 Hz, 1H), 5.78 (ddddd, J = 17.0, 10.3, 6.7, 6.7, 2.4 Hz, 1H), 5.66 (ddd, 
J = 14.6, 9.7, 4.1 Hz, 1H), 5.58 (dddd, J = 14.4, 8.3, 1.3, 1.2 Hz, 1H), 5.22 (dddd, J = 
10.9, 8.4, 4.5, 0.8 Hz, 1H), 5.01 (ddd, J = 17.2, 3.5, 1.6 Hz, 1H), 4.98 (ddt, J = 10.2, 
2.2, 1.2 Hz, 1H), 2.42 (dddd, J = 18.5, 8.5, 2.7, 2.6 Hz, 1H), 2.34 (dddd, J = 18.4, 5.6, 
4.5, 1.1 Hz, 1H) 2.18-2.04 (m, 4H), 1.50 (dddddd, J = 13.7, 13.4, 6.4, 6.3, 6.3, 6.1 Hz, 
2H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 164.4, 145.0, 138.4, 135.4, 126.9, 121.8, 
115.2, 74.0, 33.3, 30.0, 28.6, 27.3 
HRMS Exact Mass: calculate for C12H17O2 (M+H)+ 193.1229; 















10 mol % cat-C, DCE




To a small dried Pyrex pressure tube under argon was placed 2.0 mg (0.010 
mmol) phosphate 2.1, 0.6 mg Hoveyda-Grubbs II catalyst (0.001 mmol, 10 mol %) 
and a stir bar.  To this was added a solution of 4.0 mg of lactone 24.1 (0.020 mmol, 2 
equiv.) in 1 mL of degassed dichloroethane (0.01M with respect to phosphate 2.1), 
the tube flushed one more time and capped, and the solution placed in a 90 ºC oil bath 
with stirring for 24 h.  After the allotted time had passed, the tube was removed from 
heat to cool, SiO2 added and the solvent removed. Placement of the substrate 
impregnated silica on a column allowed for elution with 5:1 EtOAc: acetone to 
provide 3.0 mg (99% yield) of phosphate 24.2 in a 5:1 ratio of trans:cis isomers. 
 
[α]D: -12 (c = 0.10, CH2Cl2, 24.5 ºC) 
FTIR: (neat) 2918, 2849, 1717, 1383, 1296, 1250, 1117, 1067, 1036, 966, 924, 820, 
775 cm-1 
1H NMR (500 MHz, CHCl3-d) δ ppm 6.90 (ddd, J = 9.8, 5.7, 2.8 Hz, 1H), 6.09 (ddd, 
J = 6.7, 3.1, 2.1 Hz, 1H), 6.07 (ddd, J = 9.8, 2.4, 1.0 Hz, 1H), 6.03 (ddd, J = 15.5, 4.7, 
1.5 Hz, 1H), 5.92 (dddd, J = 15.5, 4.4, 2.9, 1.5 Hz, 1H), 5.63 (ddd, J = 11.9, 3.9, 2.6 
Hz, 1H), 5.23 (dddd, J = 23.7, 3.1, 2.2, 2.0 Hz, 1H), 5.11 (dddd, J = 12.0, 3.4, 2.0, 1.6 
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Hz, 1H), 5.03 (dddd, J = 14.7, 8.3, 5.6, 2.7 Hz, 1H), 4.99 (dtd, J = 9.5, 4.3, 1.3 Hz, 
1H), 4.40 (ddd, J = 27.9, 14.8, 6.7 Hz, 1H), 2.51 (dddd, J = 18.4, 5.7, 4.3, 1.1 Hz, 
1H), 2.41 (ddt, J = 21.1, 10.9, 2.7 Hz, 1H), 2.22 (ddd, J = 14.7, 12.1, 6.2 Hz, 1H), 
1.83 (ddd, J = 14.7, 3.5, 2.3 Hz, 1H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 163.8, 144.8, 129.6, 129.3 (d, JCP = 10.1 Hz), 
129.1, 128.5, 121.8, 77.3 (d, JCP = 32.0 Hz), 76.2, 74.9 (d, JCP = 6.2 Hz), 63.3 (d, JCP 
= 6.3), 35.3 (d, JCP = 5.7 Hz), 29.7 
31P NMR (162 MHz, CHCl3-d) δ ppm -3.76 (t, JPH = 23.6 Hz) 





DIBAL-H, 50 ºC, 5 h
then NBS, -30 ºC, 87%
Br
 
 A flame dried 250 mL round bottom flask was purged with Ar, followed by 
addition of a stir bar and 4.7 g (50 mmol) of 1-hepten-6-yne.  55 mL of 
diisobutylaluminum hydride in hexanes (1.0 M, 55 mmol) was slowly added and the 
mixture allowed to stir at room temperature for 30 minutes, followed by warming to 
50 ºC and stirring for 5 h.  The mixture was then cooled to room temperature, 30 mL 
of diethyl ether added, and then cooled to -30 ºC with stirring.  NBS was then added 
and the mixture stirred at -30 ºC for 15 min and then at room temperature for 15 h in 
the absence of light.  The mixture was then poured into 100 mL 6 M HCl (aq) in 
crushed ice.  The resulting solution was then extracted with petroleum ether (3 x 200 
mL), the organic layers washed with 1 M NaOH (aq), then washed with 10% NaS2O3 
(aq) and dried with Na2SO4, filtered, and solvent removed very gently at 22 ºC at 165 
torr.6  The crude material was then passed through a silica plug utilizing 40:1 
petroleum ether: diethyl ether and the solvent carefully removed as indicated before 
to provide 7.65 g (87% yield) of (E)-1-bromohepta-1,6-diene 26.1. 
 
FTIR: (neat) 2975, 2856, 1639, 1620, 1439, 1280, 1230, 991, 935, 912, 706 cm-1 
1H NMR (500 MHz, CHCl3-d) δ ppm 6.17 (dt, J = 13.5, 7.32 Hz, 1H), 6.02 (dt, J = 
13.5, 1.4 Hz, 1H), 5.78 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 5.01 (ddd, J = 17.1, 3.5, 1.6 
Hz, 1H), 4.97 (ddt, J = 10.2, 2.2, 1.2 Hz, 1H), 2.06 (ddddd, J = 14.7, 7.2, 2.5, 1.5, 1.3 
Hz, 4H), 1.50 (dt, J = 7.6, 7.4 Hz, 2H) 
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A 10 mL flask containing 30 mg (0.14 mmol) of ketone 2.2 was placed under 
Ar atmosphere and 1.4 mL of THF were added to generate a 0.1 M solution. The 
solution was then cooled to -78 ºC and freshly prepared Grignard of 26.1 (420 µL, 
1.0M in THF, 3 equiv.) was added slowly along the side of the flask.  The reaction 
mixture was maintained in a cooling bath at -78 ºC for 7 h, after which time 2 mL of 
sat. aq. NH4Cl was added, the flask removed from the cooling bath, and the mixture 
allowed to reach room temperature.   The reaction mixture was extracted with 3 x 10 
mL EtOAc and the organic layers collected.  The organic layers were then washed 
with 20 mL brine, dried with Na2SO4, filtered, SiO2 added and the solvent removed in 
vacuo.  The substrate impregnated SiO2 was then placed on a short column, eluted 
with 2 column volumes of 1:1 hexane: EtOAc, and then eluted with 10% acetone in 
EtOAc.  Solvent removal afforded 31 mg (70% yield) of the desired tertiary alcohol 
26.2. 
 
[α]D: -59 (c = 0.94, CH2Cl2, 25.0 ºC) 
FTIR: (neat) 3393, 2976, 2926, 2854, 1290, 1072, 1036, 986, 923, 885, 838, 771, 
711, 678, 650 cm-1 
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1H NMR (500 MHz, CHCl3-d) δ ppm 6.03 (dddd, J = 11.3, 2.7, 2.4, 1.4 Hz, 1H), 
5.80 (ddd, J = 17.3, 10.3, 3.1 Hz, 1H), 5.78 (dt, J = 15.5, 6.8 Hz, 1H), 5.58 (ddd, 11.9, 
3.9, 2.6 Hz, 1H), 5.40 (dt, J = 15.7, 1.4 Hz, 1H), 5.23 (dddd, J = 24.9, 4.2, 2.3, 1.6 
Hz, 1H), 5.00 (ddd, J = 14.9, 5.7, 2.5 Hz, 1H), 4.99 (dd, J = 17.3, 1.7 Hz, 1H), 4.95 
(ddd, 10.2, 2.0, 1.0 Hz), 4.38 (ddd, J = 14.8, 8.1, 4.6 Hz, 1H), 4.34 (dt, J = 12.3, 1.8 
Hz, 1H), 2.35 (ddd, J = 14.7, 12.0, 6.2 Hz, 1H), 2.05 (tt, J = 7.9, 4.1 Hz, 4H), 1.74 
(ddd, J = 14.8, 3.5, 2.1 Hz, 1H), 1.47 (dt, J = 15.0, 7.5 Hz, 2H), 1.42 (s, 1H), 1.36 (s, 
3H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 138.7, 131.6, 131.3, 130.2, 128.1, 115.0, 82.1 
(d, JCP = 7.4 Hz), 77.4 (d, JCP = 6.5 Hz), 73.7 (d, JCP = 9.1 Hz), 63.3 (d, JCP = 6.3 
Hz), 33.4, 31.9, 29.4 (d, JCP = 5.4 Hz), 28.5, 25.0 
31P NMR (162 MHz, CHCl3-d) δ ppm –2.76 (t, JPH = 24.8 Hz) 
HRMS Exact Mass: calculate for C15H23NaO5P (M+Na)+ 337.1181; 



















A flame dried  mL round bottom flask was charged with 16 mg phosphate 
26.2 (0.051 mmol) and  0.5 mL of CH2Cl2 to generate a 0.1M solution, followed by 8 
µL of 2,6-lutidine (0.066 mmol, 1.3 equiv.).  The solution was then cooled to 0 ºC 
and 13 µL of TESOTf (0.056 mmol, 1.1 equiv.) was added dropwise to the solution 
with stirring.  The solution was allowed to stir at 0 ºC until completion (about 1 h 
until complete by TLC, then allowed to proceed another 1 h).  The reaction was 
quenched with 1 mL of sat. aq. NH4Cl, separated, and the aqueous layer re-extracted 
3 more times with 2 mL portions of diethyl ether.  The combined organic layers were 
then washed with brine, dried with MgSO4, and filtered.  Addition of SiO2 preceded 
removal of solvent, following which the impregnated SiO2 was loaded onto a short 
column and the desired product eluted with 1:2 hexane: diethyl ether to provide 21 
mg (96% yield) of silyl protected phosphate 26.3. 
 
[α]D: -34 (c = 0.10, CH2Cl2, 25.2 ºC) 
FTIR: (neat) 2953, 2916, 2879, 1293, 1264, 1237, 1220, 1134, 1074, 1061, 1042, 
994, 978 cm-1 
1H NMR (500 MHz, CHCl3-d) δ ppm 6.00 (dddd, J = 11.8, 3.0, 2.3, 1.3 Hz, 1H), 
5.79 (dddd, J = 17.0, 10.2, 6.9, 6.7 Hz, 1H), 5.67 (dt, J = 15.5, 6.9 Hz, 1H), 5.56 (ddd, 
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11.8, 3.9, 2.6 Hz, 1H), 5.38 (dd, J = 16.7, 1.2 Hz, 1H), 5.21 (app dd, J = 24.4, 1.7 Hz, 
1H), 5.00 (dd, J = 17.2, 1.8 Hz, 1H), 4.96 (ddd, J = 10.3, 1.2, 0.8 Hz, 1H), 4.34 (ddd, 
J = 21.5, 14.7, 6.8 Hz, 1H), 4.20 (dt, J = 10.3, 1.6 Hz, 1H), 2.29 (ddd, J = 14.8, 11.9, 
6.3 Hz, 1H), 2.04 (q, J = 7.2 Hz, 4H), 1.81 (app d, J = 14.5 Hz, 1H), 1.47 (dd, J = 7.9, 
0.9 Hz, 1H), 1.37 (s, 3H), 1.25 (br s, 2H), 0.93 (t, J = 7.9 Hz, 9H), 0.59 (qd, J = 7.9, 
1.3 Hz, 6H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 138.8, 134.1, 131.5, 130.3, 127.9, 114.9, 81.9 
(d, JCP = 7.4 Hz), 77.8 (d, JCP = 6.5 Hz), 75.8 (d, JCP = 10.2 Hz), 63.2 (d, JCP = 6.4 
Hz), 33.4, 31.9, 29.9, 29.1 (d, JCP = 5.3), 28.5, 22.8, 7.3, 6.8 
31P NMR (162 MHz, CHCl3-d) δ ppm -2.81 (t, JPH = 24.4 Hz) 
HRMS Exact Mass: calculate for C21H37NaO5PSi (M+Na)+ 451.2046; 





















DCE, 90 ºC, 14 h
55 %
,10 mol % cat-C
(via syringe pump)  
To a dry pressure tube equipped with stir bar was added 0.75 mg (0.001 
mmol, 10 mol %) Hoveyda-Grubbs II catalyst, 3 mg (0.023 mmol, 2 equiv.) lactone 
2.4, and 0.8 mL dry, degassed dichloroethane.  The reaction vessel was purged with 
Ar and fitted with a cap bearing a Teflon septa to which a ballon of Ar was affixed 
through a 21 gauge needle, followed by immersion of the vessel in an oil bath at 90 
ºC.  A 0.03 M solution of phosphate 26.3 (5 mg, 0.012 mmol, 0.8 mL) was added by 
syringe pump at a rate of 0.1 mL/h, hence leading to complete addition of substrate in 
8 h.  The reaction was allowed to proceed for 6 more hours before removing the 
vessel from the oil bath and allowing to cool to room temperature.  SiO2 was then 
added to the mixture and the solvent removed, followed by placement of the substrate 
impregnated silica on a column.  Elution with 1:2 hexane: EtOAc provided 4.4 mg of 
a ~3:1 ratio of both product 27.1 and lactone dimer as an inseperable mixture 
discernable by spectroscopy. 
 
FTIR: (neat) 2914, 2876, 1722, 1420, 1385, 1294, 1263, 1236, 1220, 1134, 1074, 
1061, 1042, 993 cm-1 
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1H NMR (500 MHz, CHCl3-d) δ ppm (discernable peaks) 5.82 (dddd, J = 15.7, 9.0, 
6.5, 5.6 Hz, 1H), 5.65 (dtd, J = 15.6 , 6.7, 2.0 Hz, 1H), 5.58 (ddd, J = 16.5, 8.7, 3.6 
Hz, 1H), 5.38 (d, J = 15.6 Hz, 1H), 5.22 (app d, J = 23.4 Hz, 1H), 4.88 (dd, J = 14.4, 
7.0 Hz, 1H), 4.35 (dddd, J = 11.6, 8.0, 6.9, 6.6 Hz, 1H), 4.21 (dd, J = 14.2, 2.0 Hz, 
1H), 2.27 (ddd, J = 14.9, 12.1, 6.8 Hz, 1H), 2.06 (ddd, J =7.5, 7.1, 6.9 Hz, 4H), 1.36 
(s, 3H), 1.21 (dd, J = 7.1, 7.0 Hz, 2H), 0.93 (td, J = 7.8, 1.6 Hz, 9H), 0.58 (qd, J = 
7.4, 2.4 Hz, 6H) 
13C NMR (126 MHz, CHCl3-d) δ ppm 164.4, 145.1, 135.2, 134.3, 131.2, 130.3, 
127.9, 127.4, 121.7, 81.8, 78.4, 75.7, 72.4, 63.2, 31.8, 31.7, 30.0, 29.2, 28.3, 22.6, 7.3, 
6.8 
31P NMR (162 MHz, CHCl3-d) δ ppm -3.11 (t, JPH = 23.1 Hz) 
HRMS Exact Mass: calculate for C26H41 NaO7PSi (M+Na)+ 547.2251; 

















OHDCE, 90 ºC, 14 h
17 %





A small Pyrex pressure tube under Ar atmosphere bearing a cap with Teflon 
septa and stirring bar is charged with 1.5 mg Hoveyda-Grubbs catalyst (0.002 mmol, 
10 mol %), 3 mg of lactone 2.4 (0.0232 mmol, 1 equiv.) and 1.0 mL degassed 
dichloroethane (0.02M with respect to 2.4).  The solution is placed in a 90 ºC silicon 
oil bath and allowed to stir for 10 minutes.  Another solution containing 7.3 mg of 
phosphate 26.2 (0.0232 mmol) and 6 mg lactone 2.4 (0.0464 mmol, 2 equiv.) in 600 
µL of degassed dichloroethane is placed in a syringe and the needle of the syringe 
placed through the septa of the Pyrex tube.  The syringe is then injected via syringe 
pump at a rate of 100 µL per hour and the reaction allowed to proceed overnight.  The 
pressure tube is then removed from heat, SiO2 added, and the solvent removed.  The 
product bearing silica gel is then placed on a column for purification utilizing 100% 
EtOAc to remove the more nonpolar components followed by elution with 50% 
acetone in EtOAc to provide 1.3 mg (17% yield) of lactone appended phosphate 28.1. 
 
 
[α]D: -16.9 (c = 0.07, acetone, 24.1 ºC) 
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FTIR: (neat) 3401, 2919, 2851, 1717, 1383, 1295, 1251, 1117, 1067, 1036, 966, 924, 
820 cm-1 
1H NMR (500 MHz, acetone-d6) δ ppm 7.01 (ddd, J = 9.7, 5.7, 2.8 Hz, 1H), 6.08 (ttd, 
J = 8.9, 2.2, 1.3 Hz, 1H), 6.01 (dd, J = 15.6, 5.9 Hz, 1H), 5.95 (ddd, J = 9.7, 2.5, 1.2 
Hz, 1H), 5.94 (d, J = 15.6 Hz, 1H), 5.73 (ddd, J = 11.9, 3.8, 2.6 Hz, 1H), 5.29 (app d, 
J = 24.3 Hz, 1H), 5.00 (dddd, J = 5.5, 5.4, 5.2, 4.8 Hz, 1H), 4.87 (dddd, J = 14.8, 8.4, 
5.7, 2.7 Hz, 1H), 4.38 (m, 2H), 2.57 (dddd, J = 18.5, 4.4, 1.3, 1.0 Hz, 1H), 2.43 (ddt, 
J = 18.5, 10.8, 2.6 Hz, 1H), 2.28 (ddddd, J = 16.5, 12.1, 7.7, 6.4, 2.7 Hz, 2H), 1.34 (s, 
3H), 1.30 (br s, 1H) 
13C NMR (126 MHz, acetone-d6) δ ppm 164.0, 146.4, 137.1, 131.3, 128.4, 128.3, 
121.8, 82.0 (d, JCP = 7.4 Hz), 78.3 (d, JCP = 7.0 Hz), 78.1, 73.7 (d, JCP = 9.1 Hz), 63.6 
(d, JCP = 6.5 Hz), 30.5 (d, JCP = 3.7 Hz), 29.5, 24.4 
31P NMR (162 MHz, acetone-d6) δ ppm –3.01 (t, JPH = 24.4 Hz) 
HRMS Exact Mass: calculate for C15H19NaO7P (M+Na)+ 365.0766; 
found 365.0756 (ESI) 
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5.5 Experimental Data: References 
 
(1) Whitehead, A.; McReynolds, M.D.; Moore, J.D.; Hanson, P. R.; Multivalent 
Activation in Phosphate Tethers: A New Tether for Small Molecule Synthesis. 
Org. Lett. 2005, 7, 3375-3378. 
(2) Waetzig, J. D.; Hanson, P. R. Temporary Phosphate Tethers: A Metathesis 
Strategy to Differentiated Polyol Subunits. Org. Lett. 2006, 8, 1673-1676. 
(3) Trost, B. M.; Frederiksen, M. U.; Papillon, J. P. N.; Harrington, P. E.; Shin, 
S.; Shireman, B.T. Dinuclear Asymmetric Zn Aldol Additions: Formal 
Asymetric Synthesis of Fostriecin. J. Am. Chem. Soc. 2005, 127, 3666-3667. 
(4) Chavez, D. E. The Total Synthesis of Fostriecin (CI-920). The Development 
and Applications of an Asymmetric Hetero-Diels-Alder Reaction. Ph. D. 
Thesis, Harvard University, Cambridge, MA, 2003. 
(5)  Clarke, M. L.; Cole-Hamilton, D. J.; Slawin, A. M. Z.; Woollins, J. D. P–N 
bond formation as a route to highly electron rich phosphine ligands. Chem. 
Commun. 2000, 2065-2066. 
(6) Slightly modified from: Ney, J. E.; Hay, M. B.; Yang, Q.; Wolfe, J. P. 
Synthesis of N-Aryl-2-allyl Pyrrolidines via Palladium-catalyzed 
Carboamination of γ-(N-Arylamino)alkenes with Vinyl Bromides. Adv. Synth. 










NMR Spectra and X-Ray Data 
 252 
A.1: Chapter 2 Spectra 








































































































































































































































































































     The displacement ellipsoids were drawn at the 50% probability level.  
 
Experimental 
     A colorless plate-shaped crystal of dimensions 0.42 x 0.26 x 0.05 mm was selected for 
structural analysis.  Intensity data for this compound were collected using a Bruker 
APEX ccd area detector (1) using graphite-monochromated Mo K! radiation (" = 
0.71073 Å).  The sample was cooled to 100(2) K.  The intensity data were measured as a 
series of # oscillation frames each of 0.3 ° for 20 sec / frame.  Coverage of unique data 
was 98.7 % complete to 26.00 degrees in $.  Cell parameters were determined from a 
non-linear least squares fit of 8023 peaks in the range 3.25 < $ < 26.00°.  A total of 
12193 data were measured in the range 3.25 < $ < 26.00°.  The data were corrected for 
absorption by the semi-empirical method (2) giving minimum and maximum 
transmission factors of 0.884 and 0.986.  The data were merged to form a set of 1764 
independent data with R(int) = 0.0283.   
     The tetragonal space group P43212 was determined by systematic absences and 
statistical tests and verified by subsequent refinement.  The structure was solved by direct 
methods and refined by full-matrix least-squares methods on F2 (3).  Hydrogen atom 
positions were initially determined by geometry and refined by a riding model.  Non-
hydrogen atoms were refined with anisotropic displacement parameters.  Hydrogen atom 
displacement parameters were set to 1.2 (1.5 for methyl) times the displacement 
parameters of the bonded atoms.  A total of 127 parameters were refined against 1764 
data to give wR(F2) = 0.0999 and S = 1.014 for weights of w = 1/[%2 (F2) + (0.0700 P)2 
+ 1.3000 P], where P = [Fo2 + 2Fc2] / 3.  The final R(F) was 0.0360 for the  1762 
observed, [F > 4%(F)], data.  The largest shift/s.u. was  0.001 in the final refinement 
cycle.  The final difference map had maxima and minima of 0.514 and -0.211 e/Å3, 
respectively.  The absolute structure was determined by refinement of the Flack 
parameter(4).   
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 Table 1.  Crystal data and structure refinement for 05102. 
 
Empirical formula  C8 H11 O5 P 
Formula weight  218.14 
Crystal system  Tetragonal 
Space group  P43212 
Unit cell dimensions  a = 6.3256(4) Å != 90° 
 b = 6.3256(4) Å &= 90° 
 c = 46.035(6) Å '= 90° 
Volume 1842.0(3) Å3 
Z, Z' 8, 1 
Density (calculated) 1.573 Mg/m3 
Wavelength  0.71073 Å 
Temperature  100(2) K 
F(000) 912 
Absorption coefficient 0.292 mm-1 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.986 and 0.884 
Theta range for data collection 3.25 to 26.00° 
Reflections collected 12193 
Independent reflections 1764 [R(int) = 0.0283] 
Data / restraints / parameters 1764 / 0 / 127 
wR(F2 all data) wR2 = 0.0999 
R(F obsd data) R1 = 0.0360 
Goodness-of-fit on F2 1.014 
Observed data [I > 2%(I)] 1762 
Absolute structure parameter 0.10(14) 
Largest and mean shift / s.u. 0.001and 0.000 
Largest diff. peak and hole 0.514 and -0.211 e/Å3  
----------  
wR2 = { ( [w(Fo2 - Fc2)2] / ( [w(Fo 2)2] }1/2  
R1 = ( ||Fo| - |Fc|| / ( |Fo| 
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 Table 2.  Atomic coordinates and equivalent isotropic displacement parameters for 
05102. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
_____________________________________________________________________    
 x y z U(eq) 
_____________________________________________________________________  
 
P(1) 0.41655(9) 0.32242(9) 0.699432(11) 0.01397(18) 
O(2) 0.4293(2) 0.3823(2) 0.66616(3) 0.0167(4) 
C(3) 0.3051(3) 0.5642(3) 0.65674(4) 0.0165(5) 
C(4) 0.3620(3) 0.7566(4) 0.67479(5) 0.0173(5) 
C(5) 0.3157(4) 0.7218(3) 0.70697(4) 0.0157(5) 
C(6) 0.0850(4) 0.7083(4) 0.71416(5) 0.0181(5) 
C(7) -0.0262(4) 0.5432(4) 0.72292(5) 0.0182(5) 
C(8) 0.0514(3) 0.3210(4) 0.72716(5) 0.0180(5) 
O(9) 0.1808(2) 0.2467(2) 0.70304(3) 0.0170(3) 
O(10) 0.4325(2) 0.5342(2) 0.71706(3) 0.0159(4) 
O(11) 0.5774(3) 0.1690(3) 0.70765(3) 0.0203(4) 
C(12) 0.3421(3) 0.5969(4) 0.62437(5) 0.0192(5) 
O(13) 0.3219(3) 0.7730(3) 0.61422(3) 0.0253(4) 
C(14) 0.3920(4) 0.4074(4) 0.60620(5) 0.0253(5) 
_____________________________________________________________________ 
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 Table 3.   Bond lengths [Å] and angles [°] for  05102. 
______________________________________________________________  
 
P(1)-O(11)  1.4561(17) 
P(1)-O(10)  1.5697(16) 
P(1)-O(9)  1.5753(17) 
P(1)-O(2)  1.5800(15) 
O(2)-C(3)  1.459(3) 
C(3)-C(4)  1.517(3) 
C(3)-C(12)  1.522(3) 
C(3)-H(3)  1.0000 
C(4)-C(5)  1.526(3) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-O(10)  1.473(3) 
C(5)-C(6)  1.499(3) 
C(5)-H(5)  1.0000 
C(6)-C(7)  1.322(3) 
C(6)-H(6)  0.9500 
C(7)-C(8)  1.501(3) 
C(7)-H(7)  0.9500 
C(8)-O(9)  1.457(3) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
C(12)-O(13)  1.215(3) 
C(12)-C(14)  1.495(3) 
C(14)-H(14A)  0.9800 
C(14)-H(14B)  0.9800 





















































 Table 4.   Anisotropic displacement parameters (Å2x 103 ) for 05102.  The anisotropic 
displacement factor exponent takes the form: 
-2 )2[ h2 a*2 U11 + ... + 2 h k a* b* U12 ] 
_____________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
_____________________________________________________________________  
 
P(1) 14(1)  14(1) 14(1)  0(1) 0(1)  -1(1) 
O(2) 18(1)  18(1) 14(1)  0(1) 1(1)  1(1) 
C(3) 14(1)  18(1) 18(1)  2(1) -1(1)  1(1) 
C(4) 18(1)  15(1) 19(1)  1(1) 1(1)  -2(1) 
C(5) 18(1)  12(1) 17(1)  -1(1) -1(1)  -1(1) 
C(6) 21(1)  17(1) 16(1)  -2(1) -1(1)  3(1) 
C(7) 16(1)  23(1) 15(1)  -2(1) 2(1)  2(1) 
C(8) 14(1)  22(1) 17(1)  1(1) 4(1)  0(1) 
O(9) 16(1)  17(1) 18(1)  -2(1) 1(1)  -2(1) 
O(10) 17(1)  16(1) 14(1)  -1(1) -2(1)  -1(1) 
O(11) 18(1)  20(1) 23(1)  2(1) 0(1)  0(1) 
C(12) 11(1)  29(1) 18(1)  1(1) -2(1)  -2(1) 
O(13) 26(1)  30(1) 20(1)  7(1) -1(1)  -1(1) 
C(14) 31(1)  32(1) 13(1)  -2(1) 2(1)  -5(1) 
_____________________________________________________________________
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 Table 5.   Hydrogen coordinates and isotropic displacement parameters for 05102. 
______________________________________________________________________  
 x  y  z  U(eq) 
______________________________________________________________________ 
  
H(3) 0.1521 0.5316 0.6598 0.020 
H(4A) 0.2802 0.8799 0.6678 0.021 
H(4B) 0.5141 0.7886 0.6723 0.021 
H(5) 0.3739 0.8463 0.7177 0.019 
H(6) 0.0078 0.8363 0.7121 0.022 
H(7) -0.1713 0.5679 0.7270 0.022 
H(8A) 0.1354 0.3141 0.7453 0.022 
H(8B) -0.0717 0.2258 0.7294 0.022 
H(14A) 0.3651 0.4399 0.5857 0.038 
H(14B) 0.3026 0.2887 0.6122 0.038 
H(14C) 0.5411 0.3694 0.6087 0.038 
______________________________________________________________ 
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 Table 6.  Torsion angles [°] for 05102. 
______________________________________________________________  
 
O(11)-P(1)-O(2)-C(3) -168.14(14) 
O(10)-P(1)-O(2)-C(3) -43.79(16) 
O(9)-P(1)-O(2)-C(3) 67.06(15) 
P(1)-O(2)-C(3)-C(4) 55.1(2) 
P(1)-O(2)-C(3)-C(12) 179.08(14) 
O(2)-C(3)-C(4)-C(5) -60.8(2) 
C(12)-C(3)-C(4)-C(5) 177.93(18) 
C(3)-C(4)-C(5)-O(10) 57.2(2) 
C(3)-C(4)-C(5)-C(6) -68.8(2) 
O(10)-C(5)-C(6)-C(7) -13.4(3) 
C(4)-C(5)-C(6)-C(7) 111.0(3) 
C(5)-C(6)-C(7)-C(8) -1.9(4) 
C(6)-C(7)-C(8)-O(9) -46.0(3) 
C(7)-C(8)-O(9)-P(1) 76.3(2) 
O(11)-P(1)-O(9)-C(8) 104.04(17) 
O(10)-P(1)-O(9)-C(8) -21.42(17) 
O(2)-P(1)-O(9)-C(8) -133.47(16) 
C(6)-C(5)-O(10)-P(1) 77.1(2) 
C(4)-C(5)-O(10)-P(1) -50.2(2) 
O(11)-P(1)-O(10)-C(5) 165.92(14) 
O(9)-P(1)-O(10)-C(5) -67.01(16) 
O(2)-P(1)-O(10)-C(5) 42.10(16) 
O(2)-C(3)-C(12)-O(13) -153.2(2) 
C(4)-C(3)-C(12)-O(13) -31.0(3) 
O(2)-C(3)-C(12)-C(14) 29.6(3) 
C(4)-C(3)-C(12)-C(14) 151.8(2) 
______________________________________________________________  
  
 
